Wiskott Aldrich Syndrome protein and it's role in breast cancer by Pereira, Gordon Anthony
WISKOTT ALDRICH SYNDROME PROTEIN  
AND IT’S ROLE IN BREAST CANCER 
 
 
  
 
GORDON ANTHONY PEREIRA 
 
A dissertation submitted to the School of Medicine, Cardiff 
University in candidature for the degree of  
Doctor of Medicine (MD) 
 
Metastasis and Angiogenesis Research Group  
Department of Surgery 
School of Medicine, Cardiff University  
Cardiff, Wales 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DECLARATION 
This work has not previously been accepted in substance for any degree and is not 
concurrently submitted in candidature for any degree. 
Signed ................................................................ . (Candidate) Date .................... 
STATEMENT 1 
This thesis is being submitted in partial fulfilment of the requirements for the degree 
of MD. 
Signed ........................................................... . (Candidate) Date .................... 
STATEMENT 2 
This thesis is the result of my own independent work / investigation, except 
where otherwise stated. 
Other sources are acknowledged by explicit references. 
Signed ........................................................... . (Candidate) Date .................... 
STATEMENT 3 
I hereby give consent for my thesis, if accepted, to be available for photocopying and 
for inter-library loan, and for the title and summary to be made available to outside 
organisations. 
Signed ............................................................... (Candidate) Date ................. 
STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS 
I hereby give consent for my thesis, if accepted, to be available for photocopying and 
for inter-library loans after expiry of a bar on access previously approved by the 
Graduate Development Committee. 
Signed ............................................................... (Candidate) Date ....................... 
 
 
 
 
 
 
 
 2 
 
 
DEDICATION 
This work is dedicated to my wife Sunita, as it would not have 
materialised without her help, prayers and gentle persuasion, and to our 
beautiful daughter Geve Lolita 
 3 
ACKNOWLEDGEMENTS 
 
I am most grateful and forever indebted to my supervisors- Professor Wen G Jiang 
and Professor Robert E Mansel- for their timely and most valuable help in 
providing me with a window of opportunity to be a part of their research team. In 
addition, I am mindful that this work would not have come to fruition without their 
understanding and generosity in light of difficult personal circumstances. Being 
from a clinical background, I was largely ignorant of laboratory work, and needed 
a step-by-step instruction in order to proceed with my project. I was fortunate to 
encounter a group of highly motivated and very dedicated individuals who had the 
patience to instruct me and support my tottering steps in an entirely unfamiliar 
environment. None of my work would have been possible without the support of 
Professor Wen G Jiang [for aid with my entire project and especially Real Time 
Quantitative Polymerase Chain Reaction, Real Time Polymerase Chain Reaction 
and immunohistochemistry. I must credit Professor Jiang for the animal 
experiments, which were performed by him, that have been included in my Thesis. 
I owe special thanks to Dr. Tracey Martin for her patience and help with cloning, 
transfection, invasion and migration assays. My sincere thanks also to Mr. Gareth 
Watkins for his expertise with immunohistochemistry and staining. No 
acknowledgement would be complete without a mention of all my colleagues in the 
MARG team-Dr. Khaled Ramali, Dr. Gaynor Davies, Dr. Christian Parr, Mr. 
Sateesha Hanavadi and Mr. Alok Chhabra- for their patience, flexibility, guidance 
and encouragement towards completion of this work. 
 
 4 
Abbreviations 
Aa Amino acid 
Ab Antibody 
ABC Avidin biotin complex 
Ag  Antigen 
BCS   Breast Conserving Surgery 
bp  Base pair 
BSA Bovine serum albumin 
BSS  Balanced Salt Solution 
CaCl2  Calcium Chloride 
CCR 5  Chemokine receptor 5 
CDC42  Cell Division Control Protein 42 
cDNA  Complementary Deoxyribonucleic acid 
dATP  Deoxyadenosine triphosphate 
DAB  Diaminobenzidine tetrahydrochloride 
DCIS  Ductal Carcinoma in Situ 
dCTP  Deoxycytidine triphosphate 
dGTP  Deoxyguanosine triphosphate 
DFS   Disease free survival, 
dNTP  Deoxynucleotide 
 5 
dTTP  Deoxythymidene triphosphate 
dH2O  Distilled water 
DEPC  Diethyl pyrocarbonate 
DMEM Dulbecco’s Modified Eagles Medium 
DMSO  Dimethyl sulphoxide 
DNA  Deoxyribonucleic acid 
ECIS  Electric Cell Impedance Substrate 
ECM  Extracellular Matrix 
E. coli  Escherichia coli 
EDTA  Ethylene di-amino tetra-acetic acid 
ER  Oestrogen receptor 
ERM  Ezrin Radixin Moesin 
FCS  Foetal calf serum 
FITC  Fluorescine Isothiocyanate 
G418  Geneticin 
GTP  Guanosine Triphosphate 
HGF  Human Growth factor 
HER2  Human epidermal growth factor 2 
HBSS  Hank’s Balanced Salt Solution 
HCMF  HEPES buffered salt solution without CaCl2/MgCl2 
HRT  Hormone Replacement Therapy 
 6 
HSE  Heat shock element 
HSP90  Heat shock protein 90 
HUVEC  Human umbilical vein endothelial cell 
IGEPAL  Non ionic, non denaturing detergent 
Kb  Kilo-base 
KDa  Kilo dalton 
KCl  Potassium chloride 
KH2PO4  Potassium dihydrogen phosphate 
LB  Luria Bertani 
LFS  Li-Fraumeni Syndrome 
m  Metre 
M  Molar 
ma  Milliamp 
MCF-7  Breast Cancer Cell line  
MDA-MB-231  Breast Cancer Cell line 
mg  Milligram 
min.  Minute 
ml  Milli litre 
mM  Milli molar 
MRC-5  Fibroblast cell line 
mRNA  Messenger Ribonucleic acid 
 7 
MTT  Dimethylthiazol diphenyltetrazolium bromide 
NaCl  Sodium chloride 
NACT   Neo adjuvant chemotherapy 
NaHPO4  Sodium phosphate 
NaOH  Sodium Hydroxide 
Na3 VO4  Sodium Orthovanadate 
ng  Nano- gram 
NPI  Nottingham Prognostic Index 
NRK  Normal Rat kidney 
OS   Overall survival 
PAGE  Polyacrylamide gel electrophoresis 
PCR  Polymerase Chain Reaction 
pCR  Pathologic complete response 
PTHrP  Parathyroid hormone related peptide 
QBT  DNA purification buffer 
QPCR  Quantitative polymerase chain reaction 
RNA  Ribonucleic acid 
RNase  Ribonuclease 
rRNA  Ribosomal Ribonucleic acid 
rpm  Revolutions per minute 
RT  Reverse Transcription 
 8 
RT-PCR  Reverse Transcription Polymerase Chain Reaction 
SD  Standard Deviation 
SDS-PAGE  Sodium Dodecyl Sulfate Polyacrylamide Gel 
sec  Second 
SH3  SRC Homology 3 domain 
SOC  Super Optimal broth with Catabolite repression 
Src  protooncogene abbr. for Sarcoma 
SYBR  Synergy Brands 
TAG  Tubulo-acinar gland 
Taq  Thermus aquaticus 
TBE  Tris/ Borate/ EDTA electrophoresis buffer  
TBS  Tris Buffered Saline 
TEMED  Tetramethylethylenediamine 
TGF-P  Transforming Growth factor P 
TNM  Tumour-Node-Metastasis 
TRITC  Tetramethylrhodamine-5-(and 6)-isothiocyanate 
TRIS-HCl  Hydroxymethyl aminomethane hydrochloride 
tRNA  Transfer Ribonucleic acid 
U  Unit 
V  Volt 
WAS  Wiskott Aldrich Syndrome 
 9 
WASP  Wiskott Aldrich Syndrome protein 
WAVE  Wiskott Aldrich Syndrome protein verprolin homologue 
WT  Wild type 
 10 
SUMMARY 
Breast Cancer continues to be the most common form of cancer in women. The 
ability of tumour cells to spread from primary and metastatic tumours is the 
primary cause of death in patients with cancer. Thus, it rightly follows that 
significant research is dedicated to the pathways and mechanisms controlling 
metastases in order to guide therapeutic approaches. 
Wiskott Aldrich Syndrome [WAS] is an X-linked recessive condition with 
immunodeficiency as the clinical manifestation. It is caused by mutations of the 
Wiskott Aldrich Syndrome [WAS] gene, which codes for a cytoplasmic protein 
with multiple functions. Two major complexes that are linked to the NWASP 
family, namely the ERM family and Rho GTPases are aberrantly expressed in 
human breast cancer. Additionally, X chromosome inactivation which silences 
gene expression from one of the two X chromosomes in females, is usually 
random. Skewed X inactivation has been shown to occur more frequently in breast 
and ovarian cancer patients. Individuals with WAS are known to have skewed X 
inactivation. In addition, they are more susceptible to certain forms of malignancy, 
primarily haematological. This formed the basis of the present study, which 
sought to elucidate the role of WAS protein in human breast cancer, and to 
determine if it plays a role as a tumour suppressor. We also attempted to 
determine its biological role and association with clinical outcome in patients with 
breast cancer. We examined the correlation of NWASP with human breast cancer 
in vitro, in vivo and in human breast cancer tissue. 
Immunohistochemistry studies of frozen sectioned human breast cancer tissues 
revealed that breast cells stained positively for NWASP and that cancer cells in 
tumour tissues stained very weakly. Quantitative RT-PCR revealed that breast 
cancer tissues had significantly lower levels of NWASP compared to normal 
background breast tissue. Although no significant correlation was found with 
tumour grade and TNM staging, lower levels of transcript were seen to correlate 
with clinical outcome following a 10 year follow up. The invasive human breast 
cancer cell line, MDA-MB-231 was used to over-express NWASP, with over-
expression resulting in cells with reduced motility and invasion, increased 
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adhesion to the basement membrane and more significantly, reduced tumour 
growth in vivo. This has important implications in understanding the mechanism 
whereby cancer cells become more motile and presents an interesting tool in 
analysing the progression of human breast cancer.  
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1. Introduction  
 
1.1 Epidemiology  
Breast cancer is by far the most frequent cancer among women with an estimated 
1.38 million new cancer cases diagnosed in 2008 (23% of all cancers) and ranks 
second overall (10.9% of all cancers). It is now the most common cancer both in 
developed and developing regions with around 690000 new cases estimated in 
each region. Incidence rates vary from 19.3 per 100,000 women in Eastern Africa 
to 89.7 per 100,000 women in Western Europe, and are high (greater than 80 per 
100,000) in developed regions of the world (except Japan) and low (less than 40 
per 100,000) in most of the developing regions (Figure 1.1). The range of mortality 
rates is much less (approximately 6-19 per 100,000) because of the more 
favourable survival of breast cancer in (high-incidence) developed regions. As a 
result, breast cancer ranks as the fifth cause of death from cancer overall (458 000 
deaths), but it is still the most frequent cause of cancer death in women in both 
developing (269 000 deaths, 12.7% of total) and developed regions.  
 
Breast cancer has been the most common cancer in the United Kingdom [UK] 
since 1997, despite the fact that it is rare in men (Figure 1.2). It is by far the most 
common cancer among women in the UK, accounting for 31% of all new cases of 
cancer in females. In 2010, there were 49,961 new cases of breast cancer in the 
UK: 49,564 (99%) in women and 397 (less than 1%) in men, giving a female: male 
ratio of around 125:1.1. The crude incidence rate shows that there are 157 new 
breast cancer cases for every 100,000 females in the UK, and 1 for every 100,000 
males.  
 
The risk is strongly age-related, with more than 80% of cases occurring in women 
over 50 years of age. The highest incidence is seen in the 50-69 age range [Table 
1.4]. Hence, the national screening programme in the United Kingdom targets this 
age range [recently amended to include women up to 70]. Among cancers in 
women, Breast cancer is the most commonly diagnosed cancer in women under 35. 
By age 35 –39, almost 1,500 women are diagnosed annually. There occurs 
considerable geographic variation, with highest rates in the developed world and 
lowest rates in Africa and Asia (Ferlay et al., 2012). It has been found that 
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migrants from low to high risk countries acquire the risk of the host country within 
two generations (Ziegler et al., 1993, Tominaga, 1985). 
 
Figure 1. 1 Age standardised incidence and Mortality rates of female breast cancer in 
selected world regions, 2008. Adapted from (http://www.cancerresearchuk.org)  
 
 
 
Figure 1. 2 European Age standardised Incidence Rates per 100000 Population by 
sex, UK 2008. Adapted from (http://www.cancerresearchuk.org) 
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The incidence of breast cancer is high, and with advancements in management, the 
overall 5-year survival rates are constantly increasing [now above 75%]. This 
translates into a large population of women who are alive and have been diagnosed 
with breast cancer [Figure 1.3]. The most recent estimates suggest this figure is 
around 172,000 in the UK (Micheli et al., 2002).  
 
Figure 1. 3 Age standardised incidence and mortality rates of female breast cancer-
United Kingdom (1975-2008). Adapted from (http://www.cancerresearchuk.org). 
 
 
1.2 Aetiology and Risk Factors 
 
Broadly speaking, the risk factors can be divided as those associated with 
oestrogen exposure [age, lower parity, early menarche, late menopause, Hormone 
Replacement Therapy or Oral Contraception] or those associated with genetic 
factors [family history, carriers of BRCA 1 or 2 mutations, or previous breast, 
endometrial or ovarian cancer]. These have been summarized in Table 1.1. 
 
1.2.1 Age 
 
A diagnosis of breast cancer in the 3rd or 4th decade of a woman’s life is associated 
with a poorer prognosis (Albain et al., 1994). Young women with breast cancer 
are more likely to have a higher tumour grade and disease positive nodes (de la 
Rochefordiere et al., 1993). Early onset breast cancers are more likely to be 
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hormone receptor negative but C-erb-2 positive, and this is associated with more 
aggressive behaviour (Bertheau et al., 1998, Gusterson et al., 1992). Survival rates 
were shown to be lower by 10-20% in patients aged 30 or less (de la 
Rochefordiere et al., 1993, Lee et al., 1992). By the age of 50, around 10,000 
women were diagnosed with breast cancer (in the UK in 2010), but 80% of all 
diagnoses were in the over 50s, and 45% were diagnosed in women aged 65 and 
over (in the UK between 2008 and 2010). Age-specific incidence rates rise steeply 
from around age 35-39, level off for women in their 50s, then rise further to age 
65-69, drop slightly for women aged 70-74, then increase steadily to reach an 
overall peak in the 85+ age groups (see Fig 1.4). The estimated risk of developing 
breast cancer at the different age groups is summarized in Table 1.2. 
 
Figure 1.4: Numbers of new cases and age specific incidence rates, by sex, breast 
cancer, UK. Adapted from (http://www.cancerresearchuk.org) 
 
Nearly half (48%) of female breast cancer cases are diagnosed in the 50-69 age 
group; currently women in this age group and those aged 70 are invited for 
screening every three years in the UK through the NHS Breast Screening 
Programme. In England, a trial is taking place to look at the possible benefits of 
extending breast screening so that women aged 47 to 50 and 70 to 73 are invited. 
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1.2.2 Genetic Factors  
Although it is estimated that familial breast cancer accounts for 6-19% of cases 
(Colditz et al., 1993, Slattery et al., 1993), only 5% of breast cancers are 
hereditary, the remainder occur as a result of spontaneous genetic mutations. 
Known genetic disorders associated with breast cancer are ataxia telangiectasia, 
Cowden’s disease and Li Fraumeni syndrome (Thompson and Dixon, 1992). 
Important breakthroughs were the discovery of the tumour suppressor genes- 
BRCA 1 on chromosome 17q (Miki et al., 1994) and BRCA 2 on chromosome 13q 
(Wooster et al., 1995). BRCA 1 mutations are spread evenly across the gene 
(Couch and Weber, 1996), and the gene is involved in regulating the growth of 
breast epithelial cells (Holt et al., 1996). Women carrying the BRCA 1 gene 
mutations have an 87% life-time risk of developing breast cancer (Ford et al., 
1994), although this has subsequently been estimated at 50% (Struewing et al., 
1997). It has been shown that mutations in BRCA1 function as a novel predictor of 
response to chemotherapy (James et al., 2007). Germ line mutations in this pair of 
genes, which cause interruption of DNA repair, are responsible for the majority of 
familial breast cancers (Ingvarsson, 2004). 
1.2.3 Hormonal Factors  
Hormonal risk factors have an important bearing as is suggested by the observation 
that the longer the breast is exposed to cyclical oestrogens, the greater the risk of 
developing breast cancer. Late menarche (Peeters et al., 1995), early menopause 
(Velentgas and Daling, 1994), early full term pregnancy and greater parity (Layde 
et al., 1989); are all associated with a decrease in the risk of breast cancer 
development. The use of Hormone Replacement Therapy [HRT] over long periods 
is associated with an increased risk, but the risk disappears soon after stopping 
treatment (Vessey, 1997). However, HRT induced cancers appear to have a better 
prognosis than those in non users with improved survival prospects (Schairer et al., 
1999). Obesity (Trentham-Dietz et al., 1997) and excessive alcohol intake 
(Steinberg et al., 1991, Reichman et al., 1993) have been implicated as associated 
risk factors. The conversion of adrenal androstenedione to oestrone is related to 
body weight (Dunn and Bradbury, 1967): in normal subjects, this figure is 1%; in 
obese individuals, it approaches 10%. 
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Table 1.1: Risk factors for the development of breast cancer  
Adapted from (Kelsey and Berkowitz, 1988) 
 
 
Table 1.2: Estimated risks for different age group 
Adapted from (Kelsey and Berkowitz, 1988) 
 
 
 
1.3 Breast Morphology 
1.3.1 Normal Breast 
The human mammary gland [breast] is a modified sweat gland, and is essentially 
composed of 15-20 tubulo-acinar glandular [TAG] units defined by dense 
connective tissue that separates them. The composition of the connective tissue 
varies with age, with older women having less adipose tissue. The onset of 
puberty brings about stromal proliferation with deposition of inter and intra 
lobular connective tissue, resulting in the expansion of the TAG unit. Each TAG 
unit is composed of many lobules which in turn comprises a system of terminal 
alveoli draining into alveolar ducts. Several of these drain into a single lactiferous 
duct from each TAG unit to the nipple. 
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The ductal system of the breast is lined by cuboidal epithelial cells flanked by 
myoepithelial cells, both layered upon a prominent basement membrane. The two 
epithelial cell components are luminal epithelial and myoepithelial cells, both of 
which can be purified by immunoaffinity techniques which exploit differences in 
marker cell surface protein expression (Gomm et al., 1995, Kamalati et al., 1999, 
Clarke et al., 1994, Slade et al., 1999). Using such protocols, it has been possible 
to further study and highlights the responses of these two cell types to growth and 
morphogenic signals, thereby gaining further insight into the functionality of 
these cells in the normal mammary gland. 
The stromal structure of the breast accounts for about 80% of the volume of the 
breast (Drife, 1986). This component changes remarkably during different phases 
of the menstrual cycle. The main components of the stroma are adipose tissue, 
connective tissue (dense and loose) and blood vessels. A prominent cell type in the 
structure and stroma is the fibroblast. The luminal epithelial cells are highly 
specialized structures and display structural and functional polarity in their 
organization (Simons and Fuller, 1985). The apical surface (lumen facing) 
membrane is bound to the adjacent cell apical membrane by a tight junction 
preventing molecules from diffusing between adjacent cells (Gumbiner, 1987). In 
the ducts, they are surrounded by a discontinuous layer of myoepithelial cells. The 
latter are less marked in the smaller ductules of the lobuli.  
In the adult human breast, oestrogen receptors are expressed in approximately 20% 
of all cells (Russo et al., 1999) and are over expressed in the majority of breast 
cancers (Petrangeli et al., 1994). The luminal epithelial cells express a variety of 
keratin proteins, but cytokeratin 18 staining is the most consistent and 
homogenous, being positive in all luminal epithelial cells and negative in 
myoepithelial cells (Petersen and van Deurs, 1987). Myoepithelial cells also 
express cytokeratins, predominantly CK5 and to a lesser extent CK7, 13, 14 and 17 
(Moll et al., 1989, Nagle et al., 1986). These also express actins and myosins in 
keeping with their contractile function. 
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1.3.2 Breast Cancer 
Pathologically breast cancer is classified as non-invasive [carcinoma in situ] or 
invasive. There are different morphological variants. In invasive carcinoma, 
histological examination shows that myoepithelial cells are absent. The basement 
membrane is lost and cancer cells express markers for luminal epithelial cells 
rather than myoepithelial cells (Ronnov-Jessen et al., 1996). Gene expression 
studies indicate that there may be myoepithelial gene expression signature in a 
significant number of such tumours (Perou et al., 1999, Perou et al., 2000). 
In carcinoma in situ, the cancer cells are confined to the ductal epithelium and 
acini, without having penetrated through the basement membrane [hence non 
invasive]. Ductal carcinoma in situ [DCIS] is visible as microcalcifications on 
mammograms. This accounts for 20% of all screen detected breast cancers (Pinder, 
2001). Based on the degree of nuclear atypia within the cells, this is classified as 
high, intermediate and low grade DCIS. 
DCIS is considered premalignant, and there are conflicting opinions regarding the 
rate of progression, depending on the variety of DCIS. The natural history of low 
grade DCIS is that approximately 60 percent of lesions will become invasive at 40 
years follow up. The natural history of intermediate grade DCIS is yet unknown. 
The natural history of high grade DCIS suggests an invasive risk of at least 50 
percent at 7 years follow up (Hamilton et al., 2004). Other authors consider DCIS 
to be a nonobligate precursor to invasive breast cancer, postulating that 47-86 
percent of patients with DCIS will not progress to invasive breast cancer even 
after 30 years of follow up (Fisher and Brown, 1985, Fisher et al., 1986). In one 
cohort of patients treated with excisional biopsy alone, only 39 percent of patients 
progressed to ipsilateral breast cancer at 30 years of follow up (Bonadonna et al., 
1976). Lobular carcinoma in situ [LCIS] is usually found incidentally in biopsy 
specimens in postmenopausal women. It is less common, often multifocal and 
occurs bilaterally in 30% of cases. Almost 90% of invasive cancers are ductal in 
origin; lobular cancers make up the remaining 10% (Forrest and Alexander, 
1995). The majority of ductal carcinomas are called no special type [NST] as they 
do not display any special histological features. Histological variants include 
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medullary [5%], tubular [3%] and mucoid varieties [2%]. Variants of lobular 
cancer include cribriform, solid and tubular varieties.  
The TNM classification of malignant tumors, initially developed by Pierre Denoix 
is currently maintained by the Union for International Cancer Control. A common 
international language for classifying cancer, it is summarized in Table 1.3 below. 
Table 1.3: TNM definitions (http://cancernet.nci.nih.gov) 
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1.4 Tumour staging and prognosis 
More detailed, and therefore prognostically informative, staging can be determined 
by including pathological information. Histopathologists specifically include 
variables such as tumour size, grade, oestrogen and progesterone status, the 
number of lymph nodes involved and the presence of lympho-vascular invasion. 
Based on the following three variables, viz., tubule formation, nuclear size/degree 
of pleomorphism and mitotic count, tumours are assigned a grade from 1-3 (Table 
1.4). Each of these variables is further assigned a score from 1-3, and grade is 
arrived by adding up the final score. Grade 1: 3-5; Grade 2: 6- 7; Grade 3: 8-9. 
Patients with grade 1 tumours have a better prognosis [85% 10 year survival] as 
compared to grade 3 patients [less than 45% 10 year survival] (Pinder, 2001). 
Table 1.4: AJCC stage groupings (http://cancernet.nci.nih.gov) 
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Table 1.5 Bloom and Richardson Grading System of breast cancer (Cancer, 2010) 
 
It has been universally recognised that the single most important clinico-
pathological factor prognostically is the axillary lymph node status (Carter et al., 
1989, Fisher et al., 1983). Nodal involvement is reciprocally related to prognosis. 
In a series of 24,740 patients with breast cancer, the overall incidence of axillary 
involvement was 46% (Carter et al., 1989). Recent series, albeit smaller, have 
shown that this figure has fallen towards 25% (Martin et al., 2002). The 10 year 
survival falls from 60-70% for node negative patients to 20-30% for node positive 
patients (Dixon and Sainsbury, 1998). Tumour size is probably related to nodal 
metastasis. The incidence of positive axillary nodes varies from 3-22% for 
tumours less than a centimetre in size (Carter et al., 1989, Hindie et al., 2011, 
Hsueh et al., 2000, Veronesi et al., 1998) 
As the prognosis is an important issue that concerns patients and physicians alike, 
and there are a number of variables involved in this determination, an effort to 
combine these has been made. The Nottingham Prognostic Indicator [NPI] (Galea 
et al., 1992) has been found to accurately predict the clinical outcome of breast 
cancer. This is calculated as follows: 
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NPI = 0.2 X tumour size + histological grade [1-3] + lymph node stage [1-3]* 
* Lymph node stage is arrived at as: stage 1 if the axillary nodes are disease free, 
stage 2 if 1-3 nodes are involved, and stage 3 if more than 3 lymph nodes are 
involved. 
An NPI of less than 3.4 is associated with an 80% 15-year survival, NPI of 3.4-5.4 
is associated with 42% 15-year survival, and NPI of greater than 5.4 is associated 
with a 13% 15-year survival. The NPI has limitations in that it does not account for 
lymphovascular invasion or oestrogen receptor status, which has independent 
prognostic significance [see below]. Lymphovascular invasion is useful in 
predicting local recurrence. It is not used in planning adjuvant treatment or 
determining prognosis. 
The role of oestrogen receptor [ER] in breast cancer was elucidated after its 
isolation (Toft and Gorski, 1966). It became feasible to use an ER assay to predict 
hormone responsiveness in breast cancer (Brem et al., 1978, Gorski et al., 1968). 
Improvements in developing monoclonal antibodies and antigen retrieval have 
vastly facilitated immuno-staining techniques to allow a change in emphasis on 
ER from a prognostic indicator to a predictive test of a cancer amenable to 
treatment with anti-oestrogens. Although ER positive tumours have a 5-10% 
better chance of disease free survival, it is important to note that around 30% of 
ER positive tumours do not respond to endocrine therapy (Jordan, 1995).  
 
Progesterone receptor [PR] status often correlates with ER status. However, 
tumours which are both ER and PR have a better prognosis than those which are 
only ER positive. The newer biological marker being increasingly measured, 
particularly in younger women with breast cancer, is the Her-2 receptor, also 
called c-erb-B2 (Mosselman et al., 1996). The HER2 (human epidermal growth 
factor receptor 2) gene is part of a family of genes that play roles in regulating cell 
growth. A fraction of breast cancers, as part of their development, undergo gene 
amplification. Instead of having two gene copies of the HER2 gene in a normal 
cell, there are multiple copies. As a result, there is far more expression of the 
HER2 protein on the cell surface, resulting in aberrant cell growth regulation. 
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Tumours are faster growing, more aggressive and less sensitive to chemotherapy 
and hormone therapy. 
It is universally recognised that breast cancer patients with the same stage of 
disease can have a markedly different response to treatment and hence to the final 
outcome. The strongest predictors for metastases (for example, lymph node status 
and histological grade) fail to classify accurately breast tumours according to their 
clinical behaviour. Chemotherapy or hormonal therapy reduces the risk of distant 
metastases by approximately one-third; however, 70–80% of patients receiving 
this treatment would have survived without it. 
Recent advances have focussed around Gene Expression Profiling, initially known 
as the 70 Gene Amsterdam Signature (Mook et al., 2007). The intention was to 
develop a gene expression signature that would enable characterisation of those 
patients with early breast cancer who were either at high risk or at low risk of 
recurrence. This would then enable more individualized treatment by a process of 
risk stratification. 
To date, the earlier signatures of breast cancer gene expression did not allow for 
patient-tailored therapy strategies. More recently, DNA microarray analysis has 
been performed on primary breast tumours of young patients, and applied 
supervised classification to identify a gene expression signature strongly predictive 
of a short interval to distant metastases ('poor prognosis' signature) in patients who 
were lymph node negative (van de Vijver et al., 2002). In addition, researchers 
established a signature that identifies tumours of BRCA1 carriers. The poor 
prognosis signature consists of genes regulating cell cycle, invasion, metastasis and 
angiogenesis. This gene expression profile will outperform all currently used 
clinical parameters in predicting disease outcome. These studies and their results 
provide a strategy to select patients who would benefit from adjuvant therapy. 
There are currently 2 commercially available Gene Expression Profiling Kits: 
MammaPrint (Agendia Inc., Irvine, California) and Oncotype DX (Genomic 
Health, Redwood, California). MammaPrint was developed on 10 year outcome 
data from an untreated breast cancer patient population, thereby ensuring the 
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validity of the results regardless of the ultimate treatment regimen selected (van 't 
Veer et al., 2002). Additionally, both oestrogen receptor positive and negative 
patients were included in this evaluation. 
Initially, an unbiased genome-wide approach, in which all 25,000 genes in the 
human genome were evaluated to isolate the 231 most prognostic breast cancer-
specific genes. 70 critical genes were shown to best correlate with the likelihood 
of distant recurrence using two-dimensional cluster analysis followed by a leave-
one-out cross validation procedure. These were selected for the Gene Expression 
profile. These 70 genes affect all steps known to be important for metastasis 
alluded to in the aforementioned discussion, including cell cycle regulation, 
angiogenesis, invasion, cell migration and signal transduction. When a Gene 
expression profile is generated, it enables classification of a tumour as either high 
or low risk. When this is used in conjunction with other risk factors, it helps 
identify patients who will benefit from adjuvant therapy. Compared to the 
standard risk assessment factors described above, MammaPrint significantly 
reduces the number of patients traditionally classified with a poor prognosis. 
Simultaneously it helps identify those patients who may be at increased risk of 
recurrence despite their clinico-pathologic findings. Because gene expression 
profiling actually analyzes the gene activity of the tumour itself, individual 
treatments can be tailored to patients. This results in improved patient compliance 
and reduced adverse effects, the net result being an improvement in patient quality 
of life outcomes (Buyse et al., 2006). 
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Figure 1. 5 Gene Expression profiling: Adapted from 
(http://biomedicalcomputationreview.org/) 
 
 
1.5 Treatment 
Treatment overview 
The Multidisciplinary Team approach to the management of Breast Cancer has 
revolutionised the approach to the treatment. The biological spectrum of the 
disease is incredibly wide, and treatment options and recommendations depend on 
several factors, including: 
• The stage and grade of the tumour 
• The tumour’s hormone receptor status (ER, PR) and HER2 status 
• The patient’s age, general health, and preferences 
• The patient’s menopausal status 
• The presence of known mutations in inherited breast cancer genes (BRCA1 or 
BRCA2) 
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1.5.1 Surgery 
There has been a cascade of growth in the knowledge guiding the care patients 
with this widely prevalent disease since the observations in the 1800’s that surgery 
could help improve the quality of patients with breast cancer. In its evolution from 
Halsted to Fisher, surgery continues to be a mainstay of treatment in breast 
oncology. However, there has always been a difference of opinion with regards to 
breast cancer being a systemic or local disease at inception. Halsted advocated the 
Radical Mastectomy in an attempt to gain loco-regional control, reducing his local 
recurrence rate to 6% (Ghossain and Ghossain, 2009). In recent years, it has been 
suggested that local therapy is ineffective in reducing breast cancer mortality. This 
viewpoint has been championed by Fisher, who maintains that "because operable 
breast cancer is a systemic disease involving a complex spectrum of host-tumor 
interrelations, local-regional therapy is unlikely to affect survival" (Fisher, 1996). 
Recently, results from large trials such as National Surgical Adjuvant Breast 
Project-04 (NSABP-04) and King's/Cambridge trials showed that leaving the axilla 
untreated in patients having primary breast cancer has no impact on survival 
(Fisher et al., 1985, Baum et al., 1980). Thus, the axilla does not seem to serve as a 
nidus for further spread of the cancer, as suggested by Halsted. Additionally, the 
NSABP-06 randomized patients to lumpectomy, lumpectomy with radiotherapy, or 
mastectomy and showed that there was an increased risk of local recurrence in the 
group treated with lumpectomy alone but no difference in survival between the 
three groups (Fisher et al., 1995). This indicated that the extent of the mastectomy 
does not influence survival, a conclusion that was inconsistent with the Halstedian 
view of breast cancer as a locally progressive disease. 
In keeping with the history of evolution of breast cancer as a disease, the notion of 
breast cancer being a systemic disease at presentation is not universally accepted. 
Indeed, Hellman argues that "persistent disease, locally or regionally, may give rise 
to distant metastases and, therefore, in contrast to the systemic theory, locoregional 
therapy is important” (Hellman, 1994). The initial results of the breast cancer 
screening trials seem to lend weight to the argument of Hellman and others and, at 
least partially, refute the systemic hypothesis. If breast cancer is indeed systemic at 
onset, then one can argue that the early diagnosis and timely extirpation of the 
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primary tumor should have no impact on mortality. Yet, in stark contrast to this, a 
meta-analysis of eight randomized controlled trials and four case-control studies 
has shown that breast cancer screening reduces mortality by 30% in women older 
than the age of 50 (Kerlikowske et al., 1995). Thus, controversy surrounding the 
impact of local therapy on mortality centers on whether breast cancer is viewed as 
a systemic or locoregional disease. This debate has been the subject of intense 
speculation for more than 2000 years, and ongoing research will, no doubt, add 
weightage to both sides of the argument. 
Surgery remains vital in the management of this disease and is vibrantly in 
evolution. The newer developments have increasingly brought about less invasive 
procedures and more creative reconstructive techniques. The primary aim of 
surgery is the removal of tumour and surrounding tissue during an operation. 
Surgery is also used to examine the nearby axillary lymph nodes. In general terms, 
the smaller the tumour, the more surgical options a patient has, with the option to 
perform breast conserving surgery (BCS). Of vital importance in BCS is the 
margin status, as this has prognostic implications for all patients treated for 
invasive breast cancer. There exists no consensus on what constitutes a negative 
margin. As per NICE guideline CG-80, for ductal carcinoma in situ, a minimum 
of 2 mm radial margin of excision is acceptable (http://www.nice.org.uk/CG80, 
2009). A recent meta-analysis on margins in early stage breast carcinoma treated 
with BCS concluded that “increasing the threshold distance for declaring negative 
margins is weakly associated with reduced odds of local recurrence; however 
adjustment for covariates (adjuvant therapy) removes the significance of this 
effect. Adoption of wider margins, relative to narrower widths, for declaring 
negative margins is unlikely to have a substantial additional benefit for long-term 
local control in breast conserving therapy” (Houssami et al., 2010).   
The types of surgery include the following: 
• Wide Local Excision 
• Partial or segmental mastectomy or quadrantectomy 
• Total Mastectomy 
• Modified Radical Mastectomy 
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• Radical Mastectomy 
•  Breast Reconstruction 
Wide Local Excision 
The cancerous area and a surrounding margin of normal tissue is removed. A 
second incision may be made in order to remove the lymph nodes. This treatment 
aims to maintain a normal breast appearance when the surgery is over. 
After the wide local excision, a course of radiation therapy is usually used to treat 
the remaining breast tissue. The majority of women who have small, early-stage 
breast cancers are excellent candidates for this treatment approach. 
Partial or Segmental Mastectomy or Quadrentectomy 
During a partial or segmental mastectomy or quadrantectomy, more breast tissue 
is removed than with a wide local excision. As the name suggests, a segment or a 
quadrant of the breast is removed. The cancerous area and a surrounding margin 
of normal tissue are removed. Radiation therapy is usually given after surgery. 
Simple Mastectomy 
With a simple mastectomy, the entire breast is removed, but no lymph nodes are 
removed. Simple mastectomy is most frequently used to prevent new cancer from 
developing or when the cancer does not go to the lymph nodes. This procedure is 
usually performed to treat in-situ or stage IA breast cancers. 
Modified Radical Mastectomy 
A Modified Radical Mastectomy is a procedure in which the entire breast is 
removed, including the skin, nipple, areola and most of the axillary lymph nodes, 
but sparing the pectoralis major. This procedure is usually recommended in 
patients who have multicentric disease, prior radiation therapy to the breast or 
chest wall, inflammatory breast cancer, or positive margins after repeat re-
excision. 
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Radical Mastectomy 
Also referred to as Halsted’s procedure, removes all of the breast tissue including 
the nipple, areola, lymph nodes and the underlying chest wall muscles. This 
procedure is rarely performed today as the Modified Radical Mastectomy has 
proved to be equally effective and less disfiguring. It is now only performed when 
the cancer has invaded the pectoralis muscle beneath the breast tissue. 
Breast Reconstruction 
Breast reconstruction is an operation to create a breast shape to match the 
remaining breast and regain symmetry following mastectomy. In line with 
guidance issued by NICE in 2002, breast reconstruction should be discussed with 
all patients who require a mastectomy. This message has been reinforced by the 
Association of Breast Surgeons and the British Association of Plastic 
Reconstructive and Aesthetic Surgeons in their Guidelines for best practice, 
Oncoplastic Breast Reconstruction (www.bapras.org.uk, 2012). 
Reconstruction may be performed either at the same time as the initial 
mastectomy or at a later stage. The decision for immediate reconstruction versus 
delayed reconstruction will depend on a number of clinical issues (adjuvant 
treatment plans) as well as patient choice. There are different techniques used to 
reconstruct a breast which include either implant-only reconstruction or 
‘autologous’ reconstruction using the patient’s own tissue or a combination of 
both these methods.  
In a huge undertaking, the United Kingdom National Mastectomy and Breast 
Reconstuction Audit (NMBRA) prospectively evaluated data between January 
2008 and March 2009. It looked primarily at complications and patient reported 
outcomes from data submitted from more than 200 centres. Nearly 17000 women 
underwent mastectomy, with 21% undergoing immediate reconstruction, and 11% 
having delayed reconstruction. The results from the audit- gleaned from 
questionnaires completed at baseline, 3 and 18 months-found that patients who 
chose delayed reconstruction were happier with their outcome (Thiruchelvam et 
al., 2013). 
 40 
Management of the Axilla 
Axillary dissection was first advocated as part of the treatment of invasive breast 
cancer in the 18th century by Heister (Meyer et al., 1984). This is a surgical 
procedure that incises the axilla to identify, examine, or remove lymph nodes. 
Axillary dissection has been the standard technique used in the staging and 
treatment of the axilla in breast cancer. Axillary lymph node status is a significant 
prognostic pathologic variable in patients with operable primary breast cancer, and 
it remains the most powerful predictor of recurrence and survival. 
Over the last century, there has been a significant evolution in the management of 
the axilla in breast cancer patients. Prognostically important information is 
derived from the status of the axillary nodes. As opposed to Halsted’s beliefs, we 
now know that occult systemic metastases and tumour biology rather than surgical 
clearance of the axilla determine long-term survival after breast cancer treatment. 
The individual patient’s clinical stage, patient and tumour characteristics, and 
treatment preferences should determine the management of the axilla.  
With the understanding that breast cancer does not always spread sequentially 
from the breast to successive axillary lymph node levels, to distant sites, emerged 
an increased emphasis on systemic therapy and a focus towards less radical 
therapy in the axilla. The National Surgical Adjuvant Breast and Bowel (NSABP) 
B-04 trial-a prospective, randomised controlled trial- was pivotal in the trend 
toward individualised management of the axilla in women with breast cancer. The 
three arms of this study compared (1) radical mastectomy to (2) simple 
mastectomy with chest wall and axillary nodal radiation to (3) simple mastectomy 
alone. The ground breaking conclusions were that there was no significant 
difference in overall or disease-free survival among the 3 treatment arms at any 
point up to 25 years of follow-up. While the local and regional recurrence rate was 
highest in those who underwent total mastectomy alone (13 %), the local regional 
recurrence rate in the radical mastectomy group (9%) was not much  lower, and 
was  lowest of all in those who underwent total mastectomy with axillary 
irradiation (5 %), i.e., no axillary surgery (Fisher, 1977). 
 
 41 
The National Surgical Adjuvant Breast Project B-04 trial concluded that axillary 
dissection has no effect on survival, and this has influenced thinking about the role 
and benefits of this procedure. However, other studies provided substantial 
evidence that axillary dissection provides excellent local control of disease in the 
axilla, with a local recurrence rate of 2% or less (Veronesi et al., 1998, Cabanes et 
al., 1992) which may lead to improved overall survival (Diab et al., 1998, Haffty 
et al., 1997). 
Axillary dissection should be reserved for patients with proven axillary disease 
preoperatively or with a positive sentinel node biopsy. Axillary dissection is only 
therapeutic in patients who are node positive. Therefore, performing axillary 
dissection in all patients would lead to overtreatment of a large proportion of 
patients who are node negative. The anatomic disruption caused by axillary 
dissection may result in lymphoedema, nerve injury, and shoulder dysfunction, 
which compromise functionality and quality of life. The introduction of sentinel-
node biopsy has enabled us to establish the status of the axilla with considerably 
less morbidity for patients when compared with complete axillary dissection. 
Sentinel Lymph Node Biopsy (SLNB) 
In 1992, Morton -working with cutaneous melanoma- described the technique of 
sentinel node localisation, based on the notion that the first lymph node draining 
the primary tumour reflects the status of the regional lymph node basin (Morton et 
al., 1992). In 1994, Giuliano et al. reported on the feasibility of lymphatic 
mapping and sentinel node biopsy (SNB). In this study with no prior technique 
established, SNB had a positive predictive value of 96 % and false negative rate of 
11.9 % (Giuliano et al., 1994). Further studies further confirmed the applicability 
of SNB using a variety of techniques: subareolar (Kern, 1999), peritumoral 
(Klimberg et al., 1999), or intradermal injection (Povoski et al., 2006) using blue 
dye  alone, blue dye in combination with technetium- 99 m labelled sulfur colloid, 
or radiolabelled colloid alone. Among inexperienced surgeons and others, the 
highest success rates with SNB are achieved when both blue dye and technetium-
99 m labelled sulfur colloid are used together (Rodier et al., 2007). Irrespective of 
the technique used, between 1 and 3 lymph nodes are usually removed during 
SNB. The Axillary Mapping Against Nodal Axillary Clearance (ALMANAC) 
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study found that 99.6 % of lymph node metastases were identified within the first 
4 sentinel nodes removed (Goyal et al., 2005). 
The Sentinel Lymph node (SLN) technique is based on the observation that 
tumour cells metastasize to one or a few lymph nodes before involving other 
lymph nodes. In patients with clinically node negative breast cancer, SLNB 
identifies patients without axillary node involvement, thereby obviating the 
need for more extensive surgery (Mabry and Giuliano, 2007). A systematic 
review, performed by the American Society of Clinical Oncology expert 
guidelines panel, included 69 eligible trials of SLND in early stage breast 
cancer, representing 8059 patients (Lyman et al., 2005). The study concluded that 
SNB is an appropriate initial alternative to routine staging Axillary Lymph Node 
Dissection (ALND) for patients with early-stage breast cancer with clinically 
negative axillary nodes. Completion ALND remains the standard treatment for 
patients with axillary metastases identified on SNB. Appropriately identified 
patients with negative results of SNB, when done under the direction of an 
experienced surgeon, need not have completion ALND. 
Traditionally, patients with involved nodes have been offered further therapy, 
either by subsequent complete axillary dissection or axillary radiotherapy. There 
is an increased awareness that there exists a cohort of patients whose risk of 
having residual lymph node metastases is so small that they can be spared axillary 
clearance or completion axillary lymph node dissection. In light of this, a number 
of algorithms have been developed, and these continue to be refined in light of 
new evidence. Significant among these is the Z0011 study (Giuliano et al., 2011) 
which has challenged the need for axillary dissection in patients with one or two 
positive sentinel lymph nodes.  This study -on patients who had breast-conserving 
surgery and on sentinel node biopsy had one or two positive nodes- randomised 
them to either axillary dissection or no subsequent axillary surgery. All patients 
had whole-breast radiotherapy and 58% in both arms had adjuvant chemotherapy, 
47% in both arms had hormonal adjuvant therapy. Local recurrence and overall 
survival at a median of 6.3 years were not significantly different. 
Similar findings were reported in the IBC SG23-01 trial (Galimberti et al., 2013). 
This multi-centered randomised controlled trial looked to see if patients with 
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micro-metastatic disease (less than or equal to 2mm) might be over treated if 
subjected to axillary dissection. The 5 year disease free survival – which was the 
primary endpoint - was 87.8% in the group without axillary dissection, and 84.4% 
in the group with axillary dissection. This suggests that axillary dissection, and its 
attendant morbidity, could be avoided in patients with early breast cancer and 
limited sentinel lymph node involvement. 
This lack of benefit of axillary clearance in such patients raises questions about 
the routine use of intraoperative node assessment. After Z11 and SG23-01, new 
algorithms need to be developed to ensure that there is consistency of axillary 
node management between units in patients with disease that would have made 
them eligible for entry into Z11. The available current evidence cannot support 
routine axillary dissection for all patients with positive axillary nodes. 
1.5.2 Radiation Therapy 
Post-operative radiotherapy following breast conserving surgery or mastectomy 
has been shown to reduce the risk of loco regional recurrence. Randomised 
Clinical trials in Canada and the Netherlands have also shown that post 
mastectomy radiotherapy has a beneficial effect on survival (Ragaz et al., 1997, 
Overgaard, 1999). 
Traditionally, standard schedules of curative radiotherapy for a wide range of 
cancers deliver multiple small daily doses, called “fractions”. These are gentler 
on healthy tissues than they are on the cancer. However, if cancer is to be 
eradicated a high total dose has to be delivered. This way of treating cancer 
certainly works for squamous carcinomas of the head and neck, lung and cervix. 
The development of a nationwide initiative called the Standardisation of Breast 
Radiotherapy (START) Trial-following on from the results of the Royal Marsden 
Hospital/Gloucestershire Oncology Centre Trial (RMH/GOC) - came about to 
adequately assess efﬁcacy as well as safety of the hypothesis that a lower total 
dose in fewer, larger fractions would be just as safe and effective in women with 
breast cancer.  
The Standardisation of Breast Radiotherapy (START) Trials led by Professors 
John Yarnold and Judith Bliss was the largest evaluation of radiotherapy 
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fractionation ever undertaken in women being treated for early breast cancer 
(Bentzen et al., 2008). In START-A, a regimen of 50 Gy in 25 fractions over 5 
weeks was compared with 41·6 Gy or 39 Gy in 13 fractions over 5 weeks. The use 
of two dose levels of the 13-fraction schedules made it possible to directly 
estimate the fractionation sensitivity of breast cancer and late- responding normal 
tissues. The START A trial was significant because it challenged the traditional 
view of radiotherapy treatment for early breast cancer. Meta–analysis of the data 
generated from START A in conjunction with data from the RMH/GOC trial 
suggests that continuing to use small fractions of ≤ 2.0 Gy spares the cancer as 
much as the healthy tissue, which is of no patient beneﬁt. Meanwhile, START B 
randomised patients with early breast cancer to receive either 50 Gy in 25 
fractions of 2.0 Gy over five weeks or 40 Gy in 15 fractions of 2.67 Gy over three 
weeks. The researchers concluded that, after surgery for early breast cancer, a 
radiotherapy schedule delivering 40 Gy in 15 fractions over three weeks seems to 
offer local-regional tumour control and rates of late normal tissue effects at least 
as good as the accepted international standard of 50 Gy in 25 fractions over five 
weeks.  
Since the START results were published in March 2008, this 3 week schedule has 
largely replaced the 5 week schedule. Ten years on the principal results of the 
START trials have now been reported and published recently (Haviland et al., 
2013). This long-term follow-up confirms that appropriately dosed hypo 
fractionated radiotherapy is safe and effective for patients with early breast cancer. 
The results support the continued use of 40 Gy in 15 fractions, which has already 
been adopted by most UK centres as the standard of care for women requiring 
adjuvant radiotherapy for invasive early breast cancer. Similar results were 
mirrored other studies; it has been shown that ten years after treatment, 
accelerated hypo fractionated whole breast irradiation was not inferior to standard 
radiation treatment in women who had undergone breast conserving surgery for 
invasive breast cancer with clear surgical margins and negative axillary nodes 
(Whelan et al., 2010). 
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1.5.3 Chemotherapy 
The use of cytotoxic drugs in the treatment of breast cancer has exponentially 
expanded since the first studies detailing the use of nitrogen mustard and folates 
as anticancer drugs. Evidence to support the use of adjuvant chemotherapy comes 
from the Early Breast Cancer Trialists Collaborative group (EBCTCG). The 
EBCTCG meta-analysis in 2011 suggested that there was a significant 
improvement in risk of recurrence, reduction of breast cancer mortality and 
reduction in overall mortality using either the cyclophosphamide-methotrexate-5 
fluorouracil (CMF) or anthracycline based regimens (Peto et al., 2012). 
It is important to note that there is no single standard adjuvant chemotherapy 
regimen in the treatment of breast cancer. This is because breast cancer is a 
phenotypically diverse and heterogeneous disease, composed of various biologic 
subtypes which have distinct responses to therapy. The regimen selected will take 
into account various tumour specifics such as tumour histology, expression of 
oestrogen and progesterone receptors, tumour size and nodal status. 
Neo adjuvant-or preoperative- therapy refers to the systemic treatment of breast 
cancer prior to definitive surgical therapy. Whereas the goal of all systemic 
therapy with non-metastatic invasive breast cancer is to reduce the risk of distant 
recurrence, the primary objective of neoadjuvant therapy is to improve surgical 
outcomes in patients where a primary surgical approach is not technically feasible 
or for patients with operable breast cancer who desire breast conservative surgery 
who would otherwise need a mastectomy, or where a partial mastectomy would 
leave them with a poor cosmetic result (Kaufmann et al., 2006, Gralow et al., 
2008). It is of critical importance that patients receiving neoadjuvant systemic 
therapy are followed up by clinical examination at regular intervals during 
treatment to ensure that there is no disease progression.  
Evidence in support of neo adjuvant chemotherapy (NACT) came initially from 
the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 trial. 
The two main findings in NSABP B-18 however were (1) no difference in overall 
survival and disease-free survival between pre- and postoperative chemotherapy; 
(2) patients achieving a pathologic complete response (pCR) had a superior 
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disease free survival (DFS) and overall survival (OS) compared to patients not 
achieving a pCR. Additionally, there was a trend in favour of neoadjuvant 
chemotherapy compared with adjuvant therapy for OS and DFS in women 
younger than 50 years (Rastogi et al., 2008). A meta-analysis by Mauri and 
colleagues of nine randomised studies comparing adjuvant with neoadjuvant 
therapy found no difference with regard to death, disease progression, or distant 
disease recurrence (Mauri et al., 2005). 
Compared to the classical adjuvant treatment, NACT offers several advantages. It 
provides an opportunity to monitor response during treatment and allows 
modification or discontinuation of treatment in case of non-responsiveness.  Even 
if an advantage by changing therapy has not yet been proven, it helps avoid the 
toxicity of an ineffective treatment. Unsurprisingly, the demonstration of 
treatment efficacy motivates patients to continue therapy despite toxicities. The 
rate of breast conservation can be increased, and in case of breast conserving 
therapy, the extent of surgery can be reduced. Importantly, primarily inoperable 
tumours can be downsized allowing a curative intervention.  The residual cancer 
burden (RCB) is a powerful prognostic marker, sometimes changing the initial 
prognostic profile. From an ongoing research perspective, in neoadjuvant trials 
predictive markers, tumour biology, mechanisms of resistance, and new treatment 
approaches can be investigated more rapidly and with fewer patients than in 
adjuvant studies. 
Currently, interest is increasing in a new design of trial: the so-called window-of-
opportunity trial. In this case, a short course of targeted therapy is administered 
prior to surgical resection or prior to standard therapy. The endpoint of such a 
trial is not necessarily response rates, but changes of biological markers, for 
example, for proliferation or apoptosis. The purpose of Window trials could be to 
prove the expected mechanism of action, to identify tumour resistance and 
sensitivity, or to establish a “biologically effective” dose of the investigated 
targeted agent. A hypothesis-generating trial like this was done with metformin in 
operable breast cancer, where metformin was given twice daily for a median of 
18 days prior to surgery. The proliferation biomarker Ki-67 staining in invasive 
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tumour tissue decreased significantly and TUNEL staining increased (Niraula et 
al., 2012). 
The POETIC (Perioperative Endocrine Therapy for Individualising Care) trial is 
based on the hypothesis championed by Fisher that endocrine therapy given 
before primary therapy for breast cancer might improve outcomes. This is the 
primary end point of the study. In this trial, postmenopausal patients with ER 
positive tumours are randomised to a non-steroidal aromatase inhibitor (either 
letrozole or anastrozole) or to no treatment for two weeks before and for two 
weeks after excision. The overexpression of human epidermal growth factor 
receptor type 2 (HER2, also called ErbB-2, was first described more than two 
decades ago (Schechter et al., 1984) and occurs in 20 to 30% of invasive breast 
carcinomas. Broadly speaking, patients with breast-cancer cells that overexpress 
HER2 have decreased overall survival, and may respond differently to a variety of 
chemotherapeutic and hormonal agents (Albanell et al., 1996, Ellis et al., 2001). 
This underlies the principle behind strategies targeting HER2, recognising its 
importance in breast cancer. The humanized monoclonal antibody trastuzumab 
(Herceptin, Genentech) is one such medication. 
Trastuzumab binds to the extracellular juxta-membrane domain of HER2 and 
inhibits the proliferation and survival of HER2-dependent tumours. An 
intracellular tyrosine kinase domain exists for HER2. Phosphorylation of the 
tyrosine kinase domain by means of homodimerization or heterodimerization 
induces both cell proliferation and survival signalling. Cleavage of the 
extracellular domain of HER2 leaves a membrane-bound phosphorylated p95, 
which can activate signal-transduction pathways. Binding of trastuzumab to a 
juxta-membrane domain of HER2 reduces shedding of the extracellular domain, 
thereby reducing p95. Trastuzumab may reduce HER2 signalling by physically 
inhibiting either homodimerization or heterodimerization. It is postulated that 
trastuzumab may recruit Fc-competent immune effector cells and the other 
components of antibody-dependent cell-mediated cytotoxicity, leading to tumour-
cell death. Additionally, mechanisms such as receptor down-regulation through 
endocytosis have been proposed (Hudis, 2007). 
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The study by Slamon et al  was a pivotal randomized clinical trial that showed the 
activity of trastuzumab in combination with chemotherapy with previously 
untreated, HER2-positive, metastatic breast cancer (Slamon et al., 2001). Patients 
received first-line chemotherapy either alone or in combination with the antibody. 
The primary end point of this study was time to disease progression, which 
increased from 4.6 months among patients who received chemotherapy alone to 
7.4 months among those who received trastuzumab in addition to chemotherapy. 
The study also demonstrated an improved overall survival. Subsequently the 
results from the M77001 group- a randomized trial of docetaxel alone or with 
trastuzumab had similar results (Marty et al., 2005). 
Trastuzumab should be considered for the management of all metastatic breast 
cancers with HER2 overexpression. Patients with moderate- to high-risk, rapidly 
progressive cancer characterized by a negative hormone-receptor status, 
extensive visceral metastases, and a short disease-free interval (typically less than 
2 years) are candidates for immediate treatment with chemotherapy and should 
receive the appropriate agent (or agents) with trastuzumab. The chemotherapy 
regimen of choice should be predicated on the patient’s previous adjuvant therapy 
and coexisting conditions. Trastuzumab does not appear to diminish the quality 
of life in patients who are already receiving concurrent chemotherapy, although 
prospective quality-of-life testing is not available. It is not clear whether antibody 
therapy should precede, follow, or be added to hormone therapy for the subgroup 
of patients with HER2-positive and hormone-receptor–positive disease. Since 
trastuzumab monotherapy appears to be effective for the treatment of metastatic 
breast cancer, its use as a single agent for newly discovered metastatic disease 
can be considered (Piccart, 2001). This strategy would delay the initiation of 
chemotherapy with its attendant side effects, possibly resulting in a better quality 
of life.  
Adjuvant Therapy for Early-Stage Breast Cancer A high rate of pCR has been 
demonstrated in patients with HER2 positive breast cancer treated with NACT, 
particularly tumours that are hormone-receptor negative, thus reflecting the 
aggressive nature of these tumours (Esserman et al., 2012). Significantly, a pCR 
after chemotherapy followed by HER2 directed therapy is associated with 
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recurrence and survival advantages. A recent meta-analysis confirmed an 
increased event free survival in HER 2 positive patients who achieved a pCR 
with NACT who concurrently received chemotherapy (Cortazar et al., 2012). The 
TECHNO (Taxol, Epirubicin, Cyclophosphamide, Herceptin Neoadjuvant) trial 
confirmed a pCR of 39 percent, and showed an improvement in both event free 
and overall survival in patients who demonstrated a pCR (Untch et al., 2011). 
1.5.4 Endocrine therapy 
Breast tissue possesses high affinity protein receptors for oestrogen and 
progesterone and these play key roles in both normal breast cancer development 
and in breast cancer progression. These receptor proteins become activated when 
they are occupied by their specific hormone ligand. Activation of oestrogen 
receptor leads to the induction of numerous cellular genes, including those that 
may encode critical enzymes and secrete peptide growth factors. 
 
Surgically induced menopause in the form of bilateral oophorectomy became the 
first effective means to control advanced breast cancer. Over the last two decades, 
endocrine organ ablation has been replaced by hormonal therapy-either 
antioestrogen therapy or by the use of aromatase inhibitors. Breast cancers are 
said to be hormone sensitive if they are either Oestrogen receptor positive (ER+), 
or progesterone receptor positive (PR+). This is assessed by measuring the ER and 
PR receptor status of the tumour using immunohistochemistry. In general, if 
greater than 10% of tumour cells stain positive for the relevant nuclear receptor, 
the assay is reported as positive, and a response to hormonal therapy is likely. The 
majority of human breast cancer contain hormonal receptor either oestrogen or 
progesterone, or both. Approximately 75% of primary breast cancers express ER, 
and over half of this also expresses PR (McGuire, 1978). The presence of 
oestrogen receptor predicts the clinical response to all types of endocrine therapies 
including the hormonal therapy. Treatment aimed at inhibiting the action of ER 
represents a highly successful example of targeted therapy for clinical breast 
cancer (Campos and Winer, 2003). 
ER positive tumours have a 5-10% better chance of survival than ER negative 
tumours. Patients with ER positive tumours respond well to anti-oestrogen 
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treatment with better clinical outcome. Patients with both ER and PR positive 
have slightly better prognosis than those with ER positive but PR negative 
tumours. The introduction of Tamoxifen and aromatase inhibitors has simplified 
hormonal manipulation for the treatment of breast cancers. 
Tamoxifen is an oestrogen receptor modulator and acts as a weak agonist/ 
antagonist. It acts a competitive antagonist of oestrogen activity in breast tissue, 
but not in the other oestrogen sensitive tissues. Tamoxifen reduces the risk of local 
recurrence by 25% and mortality by 17 percent in ER/PR positive breast cancer 
patients. Aromatase inhibitors are agents that block the conversion of 
androstenedione to oestrone by inhibiting the aromatase enzyme. There is 
emerging evidence that aromatase inhibitors are at least as effective as tamoxifen 
in reducing the risk of recurrence in breast cancer with less adverse effects. 
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, a double-blind 
randomised trial, compared the aromatase inhibitor anastrozole alone with 
tamoxifen alone, or the combination, as adjuvant therapy with localised breast 
cancer (Baum et al., 2002). Initial analyses of the ATAC trial at 33 and 47 months 
of median follow-up showed that anastrozole signiﬁcantly prolonged disease-free 
survival and time-to-recurrence, and reduced the incidence of contralateral breast 
cancer, compared with tamoxifen. The combination treatment arm was closed 
because of low efﬁcacy demonstrated at the above analyses. The conclusion from 
the trial was that anastrozole should be the preferred initial treatment for 
postmenopausal women with localised hormone-receptor-positive breast cancer. 
More recently, the long-term outcomes in the Arimidex, Tamoxifen, Alone or in 
Combination (ATAC) trial that compares anastrozole with tamoxifen were 
published (Forbes et al., 2008). At a median follow-up of 100 months, disease free 
survival, time to recurrence, time to distant recurrence, and the incidence of 
contralateral breast cancer were improved significantly in the hormone-receptor-
positive populations. Fracture rates were higher in patients receiving anastrozole 
than in those receiving tamoxifen during active treatment, but were not different 
after treatment was completed. No significant difference in risk of cardiovascular 
morbidity or mortality between anastrozole and tamoxifen treatment groups was 
noted. The study establishes clearly the long-term efficacy of anastrozole 
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compared with tamoxifen as initial adjuvant treatment for postmenopausal women 
with hormone-sensitive, early breast cancer. Additionally, it shows a safety profile 
and provides statistically significant evidence of a larger carryover effect after 5 
years of adjuvant treatment with anastrozole compared with tamoxifen. 
1.6 Tumour Metastasis 
1.6.1 The biology of tumour metastasis 
Metastasis refers to the transfer of disease from one part of the body to another. In 
cancer, metastasis is the migration of cancer cells from the original tumour site 
through the blood and lymph vessels to produce cancers in other tissues. 
Metastasis is also the term used for a secondary cancer growing at a distant body 
site. 
Metastasis is responsible for a large proportion of deaths related to cancer. With 
the growth of the primary tumour, cells begin to dissociate and travel around the 
body to settle at different sites. They then begin to replicate to form 
“secondaries”. The process may then repeat itself, and this is referred to as the 
“metastatic cascade”. There are various steps involved in this process (Jiang and 
Mansel, 2000). For dissemination to occur, there must be a reduction in the 
adhesiveness between the cells and also between the cells and the extra cellular 
matrix. Subsequent migration of the cells through the matrix and vessel walls 
allows for dissemination via either the haematogenous or lymphatic routes. This 
migration is dependent upon stable adherence and traction produced by adhesion 
molecules and their ligands. Arrest in distant sites may be facilitated by the 
adherence of tumour cells to lymphoid cells/platelets resulting in larger 
aggregates composed of many cells, thereby increasing the likelihood of 
entrapment in capillaries (Gasic et al., 1973). Survival and growth of the 
metastatic deposit will only occur if there is a suitable environment [nutrients and 
extracellular matrix substrate]. 
Cell adhesion is mediated by several families of cell-surface expressed molecules 
including the cadherins (Stappert and Kemler, 1993), immunoglobulin super 
family (Simmons, 1999), selectins (Tedder et al., 1993) and the integrins (Hynes, 
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1992). Metastasis is also dependant on the development of new blood vessels 
[angiogenesis] and new lymphatics [lymphangiogenesis]. When a primary tumour 
first appears, proliferation of cancer cells may be balanced by apoptosis 
[programmed cell death] so that the tumour may remain static for years (Hanahan 
and Folkman, 1996). This gives rise to another concept of micrometastatic 
disease; i.e., an initial high rate of apoptosis in the metastatic deposits may help 
keep them clinically undetectable for years, until the rate of apoptosis is exceeded 
by the rate of proliferation. This phenomenon of tumour dormancy may depend on 
the rate-limiting role of neo-vascularisation (Holmgren, 1996). 
In breast cancer, the initial period of tumour dormancy is usually long, and 
tumours are usually in the in situ stage when neo-vascularisation occurs (Brem et 
al., 1978). Clinical and pathological observations have for long suggested that the 
most common pathway for initial dissemination is via the lymphatics, with 
patterns of spread via afferent vessels following natural routes of lymph drainage 
(Cotran et al., 1999).  
1.6.2 Breast Cancer Metastasis 
Metastatic disease in breast cancer is common. At the time of initial diagnosis, 7% 
of women with breast cancer will have metastases (Mansel et al., 2000). Even in 
women with no evident metastases who undergo potentially curative surgery, 20-
30% will develop widespread metastases (Wingo et al., 1995); this figure rises to 
50-60% in those with positive axillary nodes. This has led some to argue that 
breast cancer is a systemic disease at the time of presentation (Fisher, 1977). 
The rate of tumour growth decreases as the size of the tumour increases (DeWys, 
1972). This is because large tumours have inhibiting factors, which result in a 
larger number of cells being in a dormant state. This applies to both primaries and 
secondaries. An extension of this theory is that the rate of growth of the 
metastases may increase when the primary is removed. This would make 
metastatic foci particularly vulnerable to chemotherapy after surgery for the 
primary. An alternative theory is that of micrometastatic dormancy, whereby the 
rate of growth decreases after the initial growth spurt, only to be followed by a 
delayed increase in the rate of growth (Demicheli et al., 1997). The trigger for 
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this sudden activity has not been established yet. Recently, it has been shown that 
angiogenesis may act as one such trigger and that VEGF and VEGF-1 may be 
key to this event (Kaplan et al., 2005).The VEGF serum level may be one of the 
important indexes for monitoring forecast of therapy efficiency and disease 
prognosis. The late occurrence of local recurrence and distant metastases lends 
credence to this theory. 
W.S. Halsted was the first to put forward his theory of the natural history of breast 
cancer. He suggested that the disease remains localised at its site of origin up-to 
the point when lymphatic invasion takes place and then it becomes loco-regional. 
After a further indeterminate interval, vascular invasion and dissemination occur, 
resulting in metastatic disease. This concept was the basis for Halsted’s radical 
mastectomy, as the chance of cure was thought to be better with the amount of 
tissue excised. Fisher’s hypothesis proposed that breast cancer is a systemic 
disease by the time of clinical presentation (Fisher, 1977). Controversially, it was 
proposed that a delay in diagnosis of breast cancer does not reduce survival 
(Fisher, 1988). The first tumour cell multiplies exponentially with time: 1-2-4-
816-32 and so forth. For a tumour to reach a size of 1cm3, it will consist of 109 
cells. According to the Gompertzian model, tumour growth over time follows a 
sigmoid curve (Demicheli et al., 1997). As the tumour grows, the doubling time 
increases and the growth fraction decrease. The maximum growth rate is at 
approximately one third of maximal tumour volume, and slows to a plateau near 
lethal tumour volume. When plotted as a growth curve, there exists an upper 
horizontal asymptote, which for human malignant tumours, is the upper limit that 
the cancer cannot exceed because the tumour burden has become lethal to the 
host. This limit is conceptualized as the “lethal burden”.  A 1cm or 1cm3 tumour 
has already undergone 30 doublings as compared to the lethal tumour burden of 
40 doublings (Khonji et al., 2000). Hence, it is argued that dissemination is likely 
to have already occurred. The failure of loco regional surgery to prevent 
metastasis is further evidence in support of this theory. Contrary to this, data from 
screened trials indicate a 30% decrease in mortality (Tabar et al., 1985). This 
suggests that surgery in such patients with impalpable cancers may remove the 
primary before any viable metastases have occurred. Continuing studies and 
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analysis of data from prospective screening should shed further light on this 
ongoing debate. 
Breast cancer shows a predilection to metastasise to bone, liver and lungs. Other 
sites are the brain, adrenal gland, ovaries, peritoneal cavity and thyroid. The bones 
are the most common site for metastases. The bony deposits cause an increase in 
osteoclastic activity-this is reflected as bony destruction and hypercalcaemia in 
10-15% of patients (Body, 1995). One theory postulated for this is the inherent 
capacity of the cancer cells themselves to cause bony destruction (Eilon and 
Mundy, 1978). Another theory suggests that the tumour cells produce a local 
peptide such as parathyroid hormone related peptide [PTHrP] (Vargas et al., 
1992). In its turn, PTHrP is regulated by one of the growth factors TGF-P 
[Transforming Growth Factor P] (Yin and Stull, 1999). Liver is the second most 
common site to be affected by breast cancer metastases, and its involvement 
usually carries a poor prognosis. Local growth factors have been implicated in 
liver involvement; these are believed to induce preferential growth of these 
tumour cells. Insulin-like growth factor has been shown to be present in liver. This 
itself is a growth and motility factor for breast cancer (Nicolson, 1993). 
1.6.3 Tumour Suppressor Genes 
A tumour suppressor gene or antioncogene is a gene that protects a cell from one 
step on the path to cancer. When this gene is mutated to cause a loss or reduction 
in its function, the cell can progress to cancer, usually in combination with other 
genetic changes. 
Cell growth is regulated by tumour suppressor genes which are normally present 
within the cell (Cuschieri et al., 2002). They exert control by slowing down the 
cell cycle and encode protein products that normally exert a negative control on 
cellular growth and division, or are integrally involved in apoptosis. Damage to 
these genes may result in unregulated cell growth or failure to direct DNA 
damaged cells to a programmed death. Thereby, a loss, inactivation or 
malfunction of tumour suppressor genes may result in uncontrolled cell 
proliferation. The net result is a dysregulated proliferation of cloned cells with 
nuclear damage, possibly resulting in neoplastic growth (Cuschieri et al., 2002).  
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Unlike oncogenes, tumour suppressor genes generally follow the 'two hit 
hypothesis,' which implies that both alleles that code for a particular gene must be 
affected before an effect is manifested. This is due to the fact that if only one 
allele for the gene is damaged, the second can still produce the correct protein. In 
other words, tumour suppressors are usually recessive as opposed to oncogenes 
which are generally dominant. The two hit hypothesis was first proposed for cases 
of retinoblastoma (Knudson, 1971). It was observed that the age of onset of 
retinoblastoma followed 2nd-order kinetics, implying that two independent 
genetic events were necessary. He recognized that this was consistent with a 
recessive mutation involving a single gene, but requiring biallelic mutation. 
Oncogene mutations, in contrast, generally involve a single allele because they are 
gain of function mutations. There are notable exceptions to the 'two hit' rule for 
tumour suppressors, such as certain mutations in the p53 gene product. p53 
mutations can function as a 'dominant negative', meaning that a mutated p53 
protein can prevent the function of normal protein from the un-mutated allele. 
Other tumour suppressor genes which are exceptions to the 'two-hit' rule are those 
which exhibit haploinsufficiency. An example of this is the p27Kip1 cell cycle 
inhibitor, in which mutation of a single allele causes increased carcinogen 
susceptibility (Fero et al., 1998). 
Tumour suppressor genes, or more precisely, the proteins for which they code, 
either have a dampening or repressive effect on the regulation of the cell cycle or 
promote apoptosis, and sometimes do both. The functions of tumour suppressor 
proteins fall into several categories including the following: 
1. Repression of genes that are essential for the continuing of the cell 
cycle. If these genes are not expressed, the cell cycle will not continue, 
effectively inhibiting cell division (Sherr, 1994). 
2. Coupling the cell cycle to DNA damage. As long as there is damaged 
DNA in the cell, it should not divide. If the damage can be repaired, the cell cycle 
can continue. 
3. If the damage cannot be repaired, the cell should initiate apoptosis 
(programmed cell death) to remove the threat it poses for the greater good of the 
organism. 
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4. Some proteins involved in cell adhesion prevent tumour cells from 
dispersing, block loss of contact inhibition, and inhibit metastasis. These proteins 
are known as metastasis suppressors (Hirohashi and Kanai, 2003, Yoshida et al., 
2000).  
The first tumour suppressor protein discovered was the Retinoblastoma protein 
(pRb) in human retinoblastoma. The retinoblastoma gene-which codes the pRb- 
can be considered a model for a class of recessive human cancer genes that have 
a "suppressor" or "regulatory" function. The loss or inactivation of both alleles 
of this gene appears to be a primary mechanism in the development of 
retinoblastoma (Murphree and Benedict, 1984). However, recent evidence has 
also postulated pRb as a tumour survival factor (Goodrich, 2006). Another 
important tumour suppressor is the p53 tumour suppressor protein encoded by the 
TP53 gene. p53 is a nuclear phosphoprotein transcription factor that controls the 
expression of proteins involved in the cell cycle. Mutations in p53 are found in a 
large percentage of human cancers (Morris and Wood, 2000). Homozygous loss 
of p53 is found in 70% of colon cancers, 30-50% of breast cancers and 50% of 
lung cancers. Mutated p53 is also involved in the pathophysiology of leukaemias, 
lymphomas, sarcomas and neurogenic tumours. Abnormalities of the p53 gene 
can be inherited in Li-Fraumeni syndrome (LFS), which increases the risk of 
developing various types of cancers. Cells with p53 mutations are more resistant 
to the effects of radiation and chemotherapy since producing lethal abnormalities 
in DNA is a critical step in their mode of action  (Morris and Wood, 2000).  
Abnormalities in BCL2 and Bax also occur in some tumour types and cause many 
of the same effects as p53 mutations. The restoration of wild type p53 expression 
in cells with defective p53 is sufficient to cause growth arrest or even apoptosis. 
There is mounting evidence that expression of wild type p53 in established 
tumours can induce apoptosis in vivo as well. This has been accomplished using 
retroviral, adenoviral and non viral gene delivery vectors expressing wild-type 
p53. The induction of apoptosis by certain chemotherapeutic agents may require 
the presence of wild type p53. Transfection of the wild-type p53 gene into a 
variety of human tumor cells was shown in the late 1980s and early 1990s to 
induce apoptosis and growth inhibition. In lymphoma models, when this approach 
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was used, the activity of p53 that induced antitumor activity was seen to be 
apoptosis (Ventura et al., 2007) whereas, in a liver tumor model, the p53 activity 
induced a senescent phenotype. Dramatically, this was shown to then induce an 
intense macrophage response that cleared the tumor (Xue et al., 2007).  
 
In 1996, Jack Roth was credited with being the first to attempt p53 gene therapy in 
man. He used direct injection of a retroviral vector expressing human p53 under 
the control of an actin promoter to treat non-small cell lung carcinoma (Roth et al., 
1996). Later studies identified adenovirus vectors expressing human full length 
wild-type p53 as suitable for large scale production.  In vitro studies showed that 
such viruses could infect and inhibit the growth of many different human tumor 
cells. Remarkably such viruses did not seem to induce apoptosis or senescence in 
normal tissues or cells. The virus effectively results in a burst of p53 production in 
the infected cell and remarkably normal cells can recover from this process. In 
many tumor cells, however, an irreversible induction of apoptosis takes place 
Thus p53 gene therapy has an excellent safety profile. 
 
Unlike retrovirus based systems that have proved to be oncogenic in man, the 
adenovirus delivery system has the advantage that it does not result in integration 
of the vector DNA into the host cell. Using this initial approach has enabled many 
thousands of patients in clinical trials primarily in China and the United States to 
receive p53-based gene therapies. In 2003, the use of adenovirus gene therapy for 
the treatment of head and neck cancer in combination with radiation was approved 
in China and the product “Gendicine” has been marketed since then. An analysis 
of 2500 patients treated by Gendicine has been published by Shi and Zheng 
(2009). 
  
 
1.7 Wiskott Aldrich Syndrome and Wiskott Aldrich Syndrome Protein 
The Wiskott Aldrich Syndrome [WAS], also known as Wiskott Aldrich Huntley 
syndrome and as Werlhof’s disease bears the name of the two authors who are 
credited with first describing it-Wiskott in Germany in 1937 and Aldrich in the 
United States in 1954 (Aldrich et al., 1954). In its original descriptions, it was 
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characterised by an illness manifesting as eczema, thrombocytopenia, 
susceptibility to infection, and bloody diarrhoea, with death usually occurring 
before ten years of age. Subsequently, the main causes for death were found to be 
infection and bleeding, and also due to the development of malignancies such as 
lymphoreticular tumours, leukaemia and reticuloendothelial system malignancies 
(Bensen et al., 1996, Perry et al., 1980, Sullivan et al., 1994). Currently, it is 
characterised by the triad of recurrent bacterial infections of the sinuses and lungs, 
eczema that appears atopic in nature, and a bleeding tendency due to 
thrombocytopenia and platelet dysfunction. Less than a third has the full triad, but 
90% present with the features of thrombocytopenia. Around 5% have only 
infection and 20% only haematological problems. 
Two major complexes that are linked to the NWASP family, namely the ERM 
family and Rho GTPases are aberrantly expressed in human breast cancer (Jiang 
et al, 2003, Martin et al, 2003). Additionally, X chromosome inactivation which 
silences gene expression from one of the two X chromosomes in females is 
usually random. This skewed (nonrandom) pattern of inactivation has been 
observed in a wide range of neoplastic tissues (Busque and Gilliland, 1998) and 
can be considered a consequence of the monoclonal origin of the neoplasia. 
Nonrandom X-chromosome inactivation is frequent in the somatic tissue of 
females with invasive ovarian cancer and BRCA1 mutations (Buller et al., 1999).  
Individuals with WAS are known to have skewed X inactivation. In addition, they 
are more susceptible to certain forms of malignancy, primarily haematological. 
This formed the basis of the present study, which sought to elucidate the role of 
WAS protein in human breast cancer, and to determine if it plays a role as a 
tumour suppressor 
The incidence is about 1 in 250 000 male births or 1 in 500,000 births overall. 
Being X linked and potentially lethal, it would be expected to be almost invariably 
in males, but females have been reported in the literature. Females usually have no 
family history and so are presumable spontaneous mutations. In some cases, 
females have been shown to have non-random inactivation of the X chromosome 
bearing the functional WAS allele. The WAS gene is located on the Xp 11.22-23 
region of the X chromosome and is linked as an X linked recessive condition. 
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However, recently, an apparently autosomal dominant form has been described, 
but this is in 3 generations of a single family. A male child of a female carrier has 
a 50% chance of being affected, a female child has a 50% chance of being a 
carrier (Schwaber and Rosen, 1990). 
The discovery of the causative gene has revealed a spectrum of clinical types 
demonstrating a strong genotype/phenotype correlation. Four clinical phenotypes 
are seen: classic WAS, X-linked thrombocytopenia, intermittent 
thrombocytopenia and neutropenia (Notarangelo et al., 2008). The discovery of 
unique functional domains of the WAS gene has been instrumental in defining 
mechanisms that control activation of NWASP. Long term follow up of patients 
undergoing haematopoietic stem cell transplantation has led to important 
modifications of the procedure. Studies of NWASP deficient cell lines and 
NWASP knockout mice have paved the way for possible gene therapy. 
The exact function of NWASP is not fully elucidated, but it seems to function as a 
bridge between signalling and movement of the actin filaments in the 
cytoskeleton. It has been recognized that the Wiskott-Aldrich protein provides a 
link between CDC42, a member of the Rho family of GTPases and the actin 
cytoskeleton (Symons et al., 1996). Moreover, T lymphocytes of affected males 
with WAS exhibit a severe disturbance of the actin cytoskeleton, suggesting that 
the WAS protein may regulate its organization. The WAS protein interacting with 
GTP-dependent CDC42 was detected in cell lysates in transient transfections, and 
with purified recombinant proteins (Kolluri et al., 1996), indicating that the WAS 
protein could function as a signal transduction adaptor downstream of CDC42, 
and that cells with 5 domains involved in signaling, cell cytoskeletal abnormalities 
may result from a defect in CDC42 signaling. 
NWASP has been found to be a key regulator of actin polymerization in 
hematopoietic motility/migration, in immune synapse formation and in facilitating 
the nuclear translocation of nuclear factor kappaB (Ochs and Thrasher, 2006, 
Welch and Mullins, 2002). Mutations are located throughout the gene and either 
inhibit or dysregulate normal NWASP function. Classic WAS occurs when 
NWASP is absent, X-linked thrombocytopenia is present when mutated NWASP 
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is expressed, and X-linked neutropenia occurs when mis-sense mutations occur in 
the CDC42-binding site (Notarangelo et al., 2002, Ochs and Thrasher, 2006). 
Miki et al. first described a 65 kDa protein from brain that bound to the SH3 
domains of Ash/Grb2 (Miki et al., 1996). The sequence was homologous to 
Wiskott-Aldrich syndrome protein (WASP) and was designated NWASP [neural-
WASP]. NWASP has several functional motifs including a pleckstrin homology 
(PH) domain and a cofilin-homologous region through which NWASP 
depolymerises actin filaments. NWASP stimulated actin assembly is responsible 
for membrane ruffling (Zalevsky et al., 2001), a process that actively involves the 
cytoskeletal associated protein family ERM [ezrin-moesin-radixin] (Bretscher, 
1989, Hiscox and Jiang, 1999), and is, therefore, important for changes in cell 
motility and spread. NWASP activity is regulated by an intra-molecular 
interaction that is assuaged following concomitant binding of CDC42-GTP to the 
CDC42/Rac interactive binding (CRIB) domain and PtdIns (4,5)P2 to the 
polybasic region (Kovacs et al., 2006). It was also reported that two major 
complexes that are linked to the NWASP family, namely the ERM family and 
RhoGTPases are aberrantly expressed in human breast cancer (Jiang et al., 2003, 
Martin et al., 2003). Many different mutations have been identified (Kwan et al., 
1995) that interfere with the protein binding to CDC42 and Rac GTPases, among 
other binding partners, most of which are involved in the regulation of the actin 
cytoskeleton of lymphocytes (Snapper and Rosen, 1999). This ultra-structural 
component of cellular architecture is involved fundamentally in intracellular and 
cell substrate interactions and signalling via its role in cell morphology and 
movement. The actin cytoskeleton is responsible for cellular functions such as 
growth, endocytosis, exocytosis, and cytokinesis. 
There are several proteins that regulate dynamic actin remodelling in response to 
membrane signalling (Yin and Stull, 1999) of actin assembly. Actin filament 
growth occurs by rapid monomer addition (polymerisation) to the barbed leading 
end of a nucleated site. Nucleation, the rate-limiting step, is stimulated by a 
complex of actin-related protein Arp2/3 and NWASP. CDC42 GTPase also 
interacts with NWASP to increase this nucleation. Next, gelsolin (activated by 
Ca++) severs actin filaments to create barbed ends, but then must be uncapped 
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from the filament by phosphatidylinositol 4, 5-bisphosphonate and Rac to proceed 
with polymerization. NWASP also interacts with Rac and, thus, is involved in 
regulation of this process at multiple interrelated sites. WAS neutrophils have 
been reported to manifest abnormal NADPH autofluorescence, indicating 
defective intracellular energy flux. Presumably, NWASP mutations interfere with 
the proper signalling and growth of cells of the haematopoietic lineage, resulting 
in the platelet and immune defects observed clinically, although the exact 
mechanisms and defective pathways remain largely unknown. 
Recently published research demonstrates that the CDC42-NWASP interaction is 
necessary for certain chemo attractant-induced T-cell chemotaxis (Haddad et al., 
2001). Further studies have now demonstrated abnormal migration and motility in 
multiple key cellular components of the immune system [specifically, dendritic 
cells and neutrophils, as well as both B and T lymphocytes] (Snapper et al., 2005, 
Westerberg et al., 2005). With regard to NWASP-deficient neutrophil adhesion and 
migration abnormalities, this may be caused by profound defects in clustering β-2 
integrins (Zhang et al., 2006). Also of note, CD43 (a major T-cell 
sialoglycoprotein) is located on microvilli; disruption of NWASP regulation of 
cytoskeletal structure may be the cause of the CD43 defects often observed in 
patients with WAS (Remold-O'Donnell and Rosen, 1990). NWASP may also 
have a role in transcriptional signalling and regulation of NK cells, independent 
of its functions in cytoskeletal actin polymerisation (Zhang et al., 2006). 
Studies of genotype-phenotype correlation in WAS and closely related conditions, 
with detailed analyses of NWASP expression, have now linked absent NWASP 
expression to classic WAS, mutant NWASP expression to X-linked 
thrombocytopenia, and NWASP with missense mutations at the CDC42-binding 
site to X-linked neutropenia (Notarangelo and Mori, 2005, Ochs and Thrasher, 
2006). Extensive study is also underway to further identify and characterize 
important NWASP-associated proteins, such as NWASP-interacting protein 
[WIP] (Anton and Jones, 2006, de la Fuente et al., 2007, Konno et al., 2007) and 
several Wiskott-Aldrich syndrome proteins verprolin homologous [WAVE] 
(Soderling and Scott, 2006, Takenawa and Suetsugu, 2007). 
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1.8 Aims of the Study  
1. The primary aim of this study was to elucidate the role that Wiskott Aldrich 
Syndrome protein and its encoding NWASP gene may have in determining the 
behaviour of breast cancer cells, and, therefore, on the outcome and prognosis of 
patients.  
2. To investigate the role that NWASP has on the in-vitro invasiveness and 
migratory capacity of breast cancer cells.  
3. To investigate the potential molecular impact that the NWASP may have on the 
aggressive nature of breast cancer cells, thereby elucidating its role as a potential 
tumour suppressor gene protein product.  
4. To support the hypothesis that the Wiskott Aldrich Syndrome gene acts as a 
potential tumour suppressor oncogene by correlating its expression pattern in a 
cohort of breast cancer and normal background tissue in relation to tumour 
histopathological grade, stage, nodal status and the clinical outcome of the patients. 
 
 
 
 
 
 
 
 
 
 
 
 63 
  
 
 
 
 
 
Chapter 2 
 
 
 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 64 
2.1 General materials and methods 
In this study, we have used Human Cell lines and Human Tissue. The details of 
cell lines and Tissue used are described in the sections that follow. 
It is well recognised that the use of human tissue in medical research is vital. It 
helps increase our understanding of human disease and also aids the development 
of new and improved treatments. The emphasis is on increased efficacy with 
reduced toxicity. In keeping with the Human Tissue Act (2004), the samples were 
anonymised to the researcher and Ethical approval was obtained. The licence for 
storage for the specified activity-research- was obtained for the designated 
premises –Metastases and Angiogenesis Research Laboratories. The Designated 
Individual for overall supervision is Professor Wen Jiang. 
The advantages of using cell lines in research are that they are easy to use, one can 
have an inexhaustible stock, and the scientific community accepts the results more 
readily, as cell lines have been considered the standard for similar research in the 
past. The criticism of using cell lines is that they may not be a true reflection of 
how the cells behave in vivo. 
The purpose of using primary cells is to attempt to correlate and validate the 
results obtained from using cell lines as they are a superior model of the in vivo 
situation. Put differently, the use of primary cells gives one a meaningful link to 
human disease. Therefore, although in vitro reproducible work is powerful and 
achievable in the context of a cell line, its link to in vivo pathophysiology is 
always open to debate. Therefore, the emphasis is on targeted validation in 
primary cells of results obtained in cell lines, which would suggest that the 
biology in question is relevant to human health and disease. 
2.1.1 Materials 
The PCR master-mix for routine PCR and custom-made hot start master-mix for 
quantitative PCR was bought from Abgene Biotechnologies (Surrey, U.K.). 
Conventional PCR primers were designed in our department using Beacon 
Designer software (Biosoft International, Pao Alto, California, USA), and 
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synthesised by Life Technologies. The agarose gel extraction kit was purchased 
from Qiagen (Crawley, U.K.).The Big Dye Terminator Cycle Sequencing Ready 
Reaction Kit was purchased from PE Applied Biosystems (California, USA). The 
TOPO TA Cloning kit (pcDNA3.1/TOPO-GFP, Invitrogen, Groningen, 
Netherlands) was used for cloning. The plasmid extraction kit (Qiafilter kit) was 
also purchased from Qiagen (Crawley, U.K.). RNA extraction and reverse 
transcription kits were purchased from Abgene. The Taqman Kit for quantitative 
PCR analysis of the house keeping gene, beta-actin, was purchased from Perkin 
Elmer (Warrington, U.K.). Phosphate buffer solution (Optimax buffer) was 
obtained from Biogenex and diluted as per instructions. Molecular biological 
grade agarose was purchased from Life Technologies. The AmplifluorTM probe 
system was purchased from Intergen (Oxford, U.K.). 
The ECISTM (Electrode Cell-substrate Impedance Sensing) technology was 
purchased from Applied Bio-Physics. The models purchased were the E9600 and 
1600R. This morphological bio-sensor has a wide variety of applications, and 
these as also its principle are dealt with in more detail in the following pages. 
2.2 Preparation of breast specimens and breast cell lines 
2.2.1 Preparation of breast specimens 
153 frozen archival breast samples from 127 patients were non consecutively 
collected [with approval from local Ethics committee] from the fresh frozen bank 
in the department of surgery, University Hospital of Wales, Cardiff, immediately 
after surgery and kept at –80º C until use. These were collected between June 
1991 and July 1997. 
The samples were predominantly breast cancers (n= 120) and background breast 
tissue (n= 33). All tissues were randomly numbered, and the details were only 
made known after all the analyses were completed. Frozen sections were cut from 
each specimen for histopathology and between 25 and 30 adjacent 10µm sections 
were subsequently used for RNA extraction. 
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Patients were routinely followed clinically after surgery. The median follow-up 
period was 72 months (April 2000). The clinical data including the prognostic 
factors of each sample was collected and the Nottingham Prognostic Index was 
calculated. The presence of tumour cells in the collected tissues was verified by 
examination of frozen sections using H & E staining by a consultant pathologist 
(Dr. Anthony Douglas-Jones, Cardiff University School of Medicine). The data 
concerning patient tissues is shown in Table 2.1. 
Table 2. 1 Clinical Information for breast tumour tissues analysed (n=120) 
 
2.2.2 Preparation of growth medium and maintenance of cell lines 
Cell lines differ from primary cells as they have escaped the Hayflick limit, which 
is defined as the number of times a normal human cell will divide until cell 
division stops and reach replicative senescence (Hayflick and Moorhead, 1961). 
Cell lines can be made immortalized by introduction of viral genes, such as the 
simian virus 40 (SV40) T antigen into the cells or by impairing cell-cycle 
checkpoint pathways (p53/p16/pRb), or by accentuating telomerase activity 
through expression of Telomerase Reverse Transcriptase protein (TERT) that can 
assist in an incessant cell division (Maqsood et al., 2013). Examples of 
immortalized cell lines are A549 cells, HeLa cells, HEK 293 cells, Jurkat, 3T3 
and Vero cells. Some species-like rodents-give rise to cell lines fairly easily, 
whereas other species do not. Establishment of cell lines from human tissue is 
difficult, and no cell lines have been established from avian tissues. Cell lines are 
invaluable for experiments in labs as they are always available to researchers as a 
Tissue Type Histological 
Grade (G) 
NPI TNM Histology Outcome 
                      n= 
Background       33 
Tumour           120 
n= 
1              23 
2              41  
3              56 
n= 
1       66 
2       38         
3       16                   
           n= 
1         69 
2        40         
3 7  
4           4          
               n= 
Ductal       88            
Lobular     14         
Other         18 
                            n= 
Disease Free            81           
Metastasis                7         
Local recurrence      5 
Died of breast 
Cancer                     20  
Died of unrelated  
cause                        7   
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product and hence do not require acquisition of tissue from a host [“harvesting”] 
when cells are required. 
In our study, we used the MDA-MB-231 breast cancer cell line. This cell line was 
originally isolated from a malignant pleural effusion of a 51 year old female 
Caucasian patient. This line was chosen because these cells have been shown to be 
a suitable transfection host. Additionally, the cells show an invasive phenotype in 
vitro. The cells show abundant activity in the chemotaxis and chemoinvasion 
assays. The wild type (WT) MDA-MB-231 breast cancer cells were maintained in 
ordinary DMEM/ F12 medium which was supplemented with 10% heat-
inactivated (55ºC for 30 minutes) foetal calf serum (PAA Laboratories, Austria), 
100 units/ml benzyl penicillin (Britannia Pharmaceuticals Ltd.), 100 µg/ml 
streptomycin (Sigma) and 1% non-essential amino acids (Gibco BRL). Foetal calf 
serum contains the necessary serum factors including growth factors. 
2.2.3 Growth and maintenance of breast cancer cell lines 
Breast cancer cell line MDA-MB-231 was purchased from the European 
Collection of Animal Cell Cultures (ECACC, Salisbury, England). The cells were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM/F12, Sigma) (pH 7.3) 
containing 2 mM L-glutamine and 4.5 mM NaHCO3. DMEM was then 
supplemented with 10% heat inactivated (55ºC for 30 minutes) foetal calf serum 
(PAA Laboratories, Austria), 100 units/ml of benzyl penicillin (Britannia 
Pharmaceuticals Ltd.) and 100 µg/ml streptomycin (Sigma). The other techniques 
used in the maintenance of this cell line were the same as described previously. 
The MDA-MB-231 NNWASP transfected breast cancer cells (MDA-MB-231 
NWASPexp) and the MDA-MB-231 cell that contained a control plasmid (MDA-
MB-231GFP) was cultured in G418 selection medium (with G418 final 
concentration at 50 µg/ml). Following successful selection of transfected cells, 
the cells were maintained in a maintenance medium (with G418 final 
concentration 5 µg/ml). G418 is derived from neomycin and is able to enter 
mammalian cells to cause toxicity. pcDNA3.1/TOPO vector has a neomycin 
resistance gene, the product of which provides a selection marker allowing this 
selection process, leading to a selective growth of NWASP transfected (or control 
 68 
plasmid transfected) MDA-MB-231 breast cancer cells. The cells were seeded 
into either 25 cm2 or 80 cm2 culture flasks (Cell Star, Germany) at cell densities 
of 1x105 cells/ml for routine subculture, or 5x105 cells for experimental work. All 
flasks were loosely capped to allow gaseous exchange and placed horizontally in 
an incubator (Flow Laboratories), and incubated at 37ºC with a humidified 
atmosphere of 5% CO2 (act as a buffer with NaHCO3) in air. The flasks were left 
until sub-confluent (2-3 days) for experimental work or fully confluent (7 days) 
for sub-culture 
2.2.4 Trypsinisation of cells and counting of cells 
The cell flasks were removed from the incubator, and the medium was aspirated. 
The flasks were rinsed once with 5ml of HBSS (Hanks Balanced Salt Solution), 
which contain 137 mM of NaCl; 8 mM Na2HPO4; 3 mM KCl; 1.5mM KH2PO4. 
This removes all possible traces of serum, which would inhibit the enzymatic 
action of trypsin. 1-2 ml of trypsin / EDTA (ratio of 1:5 in HBSS buffer) was 
added, and the flask was incubated at 37ºC for 2-3 minutes to allow for cell 
detachment. The content of the flask was then transferred into a universal 
container (Sterilin, UK) and centrifuged at 1600 rpm for 5 minutes. The 
supernatant fluid was aspirated leaving clumps of cells at the bottom of the 
container. The cell pellets were re-suspended in 5 ml of DMEM. Cell counts were 
performed using an improved Neubauer haemocytometer counting chamber with 
an inverted microscope (Reichert, Austria) at 10X magnification. 
2.2.5 Storage of breast cancer cell lines 
The cells were re-suspended at a cell density of 1 x 106 cells/ml in supplemented 
medium containing 10% w/v dimethylsulphoxide (DMSO; Fisons, UK). The latter 
enabled the cells to freeze at a steady slow pace, avoiding damage to the cells. 1 ml 
aliquots of cell suspension were transferred into cryopreserve tubes (Nunclon) and 
frozen at -80º C before transferring them to liquid nitrogen (-196º C) until required. 
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2. 2.6 Re-suspension of frozen cells 
Resuscitation of the frozen cells was carried out by the initial removal of the cells 
from the liquid nitrogen store. Cells removed from the liquid nitrogen store were 
allowed to thaw rapidly by incubating in a water bath at 37ºC, and the cell 
suspension was transferred into a universal container with 2 ml of medium pre-
warmed to 37ºC. The cells were incubated at 37ºC for 10 minutes, centrifuged at 
1,600 rpm for 5 minutes. The supernatant fluid was removed, and the cell pellet 
was re-suspended in 5ml of supplemented medium and washed twice to remove 
any possible trace of DMSO. Following the final wash, the cell pellet was re-
suspended in 5ml of supplemented medium, and the cell suspension transferred to 
a 25 cm2 tissue culture flask (Nunclon). The cells were incubated at 37ºC with a 
humidified atmosphere of 5% CO2 in the air to allow for cell growth. 
2.3 RNA extraction 
2.3.1 RNA extraction using guanidine thiocyanate method 
Ribonucleic acid (RNA) is present in the cytoplasm, nucleus and mitochondria of 
all eukaryotic cells. The subtype of RNA includes ribosomal RNA (rRNA), 
transfer RNA (tRNA) and messenger RNA (mRNA). Of these, mRNA is of 
particular interest because it carries genetic information for protein synthesis. It 
accounts for less than 2% of the total cellular RNA. The presence of specific 
mRNA sequence, therefore, gives a good indication of which protein is being 
produced by the cells at any given time. 
Certain cellular enzymes called RNases are capable of degrading RNA’s under 
specific conditions. This implies that special care needs to be exercised during the 
RNA extraction and isolation in order to minimise its degradation. Consequently, 
most methods of RNA extraction rely on the use of strong denaturants to inhibit 
the action of endogenous RNases. Guanidine, thiocyanate and chloride are the 
most effective protein denaturants and inhibitors of ribonucleases. 
The RNA was extracted by Guanidine thiocyanate method described by 
Chomczynski and Sacchi in 1987. This method is a rapid procedure of combining 
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acid guanidine thiocyanate-phenol-chloroform, in a single step RNA extraction. By 
this method, the extraction of RNA was set under acidic condition, so that DNA is 
selectively partitioned into the organic phase whilst the RNA remains in an aqueous 
phase. The concentration of RNA isolated can then be detected using an ultraviolet 
light spectrophotometer at a wavelength of A260nm/A280nm. Over 20 frozen 
sections from each tissue sample were homogenised in an RNA extraction solution 
using a hand held homogeniser to extract total RNA. The concentrations of RNA 
were quantified using a UV spectrophotometer. 
2.3.2 RNA extraction from cell lines and Breast tissues 
Cell lines were grown in an 80 cm2 tissue culture flasks (Nunclon) until they 
became 80-90% confluent. The culture medium was aspirated, and the monolayer 
of cells was detached using 2 ml of RNA isolation agent (Advanced 
Biotechnologies Ltd., UK) and a cell scraper. 1ml aliquots of the resultant 
homogenates were transferred into polypropylene tubes (Nunclon) and incubated 
on ice for 5 minutes to permit the complete dissolution of nucleoprotein 
complexes. 0.2 ml of chloroform was added to the homogenate and the mixture 
was shaken vigorously for 15 seconds. The mixture was incubated on ice for 5 
minutes, and then centrifuged at 4oC (Microfuge, Sanyo) at 13,000 rpm for 15 
minutes. The homogenate separates into 2 phases: the lower organic phase (and 
interphase) containing DNA and protein and the upper aqueous phase containing 
RNA. The aqueous fraction was aspirated carefully and transferred into a 
polypropylene tube taking care not to disturb the interphase. The volume of the 
aqueous phase is about 40-50 % of the total volume of the homogenate. An equal 
volume (about 0.5 ml) of isopropanol (Sigma) was added to the aqueous phase and 
incubated on ice for 10 minutes. The samples were then centrifuged at 13,000 rpm 
for 10 minutes. The RNA precipitates at the bottom of the tube as a white pellet. 
The supernatant fraction was discarded. The RNA pellet was washed twice using 
1ml of 75% ethanol, prepared with DEPC-treated water, and centrifuged for 5 
minutes at 7,500 rpm per wash. The RNA pellet was dried at 55ºC for 2 minutes 
in order to evaporate the ethanol and then dissolved in 50 µl of diethyl-
pyrocarbonate (DEPC; Sigma) treated water by vortexing for 1 minute. The 
concentration and the purity of RNA were determined by measuring its 
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absorbance at the wavelength A260nm/A280nm (WPA UV 1101, Biotech 
Photometer). The RNA was then stored at -80ºC until ready to use in reverse 
transcription. 
Extraction of RNA from breast tissues was similar to that from cell lines, except 
frozen sections were used. The frozen sections of the fresh frozen breast 
specimens (25-30 sections) were homogenised in 1 ml of ice-cold RNA reagent 
using a hand held homogeniser (Ultra-Turrax T8, IKA Labortechnik). The 
homogenate was put on ice for 5 minutes after homogenisation. The subsequent 
steps were exactly as described previously. 
2.4 Reverse transcription 
Reverse transcription leads to the production of complementary cDNA, which is a 
single copy of DNA complement to the mRNA used. Reverse transcription (RT) is 
often followed by polymerase chain reaction (PCR), and the 2 processes are 
commonly known together as RT-PCR. RT-PCR is a versatile technique, which 
requires only small amount of RNA and provides a highly sensitive and rapid 
method of detecting genetic sequences. Additionally, it provides an alternative 
approach for the analysis of mRNA; other methods include Northern blots, RNA 
dot blots and in situ hybridisation. Reverse transcription was performed on RNA 
samples derived from endothelial cells, fibroblasts, colon cancer cells, pancreatic 
cancer cells, breast cancer cells and breast cells using a reverse transcription kit 
(Advanced Biotechnologies Ltd., UK). 1 µg RNA was used to generate cDNA 
using a commercially available RT kit (AbGene Laboratories, Essex, England). 
The following components were mixed together in a PCR tube, gently centrifuged 
to collect the sample in the bottom of the tube and kept on ice until required. 
• 1 µg of RNA template (varying volume depending on RNA concentration) 
• 1 µl of anchored oligo dT primer at a concentration of 0.5 µg/ µl. 
• Sterile water to make the total volume of the mixture to 13 µl. 
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It was recommended that the sample be heated at 70ºC for 5 minutes to remove 
any secondary structure which may have interfered with the reverse transcription 
process. 
The following components were then added to the samples: 
• 4 µl of First Strand Synthesis buffer. 
• 2 µl of dNTP mix (5nM each of dATP, dTTP, dCTP and dGTP). 
• 1 µl of reverse transcriptase (RTase). 
The final volume of 20 µl was then mixed well and briefly centrifuged. It was 
then incubated at 47ºC for 30 minutes to enable cDNA synthesis to occur. This 
was followed by incubation at 75ºC for 10 minutes to inactivate the RTase. The 
cDNA samples were then ready for amplification by PCR. They were stored at -
80º C. 
2.5 Polymerase chain reaction (PCR) 
The polymerase chain reaction is a technique of enzymatically amplifying a nucleic 
acid target sequence. This PCR process, invented by Kary Mullis in 1984, has been 
automated for routine use in laboratories worldwide (Saiki et al., 1988). The 
necessary ingredients for PCR include a pair of primers that hybridize to the 
beginning and end of the target, the four dexoyribonucleate triphosphates (dNTPs) 
and a heat-stable DNA polymerase. 
PCR reaction is a cyclical repetition of three steps (Bartlett and Stirling, 2003) 
1. Strand separation or denaturation. The two strands of the parent DNA molecule 
are separated by heating the solution to 95° C for 15 seconds.  
2. Hybridisation or annealing of two oligonucleotide primers (one is a reverse 
primer, and the other is a forward primer). The solution is quickly cooled to 54°C 
to let the primers anneal to a DNA strand. One primer anneals to the 3´ end of the 
target (template strand) while the other primer anneals to the 3´ end of the 
complementary target strand. Then each copy will be the template in the next 
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cycle. This primer annealing also depends on the melting temperature of the 
primer. 
3. DNA synthesis or elongation or extension. The solution is then heated to 72°C 
which is the optimal temperature for Taq DNA polymerase. This is a polymerase 
from a thermophilic bacterium, Thermus aquaticus, which lives in hot springs. This 
polymerase elongates both primers in the direction of the target sequence because 
DNA synthesis is in the 5 ´to 3´ direction. DNA synthesis continues on both 
strands and continues beyond the target sequence.  
All 3 steps above are considered as one cycle; it takes about 25-40 cycles in order 
to amplify DNA template. The number of cycles depends on the amount of DNA 
available and how much PCR product you want to yield. To carry out the PCR we 
will use a thermal cycler that is programmed with a protocol that goes through all 
three steps of a cycle, for a total of 35 cycles. See PCR animation.2 short synthetic 
oligonucleotides that are used as primers for DNA synthesis that hybridise to 
complimentary strands flanking the target sequence. The primers are aligned with 
the 3' ends directed towards each other. Thus, repeated cycles of denaturation 
template, annealing of primers and extension by DNA polymerase results in 
amplification. A key development in PCR technology was the use of Taq 
polymerase, a thermostable enzyme from thermus aquaticus, a species of bacteria 
native to hot springs. The use of this enzyme means that fresh polymerase does not 
need to be added after each denaturation step, because the bacteria survive 
temperature over 95ºC. Another key development was the thermal cycler. This is a 
programmable machine that can rapidly change temperature and can incorporate up 
to 96 reactions simultaneously. The combination of thermal cycler and Taq 
polymerase together facilitates automation, which enables the reaction cycles to 
proceed without delay. Routine RT-PCR was carried out using a PCR master mix 
that was commercially available (AbGene). 
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 Figure 2.1: Steps in PCR (https://www.neb.com/applications/dna-amplification-and-pcr) 
2.5.1 Primer design 
Primers were designed using the Beacon Designer software (version 2, California, 
USA), to amplify regions of human NWASP that have no significant overlap with 
other known sequences and that the amplified products span over at least one 
intron. In this way if there were any genomic DNA contamination of the cDNA, 
significantly larger PCR products will be produced in addition to the desired 
product (which would not contain intron sequence, because this is not transferred 
into mRNA). During subsequent gel electrophoresis, two different sized bands 
would appear. Therefore, if only a single band was produced, no significant 
genomic DNA contamination had occurred. 
The primers used to amplify NWASP were:  
NWASPF1 (5´gagctggatgagaacaacac´3) and  
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NWASPZR (5´actgaacctgaccgtacaaaagaagtggcaggaagagt ´3). 
2.5.2 PCR Procedure 
Amplification of cDNA templates previously prepared (from cell lines and 
mammary tissues) was performed using PCR. The method of cDNA 
amplification is outlined below. 
• 1 µl of cDNA template, diluted as necessary. 
• 1 µl of forward primer (“F primer”) at a concentration of 10 picomoles (pmol). 
• 1 µl of reverse primer (“R primer”) at a concentration of 10 pmol. 
These components were added to the pre-aliquotted (22.5 µl) PCR Reddy-Load 
Master MixTM (0.625U of Taq DNA polymerase from Thermus Aquaticus, 75mM 
Tris-HCl (pH 8.8 at 25ºC); 20 mM (NH4)2SO4; 1.5 mM MgCl2; 0.01% (v/v) 
Tween 20; 0.2mM from each of the following: dATP, dCTP, dGTP and dTTP 
(Advanced Biotechnologies Ltd, UK) in PCR tubes. PCR reactions were 
performed using a Gene Amp PCR thermal cycler (9700 system from Perkin 
Elmer). 
Amplification of cDNA after the addition of appropriate primers was carried out 
according to the following conditions: 
30 – 40 cycles of the following series of steps:  
Denaturation: 94ºC for 15 – 30 seconds. 
Annealing: 50 - 60ºC for 20 – 40 seconds.  
Extension: 72ºC for 45 seconds. 
After completion of PCR, an electrophoresis apparatus for the separation of the 
PCR products was assembled according to the manufacturer’s instructions (Gibco 
BRL, Life Technologies, Inc). The PCR products were separated on either a 0.8% 
or 2% agarose gel. Products less than 500 base pairs were separated using 2% 
agarose gel, whereas larger products were separated using 0.8% agarose gel. To 
prepare a 2% agarose gel, 4 g of agarose powder (electrophoresis grade; Gibco 
BRL) were dissolved in 200 ml of TBE (Tris Borate Electrophoresis) buffer 
(0.45M Tris-HCL; 0.44M boric acid; 12.5 mM EDTA). The solution was boiled to 
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100º C until the agarose powder was completely dissolved to form a clear 
solution. 20 ml of hot agarose solution was then poured into a universal container 
(Sterilin, U.K.) and cooled to approximately 50-60ºC (which takes about 30 
seconds) before casting it into the mould. A well-forming comb was then inserted 
into the liquid gel and allowed to set at  room temperature. Once the gel had set, 
TBE buffer was carefully poured into the electrophoretic tank until it reached a 
level approximately 5 mm from the surface of the gel. The comb was then 
carefully removed from the gel, leaving a row of wells. 
A 100 base pair ladder or 1000 base pair ladder was prepared according to the 
manufacturer’s instructions (Pharmacia Biotech, USA). The smaller ladder was 
used for PCR products less than 500 base pairs, and vice-versa. An orange loading 
dye was added to the PCR products to enable otherwise clear solution to be 
visualised while they were being loaded into wells. 6 µl of ladder was loaded into 
the first well, avoiding air bubbles. The PCR products were loaded into the 
remaining wells similarly. 
A power pack (Gibco BRL, Life Technologies, Inc) was connected to the 
electrophoresis apparatus, and a voltage of 80-100V was applied constantly across 
the tank. Electrophoresis was continued until the stained samples had migrated one 
half to one third of the way down the agarose gel (depending on the size of the 
PCR products). Subsequently the PCR products were stained with ethidium 
bromide (10 mg/ml) for 10 minutes by continuous agitation to ensure even 
staining. On occasion, this was followed by de-staining in distilled water for one 
hour to reduce the non-specific background staining on the agarose gel itself. The 
PCR products were visualised using an ultraviolet transilluminator (UVP, Inc). 
Images from the gel were captured using a digital camera (UVI camera, UVI 
technologies, Cambridge, England) and printed using a thermal printer (Mitrumishi 
Thermal printer, Wolf Laboratories, England) as a record. 
2.6 Cloning of PCR products (TOPO TA Cloning) 
This enables a large number of copies of a given PCR products to be synthesised. 
TOPO TA cloning is a fast efficient method for Taq polymerase amplified PCR 
products to be inserted into plasmid vectors, for constitutive or induced expression  
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in the desired mammalian cell line. It has the advantage that no ligase, post-PCR 
procedures, or PCR primers containing specific sequences are required. 
2.6.1 Mechanism of TOPO TA cloning 
The cloning reaction involves the ligation of PCR products (insert) into the 
leading frame of the plasmid vector. The plasmid vector (PEF6/V5-His TOPO, 
Kit Invitrogen) is supplied linearised with: 
• Single 3' deoxythymidine (T) overhangs for TA cloning (TA refers to 
thymidine and adenosine) 
• Topoisomerase I covalently bound to the vector (activated vector) 
• An ampicillin resistant gene inserted under the downstream of the 
promoter Taq polymerase has a non-template dependent terminal transferase 
activity that adds to the single deoxyadenosine (A) to the 3' ends of the PCR 
products.  
The linearised vector has single overhanging 3' deoxythymidine residue. This 
allows PCR inserts to ligate efficiently with the vector. The topoisomerase from 
vaccinia virus recognises a specific sequence (CCCTT) on double stranded DNA 
and binds to this sequence. It cleaves the phosphodiester bond at the last T, 
allowing DNA to unwind. The energy-released from the broken phosphodiester 
bond is conserved by the formation of covalent bond between the 3' bond between 
the cleaved strand and a tyrosyl residue of the topoisomerase I. The phospho-
tyrosyl bond between the DNA and enzyme can subsequently be attacked by the 5' 
hydroxyl of the original cleaved strand, reversing the reaction and releasing 
topoisomerase. In simple words, topoisomerase I facilitates binding of the PCR 
product to the linear vector to produce a circular plasmid and speeds up the 
ligation process. 
2.6.2 TOPO cloning reaction 
The reaction was set up as follows: 
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• Fresh PCR products 2 µl 
• Sterile water 2 µl 
• PEF6/V5-His TOPO vector       1 µl 
The solution was incubated at room temperature for 5 minutes. During this period 
ligation of PCR products onto the reading frame of the plasmid vector occurs, and 
this forms a circular plasmid. The products are placed on ice. Immediately after 
ligation, the cloning reaction should be transformed into E. coli, otherwise the 
transformation efficiency may decrease. 
2.6.3 Transformation into E.coli 
Following ligation, the cloning reaction was transferred gently into a 100 μl 
aliquot of the competent E. coli (TOP10, Invitrogen). The suspension was placed 
on ice for 30 minutes. During this period, the plasmid was bound to the outside of 
the cell membrane. The cells were then heat shocked in a water bath, at 42°C for 
30 seconds, and then immediately placed back in ice for 2 minutes. The heat 
shock makes the cell membrane of the bacteria become porous, so that the plasmid 
could enter the bacteria. Next, 250 μl of SOC medium was added, and the cells 
were incubated for 1 hr at 37°C with shaking at 200 rpm for 30 minutes. The 
resultant transformation mix was then plated out onto pre-warmed LB (Luria-
Bertani) agar plates. 
2.6.4 LB (Luria-Bertani) medium and agar plates (1 L) 
The Luria-Bertani (LB plates) agar plates were created as follows: 10 g of 
tryptone, 5 g yeast extract and 10 g of NaCl was dissolved in 950 ml of de-
ionised water. The pH was adjusted to 7.0 with NaOH and made up to a volume 
of 1 L. The solution was autoclaved, cooled, and 50 µl of ampicillin was added. 
The solution can then be stored at room temperature. To prepare LB plates, 15 g 
of agar was added to 1 L of LB medium. The solution was autoclaved and 
allowed to cool. While cooling 50 µl of ampicillin was added and poured into 
petri dishes and allowed to set before being stored inverted in a refrigerator at 4ºC. 
The reason to add Ampicillin was to select out positive colonies containing the 
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plasmid. E. coli are normally sensitive to Ampicillin and would, therefore, not 
normally grow in this medium. However, the pcDNA3.1-TOPO plasmid contains 
an ampicillin resistant genetic sequence which confers resistance to this antibiotic 
and to any bacteria containing the plasmid. 
After the tubes containing the bacteria and the plasmids had been incubated, 100 
µl of the solution was evenly spread out on the LB agar/ampicillin plates using a 
sterile wire loop. These were incubated overnight at 37º C. 
2.6.5 Selection and analysis of colonies 
Following overnight incubation, the plate reveals a large number of bacterial 
colonies containing the plasmid vector. The plasmid vector encodes a gene to 
enable resistance to ampicillin and when transferred into the E. coli, confers this 
resistance to these cells. Selection occurs in the presence of antibiotic because 
cells without the plasmid vector will not survive. 
The next step is to establish which of these surviving cells containing the plasmid 
vector also has the insert incorporated and arranged in a correct position and 
direction. This was identified by PCR reaction of approximately 10 colonies. 
Individual colonies were examined by using a pipette tip touched against a 
labelled colony and then placed into the PCR reaction mix. The amplification of 
the desired sequence was achieved through the use of the forward primer for the 
plasmid and the reverse primer specific for the inserted PCR products. This 
ensures that the amplified products, at the expected size, are that of plasmid and 
insert in the correct position. These colonies are then ready for amplification. 
2.6.6 Amplification and purification of plasmid DNA 
The identified plasmid vector colony, with the appropriate vector and insert 
positioning, was then transferred aseptically into 2 ml of LB medium, containing 
ampicillin and incubated until culture grows to mid-log phase at 37°C in a rotary 
shaker. The resultant culture was then added into 100 ml of LB medium (with 
ampicillin) and incubated overnight at 37°C under rotation. This results in 
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amplification of recombinant plasmid within E. coli and is ready for extraction of 
plasmid DNA. 
The plasmid DNA was extracted from within the E. coli using plasmid 
purification kit (Filter Maxi System, Qiagen, West Sussex, UK) as outlined below: 
i. The bacterial cells were centrifuged at 6000g for 15 minutes. The 
supernatant medium was removed leaving a cell pellet at the bottom. The 
pellets were then resuspended in 0.3 ml of resuspension buffer, which 
contains RNase inhibitors. 
ii. The cells were then lysed by adding 0.3 ml of cell lysis buffer, gently mixed 
by inverting the solution 6 times to avoid shearing of genomic DNA. 
iii. Following 5 minutes incubation at room temperature, 0.3 ml of 
neutralisation buffer was added, mixed gently by inverting. The mixture 
was then incubated for 5 minutes on ice. This causes the solution to become 
cloudy and viscous. 
iv. The solution was centrifuged at 13,000 rpm for 10 minutes. 
v. A Qiagen-tip (filter column) was equilibrated by applying 1 ml of buffer 
QBT to filter the column and letting it drain by gravity flow. 
vi. The supernatant from the mixture that has been centrifuged was added to the 
filter column and let drained by gravity. The plasmid DNA binds to the ion-
exchange resin within the column. 
vii. To remove all contaminants from plasmid preparation, the resin is washed 
through with 1 ml of wash buffer (a medium salt buffer). This removes RNA, 
proteins, dyes and low molecular weight impurities. 
viii. The DNA was eluted from the resin by adding 0.8 ml of a high salt elution 
buffer and was collected in a microfuge tube. 
ix. The plasmid DNA was then desalted by isopropanol (0.5 ml) precipitation. 
The mixture was centrifuged at 13,000 rpm for 30 minutes followed by 
washing in 1 ml of 70% ethanol. This leaves a precipitate at the bottom of 
the tube, and the supernatant was carefully removed, without disturbing the 
pellet. 
x. Next, the plasmid DNA pellet was washed with 1 ml of 70% ethanol, air-
dried for 5 minutes leaving the tube in an incubator for 2-3 minutes. Finally, 
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it was resuspended in DEPC water. The plasmid DNA was quantified by 
using ultraviolet spectrometer and a small amount of DNA was run on 0.8% 
agarose gel to check the purity and the size of the plasmid. 
2.6.7 Transfection via electroporation into breast cancer cells 
Transfection of cultured breast cancer cells with plasmid DNA was done by 
electroporation technique using Easy Jet Plus system (Flowgen, Staffordshire, 
UK). A voltage of 450 volts was passed across the cells, producing small 
perforations in the cell wall. This allows the passage of plasmid DNA across cell 
membrane to be integrated into the cells. The procedure is described further: 
One small flask of culture mammalian cells was trypsinised, pelleted and re-
suspended in 0.8 ml of culture medium. 3 µg of plasmid DNA was added, and the 
mixture is left to stand for 2-5 minutes at room temperature. The mixture is then 
transferred into an electroporation cuvette (Euro Gentech, Southampton, UK) 
ready for electroporation. The cuvette is loaded into the electroporator and a pulse 
of 450 volts of electric current was passed through the cuvette. The reaction is 
then immediately transferred into 10 ml of pre-warmed culture medium and 
cultured in a small flask under usual incubation condition. 
2.6.8 Selection of plasmid positive cells 
The electroporated cells are grown in culture until they become semi confluent. At 
this stage selection procedure is used to remove cells that do not contain the 
plasmid insert. Selection of plasmid positive cells was done by using selection 
medium (containing G418 50 µg/ml final concentration) for cell culture. The 
antibiotic resistant gene in the plasmid allows selection of plasmid positive cancer 
cells, whereas the cells which do not contain the plasmid insert, are killed by the 
antibiotics and removed in the selection medium. After selection, the cells were 
transferred into a maintenance medium (containing G418 5 µg/ml final 
concentration). A portion of the selected cells were frozen and stored in liquid 
nitrogen, and a portion was used for verification of the success of transfection by 
way of RT-PCR. 
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2.7 Real-Time Quantitative Polymerase Chain Reaction (QPCR) 
QPCR was first developed in 1992. It is a method which allows PCR products to 
be detected as they accumulate after each heat cycle by measuring fluorescence as 
the reaction progresses. As the level of fluorescence – which is directly 
proportional to the PCR product yield – can be continuously monitored on a 
computer screen, the term “real-time” is used. 
There are 2 varieties of QPCR. The older method uses a fluorescent dye, SYBR 
green, which nonspecifically binds to double-stranded DNA during the synthesis 
stage of PCR. As the PCR progresses, more PCR product is produced, and as more 
SYBR green gets bound, increased fluorescence results. As the method is non-
specific, the dye tends to bind to contaminants that are amplified during PCR, 
including primer dimmers. The newer method of PCR which uses a “probe” is 
more specific and hence removes this drawback. The “probe” consists of a third 
oligonucleotide sequence, which contains a fluoroscopically – labelled base 
(Fluorophore) as well as a “quencher”. At the outset, the fluorophore and the 
quencher lie next to each other, so that there is no fluorescence (“quenched” state). 
During the annealing stage of PCR, the fluorophore and the quencher become 
separated as the oligonucleotide probe becomes incorporated. The resultant 
increase in fluorescence is machine read. As the probe is designed specifically for 
the PCR product, any contaminants in the reaction which may be amplified will 
not fluoresce. This increases the specificity of the system. There are four main 
types of probe in use, viz, TaqmanTM, Molecular BeaconTM, AmplifluorTM, and 
ScorpionTM. 
In the present study, we have employed a detection system known as Amplifor 
system, initially described by Nazarenko et al., (1997). The technology uses a 
fluorescent tagged probe that is complementary to a specific designed PCR primer 
(refers to as Z-primer here). The forward primer and the Z primer are specific to 
the target gene. However, to the 5’ end of the Z primer an additional sequence (Z 
sequence which is complimentary to the probe) was added. The Ampliflor system 
used here for quantisation requires a hot start Taq polymerase, dNTPs, salts and 
DNA template. A target specific forward primer, a target specific reverse Z primer 
which incorporates a unique Z sequence, and a universal primer that is linked to 
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the fluorophore FAM. The probe also has a stem sequence that is complementary 
to the Z primer sequence. 
There are 2 key components to most quantitative QPCR systems, namely, 
excitation and detection systems. The PCR system used in this study was the 
iCyclerTM by Bio-Rad (Camberley, UK). The two components work 
simultaneously whilst the thermocycler operates. The mechanics in the system 
include a cooling fan, a tungsten halogen lamp, an infrared absorbing heat filter, a 
filter wheel that is fitted with optical filters, and finally a dual mirror arrangement 
which allows all the reaction wells to be simultaneously illuminated. Usually there 
are 96 (8 rows x 12 columns) reaction wells. Light from the lamp passes through 
the heat filter and a pre-selected colour optical filter. The type of fluorophore used 
determines the colour. The light which is reflected onto the samples by a set of 
mirrors excites the fluorescent molecules that have become unquenched in each 
reaction well. Fluorescence is then recorded by the detection system. Primary 
components of the detection system include an emission filter wheel, and image 
intensifier, and a cooled detection camera. 
Measurement of QPCR products is achieved by either semi-quantitative or 
quantitative means. During the early cycles of qPCR, there is very little change in 
fluorescence level. This is because the PCR products should double with each 
cycle and hence accumulate exponentially. With the progress of the cycles, the 
number of products increases rapidly (exponential phase), and then plateaus off 
as the substrates are consumed. The exponential phase corresponds with the 
marked increase in fluorescence visible on the real-time apparatus. The point at 
which this begins is known as the “PCR threshold”, and is often arbitrarily 
defined (for interobserver consistency) as the point at which the fluorescence is a 
variable of a number of times (often 10-12) higher than the initial fluorescence. 
In semi-quantitative analysis, the number of cycles for the reaction to produce 
threshold fluorescence is recorded. For quantitative analysis, an internal standard 
of known concentration is used. This may be a single or double stranded DNA, 
and may either be an oligonucleotide sequence or a plasmid. (Quantisation of 
plasmids is usually more accurate. This is because they consist of 3-5 kilobases, 
and hence have a much larger molecular weight compared to oligonucleotides, 
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which are usually composed of 100-200 base pairs. Additionally, large quantities 
of plasmids can easily be cloned, whereas relatively small quantities of 
oligonucleotides are purchased (cost factors). The concentration of the standard 
has to be known. The real time QPCR is then performed using differing 
concentrations of the internal standards in some reactions and unknown samples 
in other reactions. At the end of the reactions, a logarithmic standard curve is 
produced. This plots the logarithm (base 10) of the initial concentration of the 
standards used (x-axis), against the threshold cycle number for that standard (y-
axis). Using the threshold cycles of the unknown samples, and the logarithmic 
standard curve, the initial concentration of the unknown samples can be 
calculated. 
The Amplifor Q-PCR reaction comprised:  
• 8 μl hot-start Q master mix 
• 1 μl of the forward primer at 10 pmol/μl 
• 1 μl of the reverse (z-sequence) at one tenth of the forward primer 
(1 pmol/μl) and the probe 
• 1 μl of the probe at 10 pmol/μl and 5 µl cDNA of test samples 
 
In each of the test plate, a serially diluted internal standard was included for 
calculation purpose (Jiang et al., 2003, Cunnick et al., 2001)  
2.8 Histology 
Histology is that branch of biology that studies the microscopic features of plants 
and animals. Medical Histology applies microscopy to the human body, 
elucidating the nature of its structural components, their interrelation, and their 
functions. 
A summary of steps involved are as follows: 
1. Fixation to prevent post-mortem decomposition, preserve 
structure, and intensify subsequent staining. 
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2. Embedding the tissue in a block of wax or plastic, or freezing of the 
material to a firm mass. 
3. Cutting of the embedded tissue into thin sections on a microtome; 
1-l50 microns (µm) thick for light microscopy (LM); 30-60 nanometres 
(nm) for electron microscopy (EM). 
4. Mounting of the section on a glass slide or metal grid. 
5. Staining of the section with one or more reagents, e.g., solutions of 
metallic salts, in one or more stages. 
6. For light microscopy, the removal of surplus stain and water, and 
steps involved in holding a thin glass cover slip to the section with a 
mounting medium . 
7. Observation and recording by means of the microscope and 
adjunct aids. 
2.8.1 Preparation of frozen section specimens from breast tissues 
A cryostat (Leica, Germany) was used to section specimens which were kept at -
40ºC for at least an hour prior to sectioning. The sample blocks were mounted in 
the following manner: Approximately 5 ml of mounting gel was applied to the top 
of a cryostat chuck and the specimen was placed on the gel. Following this, as 
aerosol freezing spray (“cooljet”) was sprayed onto the specimen to enable “rapid 
freezing” onto the chuck. The chuck and specimen were placed into the cryostat 
and secured. After discarding a few superficial sections, six 7 µm sections were 
taken and mounted onto electrostatic slides and air-dried. This was followed by 
obtaining a further 20 adjacent 10 µm sections. These were used for RNA 
extraction (see section 2.3.2). 
2.8.2 Haematoxylin and Eosin (H&E) staining of breast specimens 
The air-dried specimens (at least 20 minutes of air drying at room temperature) 
were placed in a phosphate buffer for 5 minutes. This was followed by washing in 
water for 2 minutes, and staining in Meyer’s haematoxylin for 1 minute. A further 
wash in tap water for 2 minutes was performed prior to staining with eosin for 20 
seconds. A final wash in water for 10 seconds was then administered. The 
specimens were then dehydrated with absolute methanol, cleared (i.e., wax 
 86 
removed) with xylene and mounted using a routine mounting medium and cover 
slip. The specimens were now ready for study under the light microscope. 
2.8.3 Histopathological assessment of H&E specimens 
Standard H and E [Haematoxylin and Eosin] stain was used for tissue staining. 
Haematoxylin can be thought of as a basic dye-it binds to acidic structures 
staining them blue to purple, hence the nucleus stains blue. Eosin, an acid aniline 
dye, binds to basic structures and stains them pink. 
A light microscope (Olympus) up to a magnification of 400 was used to study the 
specimens. No prior knowledge of the formal pathology reports was available; 
i.e., assessments were blind. Assessments were subsequently verified by a 
consultant histopathologist (Dr. Anthony Douglas Jones, Department of 
Pathology, University Hospital of Wales). Discrepancies in reporting were double 
checked. The approximate percentage of tumour compared to stromal content on 
the slide was noted (to the nearest 5%) in all cancer specimens, along with the 
grade and the type of tumour. Perusal of the notes of the patients enabled an 
accurate documentation of the size of the original tumour and the nodal status 
from the original histopathological reports. 
Frozen sections of the biopsies were allowed to reach room temperature and after 
the foil was removed were fixed in acetone (Fischer Scientific Ltd., 
Loughborough, UK) for 15 minutes. Excess acetone was removed by air-drying 
the sections for 10 minutes before being washed three times in BSS buffer for 
five minutes each time. Sections were then incubated at room temperature in a 
humid box with blocking solution which contains 10% normal horse serum (in 
BSS with 0.1% TWEEN20). Excess blocking serum was removed, and the 
working dilution of primary antibody (in BSS buffer with horse serum) was 
applied and the sections incubated for 30 minutes, followed by extensive washing 
(4 washes in excess amount of washing buffer, 300 ml for each washing). 
Antibody localisation was then identified by a standard streptavidin-biotin 
peroxidase technique using Vector Elite ABC Kit (Vector Laboratories®, 
Peterborough, UK). This involved incubating the sections with a relevant 
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biotinylated secondary antibody for 30 minutes. After washing, this was followed 
by incubation with the avidin-biotin complex (ABC) reagent provided in the kit 
for a further 30 minutes. The final reaction product was developed for 10 minutes 
with 3, 3’-diaminobenzidine (DAB) substrate (0.005%) serum (Dako Ltd.®, High 
Wycombe, UK). The sections were then rinsed in washing buffer, followed by tap 
water, and then counterstained with Ehrlich’s haematoxylin solution (Merck, 
Poole, UK) for 30 seconds, and then washed again in tap water for 5 minutes. 
Finally sections were dehydrated through a graded series of alcohol solutions 
(70% and pure ethanol twice) and Xylene twice (BDH-Merck, Poole, UK) for 5 
minutes in each and mounted in DPX medium (BDH-Merck, Poole, UK) before 
mounting under a cover slip. 
Positive staining was seen as a brown / black deposit and non-stained cells as blue 
counterstained nucleated cells with no associated brown DAB stain. Images were 
obtained from a digital camera. 
2.9 Biological assays 
2.9.1 In vitro Invasion assay 
The in vitro invasion assay used in this project is similar to those described by 
Albani and her colleagues (Albini et al., 1987). In this method, the cellular 
invasion through an artificial basement membrane (Matrigel) is measured to 
determine invasion promoting or inhibitory effects of a number of extracellular 
stimuli. 
The technique works upon the principle that a culture plate equipped with an 
insert has one end sealed with a polycarbonate membrane. The polycarbonate 
membrane has a pore size of 8 µm in diameter, which is large enough to allow 
cells to migrate through it. The surface of this membrane is then coated with 
Matrigel to form a thin layer of gel matrix. As the technique indicates the capacity 
of cells to penetrate through the gel matrix and porous membrane, it indicates the 
invasive capacity of the cell. The method used in this study is described below. 
Cell culture inserts (6.5 mm diameter polycarbonate filter) (Becton Dickinson 
Labware, Oxford, UK) were placed into a 24 well plate (Nunclon). To prevent 
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irreversible gelling of Matrigel, the following procedure was carried out. A stock 
solution of Matrigel was prepared at a concentration of 0.5 mg/ml in pre-cooled 
sterile water. 100 µl aliquots of-chilled cell culture inserts. Once the inserts had a 
thin even coating of Matrigel, they were incubated at room temperature to dry out 
the Matrigel. Prior to use, the Matrigel layers were re-hydrated by incubating at 
room temperature for 1 hour using 100 µl of culture medium. 
After membrane re-hydration, 30,000 cells are aliquoted into each insert 
with/without HGF (25 ng/ml). After 96-hour co-culture at 37ºC, non-invasive 
cells are removed from the inner chamber with a cotton swab. Invaded cells on the 
underside of the insert were then fixed in 4% formaldehyde for 10 minutes at 
room temperature. The cells were then washed twice with distilled water and 
stained with 0.5% crystal violet for 10 minutes at room temperature. Excess stain 
was removed by washing the cells with distilled water. The cells are then counted 
microscopically (20 fields/insert). 
2.9.2 Cell Growth assay 
The principle behind in vitro cell growth assay is based on the ability of a 
mitochondrial de-hydrogenase enzyme from viable cells to cleave the tetrazolium 
rings of the pale yellow MTT [3-(4,5 dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide] to form a dark blue formazan crystals which is 
largely impermeable to cell membranes, thus resulting in its accumulation within 
healthy cells. Solubilisation of the cells by the addition of a detergent results in the 
liberation of the crystals, which are solubilised. The number of surviving cells is 
directly proportional to the level of the formazan product created. The colour can 
then be quantified using a simple colorimetric assay. The cells were then seeded 
onto a 96 well plate (Nunc, Denmark) at a density of 7,000/well and incubated at 
37ºC for 72 hours. MTT was added in solution to the cells (200 µg/well) and 
incubated for 4 hours at 37ºC. The cells were then lysed with Triton (10%) and the 
intensity of the colour released was determined by a plate reader (Titertek 
Multiskan, Eflab, Finland). The number of cells was shown as absorbance units. 
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2.9.3 Cell Matrix Adhesion Assay 
Cell matrix adhesion is an essential initial step for cancer cell to metastasis. The in 
vitro cell-matrix adhesion assay shows the ability of the cells to adhere to the 
matrix protein and hence indirectly demonstrating their capability to metastasis. 
The method used in this study is described below. 
Matrigel (diluted with sterile water at 1:50 in ice) was added to 96-well plates at 
strength of 10 µg/well. The plate was incubated at 37ºC for 24 hours to allow 
binding of matrix protein to the surface of the well. The wells were dehydrated 
with 50 µl of culture medium. The cells were added at 1,000 cells/well and 
incubated at 37ºC for 40 minutes. During this period the cells with the ability to 
adhere, bind to the matrix protein in the well. The excess medium in the well was 
removed. The plates were then washed repeatedly with 5% sterile BSA (Balanced 
Salt Solution) containing NaCL-8 g, KCL-0.2 g, Na2HPO4-1.1 g and KH2PO4-0.2 
g in 1litre of distilled water. Each well was then stained with 100 µl of diluted 
(1:10 with culture medium) sterile MTT. The plate was then incubated at 37ºC for 
4 hours. Examination under microscope reveals bluish spiky cells. The number of 
attached cells can be determined directly by counting under microscope. 
Alternatively after removing the excess stain, the cells can be treated with 100 µl 
of 10% tritium and the intensity of the colour as determined by plate reader gives 
the load of cells in each well. 
2.9.4 Cytodex-2-bead motility assay 
Cells are pre-coated onto cytodex-2 carrier beads (Sigma) for 2 hours in complete 
medium. After the medium is aspirated, and the cells washed (X2 in complete 
medium), they are aliquoted into wells of a 96-well plate in triplicate (300 
µl/well). HGF (25 ng/ml) is added, and the cells are incubated over-night. The 
beads are washed off in medium, and the cells that have migrated onto the floor 
of the well are fixed in 4% formaldehyde and stained with crystal violet. The 
cells are then counted microscopically.  
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2.10 Immunocytochemistry 
The two methods employed in our study for the staining of cellular adhesion 
proteins were immunocytochemistry and immunofluorescence. Both techniques 
enabled visualisation of sub-cellular location of an antigen with the use of labelled 
antibodies which were facilitated with either light or fluorescent microscopy. A 
condensed but succinct description of the techniques is described in the sections 
below. 
2.10.1 Immunocytochemical staining 
The primary reagent used in this study for immunocytochemical staining was 3, 3’-
diaminobenzidine (DAB; Sigma). DAB is a substrate for peroxidase and in the 
presence of hydrogen peroxidase (H2O2), a brown coloured precipitate is formed. 
This indicates the presence of a specific protein when used in conjunction with 
specific antibodies. 
Cell lines were grown in 16 well chamber slides (LAB-TEK) until confluent and 
subsequently treated according to the conditions outlined in the relevant 
experimental chapters (chapters 3 and 4). The cells were fixed with 4% 
formaldehyde for 5-10 minutes after aspirating the culture medium from the 
wells. HBSS buffer (137 mM NaCl; 8 mM NA2HPO4; 3 mM KCL; 1.5 mM 
KH2PO4) was used to wash the cells twice. The cells were then permeabilised 
with 0.1% Triton X-100 (Sigma) detergent for 5 minutes. Cells were again 
rinsed twice with HBSS buffer, and non-specific protein binding sites were 
blocked with 10% milk solution (5 gm of semi-skimmed milk powder dissolved 
in 50 ml of TBS buffer (20 mM Tri-HCl; 150 mM NaCl [adjusted to pH 7.5], 
containing 50 µl [0.1%] of Tween 20 detergent) for 40 minutes at room 
temperature on a rotating wheel. 
Cells were again rinsed in HBSS buffer, and 100 µl aliquots of primary antibody 
(details of antibody concentrations used are in relevant chapters 3 and 4) prepared 
in TBS buffer with 3% milk (1.5 g of semi-skilled milk powder dissolved in 50 
ml of TBS buffer) were added to each well. Cells were incubated with the 
primary antibody for 1 hour at room temperature on a rotating wheel, to ensure 
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an even coating of the antibody. Cells were washed twice with 3% milk solution 
and 100 µl aliquots of secondary conjugated antibody, prepared in the same 
manner as the primary antibody, were added to each well (relevant concentrations 
in appropriate chapters). Cells were incubated with secondary antibody for 1 hour 
at room temperature on a rotating wheel, to ensure an even coating of the 
antibody. Cells were then washed twice initially with 3% milk solution followed 
by two washes with HBSS buffer. 200 µl aliquots of DAB substrate (25mM Tri-
HCl buffer [pH 7.4]; 0.03% H2O2; 200 µg/ml of DAB) was added to each well 
and these were incubated in the dark at 37 ºC for 5 minutes (allowing a brown 
precipitate to be formed between the DAB and peroxidase). Cells were washed 
with distilled water, allowed to air dry, and the slide was mounted with styrolite 
mounting medium (BDH). DAB stained cells were used using a light microscope. 
2.11 Immunofluorescence staining 
Cell lines were grown in 16 well chamber slides (LAB-TEK) until confluent and 
treated according to the conditions outlined in the relevant experimental chapters 
(chapters 3 and 4). The procedure for immunofluorescence staining is as 
described in the previous section. However, in this protocol, the cells were 
probed with fluorescent conjugated secondary antibodies. The antibodies are 
tagged with either fluorescein isothiocyanate (FITC) or rhodamine 
isothiocyanate (TRITC) conjugates. Mounting is performed using FluorSaveTM 
(Calbiochem-Novabiochem Ltd., U.K) mounting reagent. Subsequent viewing is 
performed using a fluorescent microscope. 
2.12 Immunoprecipitation 
Immunoprecipitation provides a useful method for the detection and 
quantification of specific target antigens within cellular lysates. In addition, it is 
highly sensitive, detecting protein to the tune of around 100 pg. 
Immunoprecipitation was invaluable in unravelling events during intracellular 
phosphorylation following extra-cellular stimulation. 
The first step in this process involves cell lysis. This is followed by the addition of 
a specific antibody directed against the target protein present within the cell lysate 
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sample. The resultant antigen-antibody complexes are harvested by the addition of 
staphylococcal protein A, which is covalently attached to sepharose or agarose. 
These immune complexes are precipitated by centrifugation, separated by SDS-
PAGE and analysed by immuno-probing. 
2.12.1 Preparation of protein for immuno-precipitation 
Following adjustment of the protein concentration, appropriate primary antibodies 
were added to each sample at the appropriate concentrations, in order to 
precipitate out the desired protein for subsequent detection by immunoprobing 
(section 2.12.6). The samples were incubated at 4°C for an hour, and this was 
followed by the addition of A/G protein agarose beads at the appropriate 
concentrations. Further incubation at 4°C for an hour was followed by micro 
centrifugation (Biofuge 13, Heraeus Sepatech) at 13000 rpm for 15 minutes. This 
removes cellular debris and unbound protein complexes form the supernatant 
faction. The agarose pellets (with antigen-antibody now bound to the bead 
surface) were washed twice using 200-300 µl of a lysis buffer with the addition of 
the following ingredients: 10 mM Na3VO4, 10 U/ml apotinin, 1 mM 
phenylmethylsulfonyl fluoride, 1.5% Triton X-100, 0.1% IGEPAL CA-630 and 4 
mM CaCl2. The pellets were suspended in 40-60 µl of sample buffer (10% 
glycerol; 5% 2-mercaptoethanol; 3% SDS; 80 mM Tris-HCl [pH 6.8]; 0.012% 
bromophenol blue, and denatured under reducing conditions by boiling at 100°C 
for 5 minutes. The samples were then stored at -20°C until ready to use for SDS-
PAGE. 
2.12.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE)  
SDS-PAGE was used to determine the expression of cell adhesion molecules at 
the protein level in the cancer cell lines used in this study, and was based on the 
method used by Laemmli (1970). The technique works on the basis that when a 
protein sample is heated in the presence of a reducing agent such as 2-
Mercaptoethanol (2-ME; Sigma) SDS, the protein becomes denatured with 
subsequent protein coating from SDS. This coating gives the protein a high 
negative charge which is proportionate to the length of the polypeptide chain. 
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The samples are then loaded onto a polyacrylamide gel, and a high voltage is 
applied; this causes the protein components to migrate in the direction of the 
positively charged anode. The ionic detergent SDS binds to proteins in 
proportion to their molecular weights and this binding is independent of their 
sequence. Furthermore, the resultant protein-SDS complexes are then separated 
on the basis of their molecular weights, and show different mobilities due to 
sieving properties of the polyacrylamide gel matrix. The size of the separated 
proteins can then be determined by comparing the gel mobilities of a particular 
band, with that of a known protein standard. Alternatively, a plot of molecular 
weight from known protein standards can be plotted against their mobility, in 
order to determine the size of unknown protein bands. Following 
electrophoresis, proteins are electro blotted onto nitrocellulose membranes for 
subsequent probing with relevant antibodies. 
2.12.3 Preparation of polyacrylamide gels for SDS-PAGE 
Electrophoresis using a polyacrylamide gel is the most commonly used method 
employed for the separation of proteins from cell and tissue lysate samples. The 
electrophoretic procedures are relatively rapid and sensitive enough for the 
detection of protein size. Acrylamide gels (30% acrylamide mix, crosslinker ratio 
29:1; Bio-Rad) are formed by polymerising acrylamide with a cross linking agent 
(methylene-bis-acrylamide) in the presence of a catalyst/chain initiator mixture, 
producing a cross linked matrix with a particular pore size. The most commonly 
used initiator is the persulfate ion (s208-) obtained in the form of ammonium 
persulfate (Sigma), and the catalyst used most frequently is TEMED (N,N,N,N-
tetramethylethylenediamine; Sigma). Varying the concentration of the 2 
components allows control at which rate the gels set. The relative proportions of 
the acrylamide monomer and the cross linking agent determine the porosity of the 
gel. 
Gels are usually referred to in terms of the total percentage of acrylamide, 
monomer and bis present. Most protein separations are carried out using gel 
concentrations of between 5 and 15%. The appropriate choice of acrylamide 
concentration used in this study was based on the separation range required for the 
protein. Therefore, a low percentage gel (large pore size) would be used if one 
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were dealing with proteins of a high molecular weight, and conversely, a high 
percentage gel (small pore size) would be used if one were to separate proteins of 
low molecular weights. The table below outlines the reagents used and 
concentrations employed in preparing the acrylamide gels used in this study. 
Table 2.2 Preparation of SDS-PAGE Gel 
Resolving gel composition 
(10mls) 
Strengths (mls) Strengths (mls) 
10% 8% 
Distilled Water 4.0 4.6 
30%Acrylamide/ 
0.8% Bisacrylamide 
3.3 2.7 
1.5M Tris (pH = 8.8) 2.5 2.5 
10% SDS 0.1 0.1 
10% APS 0.1 0.1 
TEMED 0.004 0.006 
Table 2. 3 SDS-PAGE resolving and stacking gel components. The volumes 
shown are for 10ml (resolving gels) and 2 ml (stacking gels) respectively. 
Stacking gel composition 
(2mls) 
Strengths (mls) 
5% 
Distilled Water 1.4 
30% Acrylamide/  
0.8% Bisacrylamide 
0.33 
1.0M Tris (pH = 6.8) 0.25 
10% SDS 0.02 
10% APS 0.02 
TEMED 0.002 
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SDS PAGE was carried out by assembling the gel (Mini Protean II gel system) 
apparatus according to the manufacturer’s instructions (Bio-Rad Laboratories, 
Richmond CA, USA). 
The appropriate concentration of resolving gel was chosen and prepared as 
described in the table above. A 1 ml transfer pipette was used to add the resolving 
gel mixture to the gel system by carefully running the gel solution down one side 
between the glass plates. The solution was added until it reached a position of 0.3 
cm from the cut-away edge of the gel plate. To ensure that the gel set with a 
smooth surface, a 0.1% solution of SDS was run down the side between the glass 
plates until a layer of about 2 mm formed on top of the gel solution (the great 
difference in densities between the SDS solution and the gel resulted in the SDS 
solution resting on the surface of the gel mixture without causing any untoward 
mixing of the two solutions). This was allowed to set for 30 minutes. When this 
was achieved, a very clear change in the refractive index was observed between 
the polymerised gel and the overlaying SDS solution. The excess SDS solution 
was absorbed using a filter paper and the gel rinsed once with distilled water. The 
stacking gel was then prepared as outlined in the previous table. Its purpose in 
SDS PAGE is detailed below. 
2.12.4 The use of stacking gels in SDS-PAGE 
The use of SDS gels enables protein samples to be directly applied onto the top of 
the resolving gel in which separation of the protein is to occur. However, in these 
cases, the sharpness of the protein bands produced in the gel is limited by the size 
(or its volume) of the sample applied to the gel. This problem may be overcome by 
polymerising a short stacking gel on the top of the resolving gel. The stacking gel 
allows samples to be electrophoretically concentrated into a thin band during the 
initial stages of electrophoresis. Furthermore, it allows proteins to stack resulting 
in sharper protein bands forming in the resolving gel. This modification to SDS-
PAGE allows relatively large sample volumes to be applied to the gel without any 
loss of resolution. 
The underlying principle of sample concentration within the stacking gel is based 
on isotachophoresis of the protein sample. The band sharpening effect relies on 
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variable electrophoretic mobility of the constituents. Thus, the negatively charged 
glycinate ions (in the reservoir buffer) have a lower electrophoretic mobility than 
the protein-SDS complexes, which in turn have a lower mobility than the Cl- ions 
present in both the loading buffer and the stacking gel. When the current is turned 
on, all the ionic species have to migrate at the same speed in order to maintain the 
electric circuit. The glycinate ions can only move at the same speed as the Cl- 
ions if they are in a region of higher field strength. Field strength is inversely 
proportional to conductivity, which is proportional to concentration. The net 
result is that the three species of interest adjust their concentrations so that (Cl-) > 
(protein-SDS) > (glycinate). There is only a small quantity of protein-SDS 
complexes, and hence they concentrate into a very tight band between the Cl- and 
glycinate boundaries. Once the glycinate ions reach the resolving gel, they 
become fully ionised and their mobility increases within the higher pH 
environment. Therefore, the interface between the glycinate and the Cl- ions 
leaves behind the protein-SDS complexes which are then left to electrophorese at 
their own rates. 
In the present study, the stacking gel was added to the gel cassette in the same 
manner as the resolving gel until it reached the cut-away edge of the gel plate. A 
well forming comb was gently inserted between the glass plates until it reached 
within 1mm from the top of the resolving gel, and then left to set at room 
temperature. The refractive changes around the comb indicate that the gel had set. 
The comb was carefully removed from the stacking gel, and the gel cassette was 
assembled in the electrophoresis tank as per the manufacturer’s instructions (Bio-
Rad Laboratories, Richmond, California, USA). 
The central reservoir was then filled with the running buffer (25mM Tris-HCl; 
3.5 mM SDS; 192 mM glycine) so that it flooded over and filled the wells. The 
bottom of the electrophoresis tank was filled with about 300 ml of running buffer. 
The previously prepared protein samples were loaded into the wells (10-15µl per 
well). This was done by placing the loading gel tip through the buffer and 
locating it just above the bottom of the well. The sample was slowly delivered 
into the well until it was full. The protein samples were pre-mixed with a dense 
loading buffer (10% glycerol; 5% 2-mercaptoethanol; 3% SDS; 80 mM tris-HCl 
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[pH 6.8]; 0.012 bromophenol blue) which ensured that the sample settled at the 
bottom of the well. This procedure was continued until all the samples had been 
loaded onto the gel. The protein standard or high molecular weight markers were 
prepared according to the manufacturer’s instructions (detection range 29-205 
kDa) and loaded (10µl/well) in the same manner as the protein samples. The 
power pack was connected to the apparatus, and the gel was run at a constant 
current of 15 mA per gel. Electrophoresis was continued until the samples had 
reached the bottom of the gel (as indicated by the bromophenol blue present in 
the loading buffer). 
2.12.5 Western Blotting of proteins onto nitrocellulose membranes 
This technique, also called Electroblotting, involves the immobilisation of protein 
antigens which have been separated by SDS-PAGE. Proteins are transferred onto 
an inert membrane support (eg., nitrocellulose or nylon). Once attached, the 
protein of interest may be detected by a specific monoclonal or polyclonal 
antibody against it. Following SDS-PAGE, the gel was removed from the gel 
cassette and rinsed in transfer buffer (25 mM Tris-HCl; 192 mM glycine; 20% 
[v/v] methanol) to facilitate the removal of electrophoresis buffer, salts and 
detergents. The gel was then left to equilibrate in transfer buffer for 10-20 
minutes. Simultaneously, nitrocellulose membrane (Amersham, International plc) 
and filter paper were cut to the dimensions of the gel (9x6 cm) and soaked in 
transfer buffer for 10-20 minutes. This ensures proper binding of the protein to the 
membrane. Electroblotting of the proteins was carried out using the following 
procedure: 
1. Two pieces of wetted filter paper were placed on the bottom electrode 
(cathode), and on top of this was placed one piece of pre-wetted 
nitrocellulose membrane. 
2. The gel was carefully transferred on top of the nitrocellulose 
membrane, and this was then covered by two further pieces of wetted 
filter paper, forming a sandwich 
3. The surface of this sandwich was carefully smoothed out using a 
transfer pipette as a rolling pin. This prevents the formation of air 
bubbles which may interfere with protein transfer. 
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4. The second electrode (anode) was applied to the top of this sandwich, 
and a current was applied. 
5. The proteins were then transferred for 30-40 minutes (depending on 
their size) using the following settings: 5 Volts, 500 mA and 8 Watts. 
Following electroblotting, the nitrocellulose membranes were removed and stained 
in Ponceau S (40 ml of 2% w/v Ponceau S concentrate containing 30% w/v 
trichloroacetic acid and 30% w/v sulphosalicyclic acid (Sigma) was diluted with 
360 ml of distilled water to provide a 1:10 working solution) for one minute at 
room temperature. The staining of proteins on nitrocellulose membranes using 
Ponceau S has two functions: firstly, it verifies that the proteins have been 
transferred to the membranes, and secondly, it aids in the visualisation of the 
molecular markers. Additionally, Ponceau S stain is a reversible protein stain, and 
does not interfere with subsequent immuno-probing steps. Excess stain was then 
removed by rinsing in distilled water, and the position of the molecular weight 
markers were indicated on the membranes using a pencil. 
2.13 Electrode Cell-substrate Impedance Sensing (ECIS) 
The ECIS core technology is based on a technique of measuring the change in 
impedance of a small electrode to AC current flow. The heart of the measurement 
is a specialized slide that has 8 individual wells for cell culturing. The base of the 
device has an array of gold film electrodes that connect the ECIS electronics to 
each of the 8 wells [Figures 2.1 - 2.5] 
 
Figure 2. 2 8-Well Electrode Array. Adapted from (www.biophysics.com)  
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 Figure 2. 3 Array well detail. Adapted from (www.biophysics.com) 
Array with the wells removed showing more clearly the patterns of gold and 
insulating films. The current flows between a 250 µm diameter electrode and a 
larger counter electrode using normal culture medium as the electrolyte. 
 
Figure 2. 4 Schematic representation of current flow. Adapted from 
(www.biophysics.com) 
Electrode top view indicating AC current flow between the small active electrode 
and the counter electrode. Without cells, the current flows unrestrained from the 
surface of the electrodes. 
 
Figure 2. 5 Electrode cross section. Adapted from (www.biophysics.com) 
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With cells attached and spread upon this region, the current must now flow in the 
spaces under and between the cells, as the cell membranes are essentially 
insulators. 
 
 
Figure 2.6 Micrograph of the gold electrode. Adapted from (www.biophysics.com) 
This is a micrograph of the 250 µm diameter gold electrode. The shaded-hatched 
area outside the circular electrode is an insulating film that defines the electrode 
perimeter. Both regions are excellent substrates for cell culture and essentially 
mimic the surfaces of normal tissue culture ware. At the start of the measurement, 
the electrode has no cells attached to it and the resistance is about 2000 ohms 
[Figure 2.6]. Upon inoculation, cells anchor and spread on the base of the well 
including the active 250 µm electrode. With the presence of the cells, their 
insulating plasma membranes constrain the electrical current and force it to flow in 
regions beneath and between the cells. This convoluted current path causes large 
changes in the measured impedance. Although this is taking place at both the small 
electrode as well as at the counter electrode, the impedance of the small electrode 
is several hundred times larger, and so the contribution of the large counter 
electrode is a fraction of a percent and can be ignored. In addition to the overall 
increase in the impedance, small fluctuations can be easily observed, because the 
live cells continuously alter their morphology and hence the impedance. With the 
confluent cell layer in place, the resistance now has reached nearly 15,000 ohms. It 
is important to note that the AC current used in making these measurements 
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(approximately 1 microampere) and the resulting voltage drops across the cells (a 
few millivolts) has no detectable effects upon them; the measurement is non-
invasive. 
 
Figure 2.7 Representative Graph generated during ECIS Adapted from 
(www.biophysics.com) 
This technique is a patented technology known as ECISTM, an acronym for 
Electric Cell-substrate Impedance Sensing. Cell densities ranging from a heavy 
confluent layer to very sparse layers can be measured with this approach. The size 
of the electrodes restricts the maximum number of anchored cells that can be 
observed from 100 to 1000 cells (dependent upon the type of electrode array used 
in the instrument), but even a single isolated cell results in impedance changes that 
can be monitored. 
2.13.1 Impedance Measurement 
ECIS measurements are made using an AC signal, where the current oscillates in 
a sinusoidal manner from as low as a few hundred to nearly 100,000 Hz in 
different measurements. Using AC instead of DC signals to monitor the cells 
upon electrodes has two important consequences. First, an AC source is used 
such that the electrolytes in the culture media are not deposited upon the 
electrode causing the properties of the electrodes to change or polarize. The other 
important advantage conferred by using an AC signal is described below. 
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Up until now, reference has only been made to impedance, the AC equivalent to 
resistance, and this is often the only parameter one may wish to follow to study 
many aspects of cell behaviour. If one were to apply the AC current (I) to the 
electrode system and measure the resulting voltage (V) across the electrodes, the 
impedance (Z) is simply given by the AC equivalent of Ohm's law: 
Z=V/I 
The ECIS Zθ instrument, however, is capable of monitoring both the voltage and 
the phase of the voltage relative to the current. Combining these parameters, the 
impedance can be broken down into two parts -- one due to pure resistance and 
the other to the reactance of the system. The reactive part (Xc) in this case is due 
to the capacitance (C) associated with the metal surfaces in the tissue culture 
medium (the electrolyte). 
We have elected to represent the signal received from the ECIS electrodes as a 
simple resistor and capacitor in series. 
For this simple RC circuit, the impedances of each of the circuit elements are 
given by: 
R=V(in phase)/I 
Xc=V(out of phase)/I 
and the total impedance is given by, 
Z= (R2 + Xc2) 0.5 
Xc (the capacitive reactance in ohms) depends upon the AC frequency (f) is given 
by: 
Xc =1/(2Π f C) 
Since we know the frequency, we can obtain the capacitance (C) from this term. 
 103 
With this information, it is possible to state more regarding the cells than simply 
the time changes in impedance. We, of course, can now report changes over time 
in the pure resistive (R) as well as the capacitive portions (C) of the impedance, 
and these are very useful. We shall also see that these data can be further refined 
using a model that gives back information on the barrier function of cell layers, 
the spacing beneath the cell and its substratum, and the capacitance of the cell's 
plasma membranes. 
2.13.2 AC Phase measurements 
The ECIS Zθ applies an approximately constant current through the ECIS 
electrodes of about 1 microampere or less. This current result in a voltage across 
the electrodes that varies in a sinusoidal fashion at the same frequency as the 
applied current. Were this simply a measurement of a pure resistance, the two sine 
waves- that of the voltage and of the current-would be exactly in phase -- the 
waveforms would have different values, but would coincide exactly. 
Were this a measurement of a pure capacitance, the two sine waves would be said 
to be 90 degrees (one quarter wavelength) out-of-phase -- the voltage lagging the 
current. In this case, when the current is at its peak, the voltage is zero, and when 
the current is at zero, the voltage is at a peak. We refer to the voltage in this case as 
the out-of-phase voltage. 
In the actual ECIS measurement, since we have resistance and capacitance, the 
voltage and current are somewhere in between these two situations. The ECIS 
instrumentation in the 1600R model -the model used in this study- measures this 
phase difference and breaks this voltage down into two pure in and out-of-phase 
components that together -add up to the actual signal. These are the voltages used 
in finally calculating the resistance and capacitance of the ECIS electrodes  
2.13.3 Time Course Measurements 
The impedance can be sampled as often as several times per sec to as slowly as 
desired. Each impedance reading is plotted as a point, in Ohms or Nano-farads 
(nF), versus time. The total acquisition time is user controlled and can range from 
 104 
a fraction of an hour to several days. The following graph [Figure 2.7] is a 
measurement of cells attaching and spreading in two different wells of an array. 
Curve no.4 are BCS cells and curve no.5 are NRK (Normal Rat Kidney) cells. 
The electrode in each well was sampled at a few second intervals for 15 hours. 
Following inoculation at time zero, impedance increases as the cells attach to the 
electrode and begin spreading. The impedance continues to increase until the cells 
reach confluence at 2 hours for the BCS cells and 10 hours for the NRK cells. The 
small fluctuations in the curves are due to micro motion from the constant 
movement of the monolayer of cells on the electrode. 
 
Figure 2.8 Representative Graph generated during ECIS-Time Course   
Measurements. Adapted from (www.biophysics.com) 
The above graph is a measurement of cells attaching and spreading in two 
different wells of an array. Curve no.4 are BCS cells and curve no.5 are NRK 
cells. The electrode in each well was sampled at a few second intervals for 15 
hours.  
 
2.13.4 Wounding/Electroporation 
With the wounding option, an elevated voltage is applied to the electrode for 
several seconds. The cells on the electrode are killed, presumably from severe 
electroporation. Closer analysis of the graph reveals that the impedance falls back 
from its peak value at cells confluence to that of an open electrode because the 
cells no longer offer a resistance to the current flow. 
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 Figure 2. 9 Representative Graph generated during ECIS-Wounding study Adapted 
from (www.biophysics.com)  
The time and intensity of the elevated voltage can be user controlled and reduced 
so the cells can also be electroporated without cell death. 
2.14 Statistical Analysis 
Statistical analysis was performed by MINITAB version 13.32 (Minitab Inc. State 
College, PA, USA) using a two-sample student t-test and the non-parametric 
Mann-Whitney confidence interval and test, where appropriate. Statistical analysis 
was carried out using Mann-Whitney U test and the Kruskal-Wallis test for tissue 
samples and the Pearson Correlation between related molecules. 
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Expression of NWASP [Neuronal Wiskott 
Aldrich Syndrome Protein] Gene Products in 
Human Breast Cancer 
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3.1. Introduction 
Wiskott-Aldrich Syndrome [WAS] is an X-linked recessive condition with 
immunodeficiency as the underlying problem. Currently, it is characterised by the 
triad of recurrent bacterial infections of the sinuses and lungs, eczema that appears 
atopic in nature, and a bleeding tendency due to thrombocytopenia and platelet 
dysfunction. 
The exact function of NWASP is not fully elucidated, but it seems to function as a 
bridge between signalling and movement of the actin filaments in the cytoskeleton. 
It has been recognized that the Wiskott-Aldrich protein provides a link between 
CDC42, a member of the RHO family of GTPases and the actin cytoskeleton 
(Symons et al., 1996). The WAS protein interacting with GTP-dependent CDC42 
was detected in cell lysates in transient transfections, and with purified 
recombinant proteins (Kolluri et al., 1996), indicating that the WAS protein could 
function as a signal transduction adaptor downstream of CDC42, and that cells 
with 5 domains involved in signaling, cell cytoskeletal abnormalities may result 
from a defect in CDC42 signaling. 
NWASP has been found to be a key regulator of actin polymerization in 
hematopoietic motility/migration, in immune synapse formation and in facilitating 
the nuclear translocation of nuclear factor kappaB (Ochs and Thrasher, 2006, 
Welch and Mullins, 2002). Mutations of NWASP are located throughout the gene 
and either inhibit or dysregulate normal NWASP function. Classic NWAS occurs 
when NWASP is absent, X-linked thrombocytopenia is present when mutated 
NWASP is expressed, and X-linked neutropenia occurs when mis-sense mutations 
occur in the CDC42-binding site (Ochs and Thrasher, 2006, Notarangelo et al., 
2002). 
Miki and co-workers first described a 65 kDa protein from brain that bound to the 
SH3 domains of Ash/Grb2 (Miki et al., 1996). The sequence was homologous to 
Wiskott-Aldrich syndrome protein (NWASP) and was designated NWASP 
[neural-WAS]. Stimulated actin assembly is responsible for membrane ruffling 
(Zalevsky et al., 2001), a process that actively involves the cytoskeletal associated 
protein family ERM [ezrin-moesin-radixin] (Bretscher, 1989, Hiscox and Jiang, 
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1999), and is, therefore, important for changes in cell motility and spread. We have 
recently reported that two major complexes that are linked to the NWASP family, 
namely the ERM family and RhoGTPases are aberrantly expressed in human 
breast cancer (Martin et al., 2003, Jiang et al., 2003). 
Presumably, NWASP mutations interfere with the proper signalling and growth 
of cells of the haematopoietic lineage, resulting in the platelet and immune 
defects observed clinically, although the exact mechanisms and defective 
pathways remain largely unknown. The aim of this part of the study was to 
determine which cells found in breast tissue express NWASP. In order to 
determine which cell types in breast tissue express these molecules, it was 
necessary to use other cell lines in addition to breast tissue. Breast tissue contains 
epithelial cells lining the ducts, stromal cells including fibroblasts, endothelial 
cells lining the blood and lymphatic vessels, components of blood (red and white 
blood cells and platelets), and nerve cells. The following representative cell lines 
were chosen: MDA-MB-231, MRC-5, MCF7 and human umbilical vein 
endothelial cells (HUVECs). These cells are described below. 
MRC-5: These cells are fibroblasts which originated from the normal lung tissue 
of a 14 week old male foetus. These cells replicate rapidly, making them useful for 
cell culture. 
MCF7: This cell line consists of human breast adenocarcinoma cells that were 
originally obtained from the pleural tap of a 69 year old female Caucasian. The 
cells exhibit some of the features of differentiated breast epithelium including 
oestriol synthesis. They are oestrogen receptor positive. 
MDA-MB-231: These are also human breast adenocarcinoma cells extracted 
from a pleural effusion. They are highly anaplastic cells, which form grade 3 
tumours in nude mice. They are oestrogen receptor negative. 
HUVECs: These cells, as their name indicates, derive from human umbilical vein 
taken from a full term baby shortly after delivery. The lumen is emptied of blood. 
Various enzymes, including trypsin and collagenases, are infused into the vein. 
These enzymes cause the endothelial cells to become detached from their 
 109 
underlying basement membrane. The cells are subsequently collected and purified. 
HUVECs are, therefore, relatively immature cells which express a variety of 
endothelial markers. 
3.2 Materials and Methods 
RNA extraction and subsequent synthesis of equal amounts of DNA were 
performed using RNA extraction (RNAZol) and Avian Reverse Transcription kits 
which were obtained from Abgene Ltd (Epson, UK). PCR primers were designed 
using Beacon Designer software (Palo Alto, California, USA) and synthesised by 
Invitrogen Ltd. (Paisley, UK). Molecular-biology grade agarose and DNA ladder 
were from Invitrogen. Master mix for routine PCR and quantitative PCR was from 
Abgene. 
Breast Cancer cell lines (MCF-7, MDA-MB-231) were obtained from European 
Collection of Animals Cultured Cell (EACC, Salisbury, England). Cell lines were 
routinely maintained in DMEM1 F12 medium (Cambrex bioscience, Verviers 
Belgium) supplemented with 10% foetal calf serum (PAA Laboratories, Yeovil, 
UK) and antibiotics (Penicillin with Streptomycin). 
3.2.1 Cell culture conditions 
Control cells were grown in DMEM F12 medium (supplemented with 10% foetal 
calf serum and antibiotics). NWASP transfected breast cancer cells 
(MDAMBNWASP+) were grown in medium containing amoxycillin derivative to 
which MDAMBNWASP+ cells carried the resistance marker. Cell cultures were 
routinely incubated in a humidified incubator maintained at 37°C. 
3.2.2 Collection and storage of cells 
The cells-153 frozen archival breast samples from 127 patients- were collected 
between June 1991 and July 1997 with the approval of the local ethical committee 
(BroTaf Health Authority and South East Wales Local Research Ethics sub-
committees). All tissues were randomly numbered, and the details were only made 
known after all the analyses were completed. Frozen sections were cut from each 
 110 
specimen and 25-30 adjacent 10µm sections were subsequently used for RNA 
extraction. 
3.2.3 RNA extraction and RT-PCR for NWASP detection in breast cancer 
Total cellular RNA was isolated from either cell line monolayers or homogenised 
breast tissues using RNA-Zol reagent (Abgene, Epsom, UK) according to 
manufacturer’s instructions. cDNA was generated from 1µg of RNA using the 
AMV-reverse transcription kit (Abgene, Epsom, Surrey, UK). Conventional PCR 
Primers were designed using Beacon Designer software (Paolo Alto, California, 
USA) to allow amplification of regions that have no overlap with known genes and 
span at least one intron. PCR was carried out using the following Primer pairs: 
NWASPEXF1 atgagctccgtccagcag (forward primer) 
NWASPEXR1 tcagtcttcccactcatcatc (reverse primer) 
PCR reactions were performed using a GENE Amp PCR system 9700 (PE 
Biosystems, Warrington, UK) thermal cycler. Amplification of cDNA was carried 
out at the following conditions: 94ºC for 15 seconds, 56ºC for 15 seconds, 72ºC for 
45 seconds, followed by a final extension phase of 7 minutes at 72ºC for 36 cycles. 
The PCR products, including a 1-KB ladder were separated on 0.8% agarose gels. 
PCR products were then visualised using ethidium bromide (10mg/ml) and a UV 
transilluminator (UVItec, Cambridge, UK). Resulting stained agarose gels were 
photographed using a Unisave camera (Wolf Laboratories) and subsequent images 
documented using Adobe Photoshop Elements software. 
3.2.4 Real Time Quantitative PCR analysis of NWASP in breast cancer 
The quantity of NWASP transcripts were assessed using RT-PCR and RT-QPCR. 
RT- QPCR was carried out using iCycler IQTM system (Bio-Rad, Camberley, UK), 
which incorporated a gradient thermocycler and a 96-channel optical unit. 
Universal probe system (UniPrimer TM) was used in this study (Intergen, Oxford, 
UK). The internal standards used in this study were specific plasmids generated 
using Pcr2.1-cloning vector (Invitrogen, Paisley, Scotland). Conditions for the 
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QPCR were as follows: 50 cycles of denaturing at 95ºC for 15seconds; annealing 
at 54ºC for 20 seconds and extension at 60ºC for 40 seconds. 
3.2.5 Immunofluorescent staining of NWASP protein 
For immunofluorescence staining, cells were grown in 16- well chamber slides 
(LAB-TEK) (30,000 cells/well) in the presence or absence of HGF (50 ng/ml) and 
incubated in a 37ºC 5% CO2 incubator for a set period of time (0–24 h). After 
incubation, the culture medium was aspirated, the wells rinsed with balanced salt 
solution (BSS) buffer and the cells fixed in methanol for 20 min at 20ºC. After 
fixation, the cells were washed twice using BSS buffer and permeabilised by the 
addition of 200 µl of 0.1% Triton X-100 (Sigma) detergent in Phosphate buffered 
solution (PBS) for 5 min at room temperature. Cells were rinsed twice with BSS 
buffer and 200 µl of blocking buffer (10% horse serum in TBS) was added to each 
well, and the chamber slide incubated for 40 min at room temperature on a bench 
rocker. The wells were washed once with wash buffer (3% horse serum in TBS 
buffer containing 0.1% Tween20) and 100 µl of primary antibodies prepared in 
wash buffer was added to the appropriate wells. The chamber slide was incubated on 
the rocker for a further 60 min at room temperature. Wells were washed twice with 
TBS buffer (with 0.1% Tween20), and cells were incubated in 100 µl of secondary 
antibodies (TRITC) (diluted in the same manner as the primary antibodies) for 50 
min. The chamber slide was wrapped in foil to prevent light reaching the 
conjugate. Finally, the wells were rinsed twice with wash buffer, once in BSS 
buffer mounted with FluorSave (Calbiochem-Novabiochem Ltd, Nottingham, UK) 
reagent and visualised using an Olympus BX51 microscope with a Hamamatsu 
Orca ER digital camera at 9100 using oil immersion lens. 
Total tissue or cell lysates were prepared as follows: cell or tissue were lysed in 
HCMF buffer plus 0.5% SDS, 0.5% Triton X-100, 2 mM CaCl2, 100 mg/ml 
phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml aprotinin and 10 mM 
sodium orthovanadate for 40 min, sample buffer was added and the protein boiled 
at 100°C for 10 min before clarification at 13000g for 10 min. Equal amounts of 
protein from each sample were added onto an 8% polyacrylamide gel. Following 
electrophoresis, proteins were blotted onto nitro-cellulose sheets and blocked in 
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10% horse serum for 60 min before probing with primary antibodies, following 
with peroxidase-conjugated secondary antibody (1:2,000). Protein bands were 
visualised with Supersignal West Dura Extended Duration Substrate 
chemiluminescent system (Perbio Science UK Ltd., Cramlington, UK) and 
detected using a CCD UVI prochemi system (UVItec Ltd., Cambridge, UK). 
3.3 Results 
3.3.1 Expression of NWASP in normal breast and breast cancer tissues. 
We screened two breast cancer lines (MDA-MB 231, MCF 7) and two other cell 
lines (MRC 5 and HUVECs) to assess the expression of NWASP using RT-PCR. 
The mRNA level of NWASP in these cell lines are shown in Fig. 3.1a and 
Fig.3.2. From the initial RT-PCR experiments, it became evident that most of the 
tumour cells exhibited low levels of NWASP transcript. Further confirmation was 
obtained by using two NWASP antibodies and confirming the lower protein 
expression in the same tissue samples using Western blotting technique (Fig. 
3.1b), β-actin was used as a house keeping control. 
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Figure 3. 1 Expression of NWASP in cancer cell lines and in breast tissues. 
(a) Tumour tissues showed low levels of NWASP transcript as shown by RT-PCR. (b)This 
is supported by the reduced protein expression in the same tissue samples using Western 
blotting (2 NWASP antibodies used for confirmation). β-actin is shown for comparison. 
The figures (a) and (b) refer to a different set of patients; i.e., they are not matching pairs. 
(c) The human breast cancer cell lines [3 (MDA-MB-231) and 6 (MCF 7)] included 
in the screening did not show a signal for NWASP as demonstrated using RT-PCR. 
Note: the other numbered cells were lines being concomitantly studied in the 
department and are not part of this research work. 
 
3.3.2 Correlation of NWASP gene transcript with clinical and pathological 
features in Breast cancer using Q-RTPCR 
The levels of NWASP transcript in tumour and normal tissues were compared. 
Figure 3.2 shows a significant difference in the level of NWASP transcript 
expressed in normal breast tissue and breast cancer tissue. This difference was 
statistically significant [p<0.05]. In the current study, the Nottingham Prognostic 
Index (NPI) was used as a prognostic indicator, taking into consideration the size 
of tumours, number of lymph nodes and tumour grade. Patients were divided into 
those with good prognosis (NPI-1), with moderate prognosis (NPI-2) and those 
with poor prognosis (NPI-3). There was a stepwise decrease of the levels of N-
NWASP transcript from good to poor prognosis, with the difference between good 
and poor prognoses being statistically significant (Fig. 3.3). The difference 
between moderate and good, or moderate and poor did not reach statistical 
significance (P<0.05). The Kruskal Wallis test of the levels of NWASP transcript 
against the prognostic index did not reveal a significant correlation. This suggests 
c 
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that a linear correlation between these two parameters does not exist. However, 
overall, the very low levels indicate poor prognosis. There was an observable 
difference between node negative and node positive tumours (Fig. 3.3b) but again, 
statistical significance was not reached. 
 
Figure 3.2 NWASP transcript in mammary tissues, number of NWASP 
transcripts/50 ng RNA. The levels of NWASP transcript were significantly lower in 
breast cancer tissues compared with normal background mammary tissues * P < 0.05 
[Mann Whitney U Test]. 
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Figure 3.3 NWASP transcript levels were associated with Nottingham Prognostic 
Index (a) and Nodal involvement (b) NPI3 (NPI > 5.4) tumours had significantly lower 
levels of NWASP than those of NPI1 status (NPI < 3.4), * p < 0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 116 
 
 
 
Table 3.1 Transcript levels of NWASP in human breast cancer tissues; TNM staging, 
Grade and tumour type 
 
Prognostic Indicator 
TNM staging 
 TNM 1 0.788 ± 0.443 
 TNM2 1.116 ± 0.584 
 TNM3 0.605 ± 0.406 
 TNM4 0.198 ± 0.124 
Grade 
 1 0.279 ± 0.2 
 2 0.253 ± 0.07 
 3 1.45 ± 0.68 
Tumour type 
 All 0.83 ± 0.303 
 Ductal 0.932 ± 0.38 
 Lobular 0.0531 ± 0.04 
 Others 1.351 ± 0.813 
 
3.3.3 Levels of NWASP transcript correlated with clinical outcome 
The current analysis was based on a patient follow-up period of 72 months. It 
revealed that patients with metastatic disease and patients who died of breast 
cancer (excluding those whose died of diseases unrelated to breast cancer) had 
significantly lower levels of NWASP than those who remained disease free (Fig. 
3.4). 
Although patients with local recurrences also had lower levels of the transcript, the 
difference is yet to be statistically significant (P = 0.06). In addition, survival 
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curves showed that higher levels of NWASP expression were associated with 
disease- free survival, P = 0.0498 (Fig. 3.5a) but that decreased levels of NWASP 
expression were associated with poor overall survival in patients with breast 
cancer (Fig. 3.5b). We did not find a significant correlation between tumour grade, 
TNM staging and histological type (Table 3.1). 
NWASP transcript is one variable in a disease [breast cancer] that has a number of 
factors which influence survival. Therefore, it is possible that Fig. 3.5 represents 
patients who died of breast cancer [with metastases as it does not state that they 
did not have metastases, merely that they died of breast cancer] because of other 
poor prognostic variables of the disease [not looked at or accounted for in this 
study]. The small number of patients in each category may have also introduced an 
artificial bias accounting for the visualised discrepancy in the transcript levels 
between patients with metastatic disease and those having died from breast cancer.  
                 
Figure 3.4: Significantly lower levels of NWASP Transcript were seen in those 
patients with metastatic disease (** P<0.01) and in those patients who died of breast 
cancer (* P<0.05). 
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Figure 3.5 NWASP association with survival. Fig 3.5a indicated that NWASP was 
associated with disease-free survival in patients with breast cancer. Fig 3.5b indicated 
reduced levels of NWASP were associated with poor overall survival of patients. The 
Green line represents patients with higher levels of NWASP, and the blue line represents 
patients with a lower level of NWASP [based on the median level of NWASP in the NPI 
2 group (NPI 3.5-5.4)] 
 
Survival was analysed using the Cox-proportion-Hazardous test and showed a 
0.0360 probability of low NWASP levels indicating low survivability. The 
apparent discrepancy of transcript levels between patients with metastatic disease 
and those having died from breast cancer may be an artificial bias due to the 
relatively low numbers of these patients in each category. 
3.3.4 Immunohistochemical staining of NWASP in normal cells and breast 
cancer cells 
Although the principles underlying Immunohistochemistry [IHC] were well 
established in the 1930’s, the first published report was not until 1942 (Coons, 
1971). Subsequent improvements in protein conjugation, tissue fixation, detection 
labels and microscopy have made IHC an essential tool in research and diagnostic 
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laboratories. The far reaching applications of IHC now encompass biological 
research, disease diagnosis and drug development. 
We examined the presence of NWASP in normal breast tissue by immunostaining. 
This was then compared to the staining pattern in breast tumour tissue. The 
staining of NWASP was most abundant in the normal breast epithelial cells, and 
moderate in the stromal tissue. By comparison, breast cancer cells had low to 
moderate NWASP staining. 
In Fig. 3.6 we have captured the immunostaining of NWASP in human breast 
cancer tissue at increasing powers of magnification. The serial images a1-a3 show 
the background tissue at magnification levels of 40, 100 and 200 respectively. 
NWASP staining is primarily seen in the cytoplasmic region of the normal 
epithelial cells, with low degree of nuclear staining. Staining was visible in the 
cytoplasmic regions of the cancer cells as well, but was much weaker in 
comparison to normal epithelial cells. Fig. 3.7 panels b1 and b2 further show 
matched tumour tissue at magnification as above, further showing the 
immunostaining characteristics of NWASP in human breast cancer cells. Fig. 3.7 
panels b3 and b4 further show a second magnified section (X200) of the same 
tumour tissue. Finally, in Fig. 3.8 panels c1 (X100) and c2 (X100) respectively, 
the negative and positive controls for NWASP are displayed. There was a 
reduction in the staining in cancer cells with increased location of the NWASP 
protein to the cell periphery. 
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 Figure 3. 6 Immunohistochemical staining of NWASP in human breast tissue. 
Panels a1– a3 show background tissue at increasing magnification (X40, X100 and 
X200). 
 
 
  
 
 
Figure 3.7 Immunohistochemical staining of NWASP in human breast 
cancer tissue. Panels b1–b2 show matched tumour tissue at the magnification 
(X40, X100). Panels b3–b4 showing a further magnified section (X200) of the 
same tumour tissue. 
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Figure 3. 8 Immunohistochemical staining of NWASP in human breast cancer 
tissue.  Panels c1 (X100) and c2 (X100) show the negative and positive controls for 
NWASP respectively. There was a reduction in the staining in cancer cells with 
increased location of the NWASP protein to the cell periphery. 
3.4 Discussion 
This study has confirmed that NWASP is found in both normal and aberrant 
[tumour] tissues. The levels of NWASP were lower in tumour tissues. NWASP is 
primarily a cytoplasmic protein, and the levels of staining were lower in breast 
tumour tissue as compared to normal epithelial tissue. 
We are aware that NWASP is involved in regulation of the actin cytoskeletal 
remodelling. Cell migration which is essential in any metastatic process is a 
complex process, one of the key steps of which is the formation of protusive 
structures-lamellipodia and filopodia. Actin polymerisation is essential in the 
formation of these structures and is mediated by the Arp 2/3 complex, which in 
turn is regulated by NWASP. The subcellular relocalisation of NWASP-from 
nuclear/peri nuclear region to the cytoplasm would serve to promote actin 
polymerisation in the leading edge of the cells. Upon activation, there is a 
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reduction in the peri nuclear concentration of NWASP accompanied with its 
relocation to the leading edge of the lamellipodia (Sukumvanich et al., 2004). 
Suetsugu and Takenawa demonstrated that unphosphorylated NWASP is located 
at the nucleus, and this causes suppression of HSP90, HSE and Src family kinase 
(Suetsugu and Takenawa, 2003). Phosphorylation of NWASP converts it to its 
active form with subsequent relocation to the cell periphery where CDC42 and 
Src are activated, thus regulating events involving the actin cytoskeleton i.e. 
motility, migration. The differential expression of NWASP in human breast 
cancer could incur aberrant activation in cancer cells and may lead to changes in 
regulation of migration and hence to metastatic spread. This would require further 
investigation and would form the basis of a novel research project. 
The aberrant expression of the NWASP at mRNA levels in human breast cancer 
was reported for the first time. Additionally, this possibly has a significant bearing 
in the clinical outcome of the patients. Comparing the levels of NWASP against 
the known prognostic factors showed a significantly lowered level of NWASP in 
patients with either nodal involvement or metastatic disease, both indicators of 
poor prognosis. The lower levels of NWASP correlated well with a shorter disease 
free interval, thereby further illustrating the link between NWASP levels and 
mortality. The findings from the immunohistochemical analysis mirror those of the 
quantitative transcript analysis. However, owing to a paucity of samples for subset 
histological analysis, the immunohistochemical analysis was carried out on only a 
limited number of samples. This precluded any statistical analysis on the 
Nottingham Prognostic Indicator and Grade subgroups. Although small, the 
favourable results from the immunohistochemical tests suggest that it would be a 
worthwhile exercise to conduct a more in-depth analysis on a suitable cohort of 
breast tumour tissues in the future. 
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Chapter 4 
 
 
 
Cloned NWASP tumour Suppressor gene reduces 
the invasive and migratory capacity of human 
breast cancer cells 
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4.1 Introduction 
One of the key features of malignant cells is their ability to locally invade 
surrounding tissues and also to metastasise to distant sites. Different tumours show 
a propensity to metastasise to different sites. For example, breast tumours to bone, 
liver, and lung and colonic cancers to liver and lungs. Lung cancer cells have a 
very high rate of metastasis with cells invading virtually every organ in the body 
with a predilection to brain, bone, bone marrow and liver. Key events in the 
complex process of metastasis include cell transformation and proliferation, 
basement membrane degradation at primary site with associated vascular transport 
through capillary or lymphatic vessels, adherence or attachment of the tumour cells 
to endothelial or sub-endothelial structures at the secondary site, and the 
subsequent growth of the secondary tumour mass. 
In order to metastasise to various organs, tumour cells need to acquire a number of 
highly differentiated characteristics that define the metastatic phenotype. The 
metastasising cells show functions that are similar to those seen in the normal 
processes of embryonic development, tissue remodelling, mammary gland 
involution or trophoblast implantation. The main distinction between the normal 
processes and those in the cancer pathway is dysregulation. This can be attributed 
to high mutation rates and genetic instability. The net result of a high mutation rate 
is the development of clonal populations with metastatic capabilities. It is further 
observed that the neoplastic element must expand considerably prior to invasion or 
metastasis occurring. 
Numerous studies have compared the similarities between metastasis and the 
responses of inflammatory cells, an essential component of both processes being 
the initial recruitment and subsequent migration of cells through basement 
membranes and connective tissues. In inflammation, the trigger for migration has 
been identified as signalling initiated by bacterial or complement-mediated 
signalling. The responsible factors and triggers are less well defined in metastasis. 
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4.1.1 Models of invasion and Motility 
Essentially, the models are classified into in vitro and in vivo. Major emphases on 
cancer invasion motility have focused on in vivo models, in which tumour cells 
are injected intravenously or subcutaneously into mice, and the number of 
metastases determined. However, this process is relatively expensive, and 
involves sacrifice of the subject in order to determine results. Therefore, more 
emphasis is now being placed on the in vitro studies. The in vitro models used in 
this study were the following four assays: 
1. Matrigel Invasion Assay 
2. Cell Growth assay 
3. Cytodex 2-bead Motility Assay 
4. Cell Matrix Attachment Assay 
The full details regarding the various assays are dealt within the relevant sections 
in Chapter 2. They are briefly touched upon in the following section. Their main 
advantage is the cost effectiveness and relatively low level of expertise required to 
perform the assays. Their main disadvantage relates to the lack of reproducibility, 
the human error and the laborious nature of the experiments. These disadvantages 
are minimised by using the Electrode Cell-substrate Impedance Sensor (ECIS) - a 
bio-morphological Assay method which is described in the next chapter. 
4.1.2 DNA cloning 
DNA cloning produces many identical copies (amplification) of a foreign DNA 
fragment that may be of particular interest. Ideally, it would be possible to isolate 
a single DNA fragment and purify it prior to cloning. Although this is feasible in 
a small number of cases, more commonly, in order to clone a particular 
nucleotide sequence (DNA fragment), the total cellular DNA is first cleaved with 
a specific restriction enzyme, resulting in hundreds of thousands of fragments. 
Each of the resulting DNA fragments is joined to a DNA vector (carrier) 
molecule to form a hybrid molecule. Following this, each hybrid recombinant 
DNA molecule conveys its inserted DNA fragment into a single host cell, e.g. a 
bacterium, where it is replicated (amplified). Subsequent multiplication of the 
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host cell leads to the formation of a clone in which every bacterium carries 
copies of the same inserted DNA fragment. This technique is, therefore, referred 
to as “cloning” (Champe et al., 2005). The cloned DNA can eventually be 
released from its carrying vector by cleavage using the appropriate restriction 
endonuclease, followed by its isolation. 
4.1.3 Vectors 
A vector is a molecule of DNA to which the fragment of foreign DNA of interest 
to be cloned is joined. Vectors in common use are: 
1. Plasmids 
2. Bacterial viruses 
3. Animal viruses 
A vector must have certain essential properties. These are listed below: 
1. It must be capable of autonomous replication within a host cell. 
2. It must carry at least one gene that confers the ability to select for the 
vector, such as an antibiotic resistance gene. 
3. It must contain at least one specific nucleotide sequence recognised 
by a restriction endonuclease. 
Prokaryotic organisms contain single, large, circular chromosomes which behave 
as a plasmid would. Additionally, most species of bacteria contain small, circular 
extra-chromosomal DNA molecules called plasmids. Plasmids may carry genes 
that confer upon the host bacterium properties such as antibiotic resistance. 
We isolated full length human NWASP DNA fragment and then cloned it using 
pCR3-GFT-NT expression vector using the chemically competent Escherichia coli 
bacteria. The cloned NWASP gene was then transfected into highly malignant 
MDA-MB-231 breast cancer cells and grown in G418 selection medium. These 
cells were then used for function studies (invasion and migration capacity) with 
wild type and GFP MDA-MB-231 breast cancer cells as controls. Following this, 
the above cells were subjected to immunocytochemical and immunofluoroscopic 
analysis as detailed previously. 
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4.2 Materials and Methods 
Four assays were used to determine what, if any, effect over-expression of N-
NWASP would have on the human breast cancer cell line MDA-MB-231. HGF at 
25 ng/ml was used as a stimulator of motility and invasion. There were no obvious 
differences in cell morphology between the wild type and transformed cells. 
4.2.1 Invasion Study 
Invasiveness of MDA-MB-231 breast cancer cell line was assessed using the 
following in vitro assay. Transwell chambers equipped with 6.5 mm diameter 
polycarbonate filter (pore size 8 µm) (Becton Dickinson Labware, Oxford, UK) 
were pre-coated with 50 mg/membrane of solubilised basement membrane in the 
form of Matrigel (Collaborative Research Products, Bedford, MA). After 
membrane re-hydration, 15,000 cells were aliquoted into each insert with/without 
HGF/SF (25 ng/ml). After 96 hours, co-culture non-invasive cells were removed 
with cotton swabs. Invaded cells on the underside of the insert were fixed and 
stained with crystal violet, followed by microscopic counting (20 fields/insert). 
4.2.2 Cell Motility Study 
A cell motility assay was carried out. Briefly, cells were pre-coated onto cytodex-2 
carrier beads (Sigma-Aldrich, Poole, UK) for 2 hours in complete medium. After 
the medium was aspirated, and the cells washed (X2 in complete medium), they 
were aliquoted into wells of a 96-well plate in triplicate (300 µl/well). HGF (25 
ng/ml) was added, and the cells incubated over-night. The beads were washed off 
in medium, and the cells that had migrated onto the floor of the well fixed (4% 
formaldehyde) and stained with crystal violet. The cells were counted 
microscopically (940). 
4.2.3 Cell Adhesion Assay 
The cell-matrix attachment assay was carried out as previously reported. Briefly, 
Matrigel (10 µg/well) was added to 96-well plates, which were incubated for 24 
hours to allow binding of matrix protein to the surface of the well. The plates 
were then washed and blocked with 5% Bovine serum albumin (BSA). Cells were 
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added at 104/well for 30 min, followed by aspiration and washing. The number of 
attached cells was determined by direct counting under microscope (7 counts per 
experimental setting). 
4.2.4 Cell growth Assay 
The principle behind in vitro cell growth assay is based on the ability of a 
mitochondrial de-hydrogenase enzyme from viable cells to cleave the tetrazolium 
rings of the pale yellow MTT [MTT stock solution 5mg/ml, 40µl/well, thus 
equaling 200µg MTT/well] to form dark blue formazan crystals which are largely 
impermeable to cell membranes, thus resulting in its accumulation within healthy 
cells. Solubilisation of the cells by the addition of a detergent results in the 
liberation of the crystals, which are solubilised. The number of surviving cells is 
directly proportional to the level of the formazan product created. The colour can 
then be quantified using a simple colorimetric assay. 
The cells were then seeded onto a 96 well plate (Nunc, Denmark) at a density of 
7,000/well and incubated at 37ºC for 72 hours. MTT was added in solution to the 
cells (200 µg/well) and incubated for 4 hours at 37ºC. The cells were then lysed 
with Triton (10%) and the intensity of the colour released was determined by a 
plate reader (Titertek Multiskan, Eflab, Finland). The number of cells was shown 
as absorbance units.  
4.2.5 In vivo growth assay analyzing NWASP gene transformed breast 
cancer cells 
The in vivo tumour progression model was adapted from similar previously 
described protocols. Briefly 2 x 106 cells in 100 µl were mixed in a 0.5 mg/ml 
Matrigel suspension and subcutaneously injected into the left and right flanks of 
4–6 weeks old athymic nude mice (CD-1; Charles River Laboratories, Kent, 
England, UK) and allowed to grow. The mice were maintained in filter top units 
and were weighed on a weekly basis. The tumour size was measured weekly using 
Vernier calipers under sterile conditions. Humane end points were: 
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(a) mice which suffered 25% weight loss 
(b) development of tumours exceeding 1 cm3 (subject to schedule 1 method 
according to the United Kingdom Home Office and the United Kingdom 
Coordinating Committee on Cancer Research (UKCCCR) guidelines).  
At the conclusion of the experiment, the animals were weighed, humanely killed 
under schedule 1 and the tumours were removed and stored. Tumour volume was 
determined using the following formula; tumour volume mm3 = 0.523 x width2 x 
length. 
4.3 Results 
4.3.1 Over expression of NWASP in breast cancer tissues 
The human breast cancer cell line MDA-MB-231 was chosen to study the forced 
expression of NWASP as these cells did not show a signal for this molecule. Initial 
detection of the NWASP protein was performed using RT-PCR, and confirmation 
was obtained using western blotting (Fig.4.1a) and immunofluorescence (Fig. 
4.1b). 
 
Fig. 4.1a: Over-expression of NWASP in human breast cancer, western blotting. 
NWASP was successfully over-expressed in MDA-MB-231 cells (MDA-MB-231 
NWASP). The successful expression of NWASP protein in transfected MDA-MB-231 
cells (MDS-MB-231NWASP) is shown by western blotting. β-actin was used as the loading 
control. 
 
 130 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
MDA-MB-231 WASP 
MDA-MB-231 GFP 
MDA-MB-231 WT 
 131 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
MDA-MB-231 WT 
No primary control 
MDA-MB-231 WASP 
MDA-MB-231 GFP 
 132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1b: Over-expression of NWASP in human breast cancer, fluorescence 
microscopy. NWASP was successfully over-expressed in MDA-MB-231 cells 
(MDA-MB-231NWASP+). The successful expression of NWASP in transfected cells 
(MDS-MB-231NWASP+) is shown in the fluorescent microscopy images (X100). The 
figure clearly shows the expression of the protein at both a sub cellular and peripheral 
location within MDA-MB-231NWASP+cells. The absence of NWASP in both GFP control 
plasmid cells (MDA-MB-231GFP) and MDA-MB-231WT cells is also demonstrated. 
Bright field images are shown to indicate the presence of cells (X100). 
MDA-MB-231 WASP 
MDA-MB-231 WT 
MDA-MB-231 GFP 
No secondary control 
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4.3.2 In vitro studies of MDA-MB-231NWASP+ cells 
Subsequent assay on the stable MDA-MB-231NWASP+ cells was carried out to 
determine the effects of NWASP on this invasive human breast cancer cell line. 
Changes in invasiveness were assessed, with MDA-MB-231NWASP+ cells showing 
significantly reduced invasion compared to the wild type cells (MDA-MB-231WT) 
and GFP-plasmid control cells (MDA-MB-231GFP) (Fig. 4.2) (P<0.0001). 
This invasiveness remained reduced even in the presence of HGF (25 ng/ml), 
which actively induces invasion in this cell type (P<0.0001). Motility of the cells 
was also significantly reduced (P<0.001) compared to the wild type and plasmid 
control cells (Fig. 4.3), which is consistent with the role of NWASP as a regulator 
of the actin cytoskeleton, and again remained reduced in the presence of HGF. The 
adhesion of these cells was increased (MDA-MB-231NWASP+ 10.4: 3.8 versus 
MDA-MB-231WT 7.6: 2.2; P = 0.05), as shown in Fig. 4.4. This would support the 
argument that the cells that express NWASP show an increased adhesiveness, and 
therefore, a decreased potential for invasiveness or metastasis. 
The effect of HGF on the temporal and spatial distribution of NWASP was 
determined by immunofluorescence over 90 min (Fig. 4.5). It appears that the 
nuclear and cytoplasmic expression of NWASP was modified upon treatment with 
HGF by 30 min incubation, with the redistribution of NWASP towards the cell 
periphery. This was clearly evident by 60 min incubation, with NWASP clearly 
located at the ruffling, leading edge of the cell. By 90 min incubation, the effect 
was beginning to abate. There was no loss of expression of NWASP, merely a 
redistribution of this protein. 
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 Figure 4.2 Forced expression of NWASP resulted in cells with significantly lower 
levels of invasiveness (P<0.0001), in response to HGF (25 ng/ml) 
 
 
Figure 4.3 Forced expression of NWASP resulted in cells with significantly lower 
levels of motility (P<0.001), in response to HGF (25 ng/ml) 
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 Figure 4.4 Forced expression of NWASP resulted in cells with increased adhesiveness 
to basement membrane (P = 0.05) in response to HGF (25 ng/ml) 
 
 
Figure 4.5 HGF (50 ng/ml) effected a temporal and spatial re-location of NWASP in 
the transfected cells, as indicated by arrows. A nuclear/peri nuclear expression gave 
way to increased cytoplasmic and cell peripheral location by 60 min incubation with HGF. 
 
4.3.3 In vivo tumour growth of MDA-MB-231NWASP+ cells 
The tumours induced in the athymic nu/nu female mice were measured over 28 
days. During the growth period and at the experimental end point, the MDA- MB-
231NWASP+ tumours were consistently slower growing compared to the MDA- MB-
231WT and MDA- MB-231GFP control cells (Fig. 4.6). After 28 days, the tumour 
volume of the MDA MB-231NWASP+ cells was significantly smaller than both 
control cell groups, indicative of an inhibitory effect of NWASP in these human 
breast cancer cells (Final tumour volume mm3: MDA-MB-231NWASP+ 132.57 ± 
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48.69 versus MDA-MB-231WT 390.72 ± 125.66 and MDA- MB-231GFP 431.84 ± 
162.79; P = 0.002). 
 
 
Figure 4.6 The over expression of NWASP in human breast cancer cells and in vivo 
tumour growth. The growth of tumours was significantly reduced in MDA-MB-231NWASP 
cells compared to the wild type (MDA-MB-231WT) and plasmid control cells (MDA-MB- 
231GFP) (p=0.002).  
 
4.4 Discussion 
An extensive literature review provided an extreme paucity of quality data as 
regards NWASP and its role in breast cancer. This stimulated interest and was 
pronounced in paving the way for this project. 
In the previous chapter, we had shown that low levels of expression of NWASP 
were associated with a poor prognosis in Breast cancer, both in terms of disease 
free and overall survival. In this chapter, the aim was to study the effect of 
NWASP in relation to the invasive and migratory capacity of breast cancer cells. 
The hypothesis being that NWASP expression should correlate with reduced 
migration and invasive capacity, and thereby lower levels of NWASP expression 
correlated with poorer outcomes in individuals with breast cancer. 
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Towards this end, the invasive and migratory capacity of breast cancer cells MDA-
MB-231 were compared both prior to forced expression of NWASP [MDA-MB-
231WT (Fero et al., 1998), and post expression of NWASP [MDA-MB-231NWASP+]. 
As shown in the results section, changes in invasiveness were observed with MDA-
MB-231NWASP+ cells showing significantly reduced invasion compared to the wild 
type cells (MDA-MB-231WT) and GFP-plasmid control cells (MDA-MB-231GFP) 
(P<0.0001). This invasiveness remained reduced even in the presence of Human 
Growth Factor, which, under normal circumstances, actively induces invasion in 
this cell type (P<0.0001). Additionally, the motility of the cells was also 
significantly reduced (P<0.001) compared to the wild type and plasmid control 
cells, and motility remained reduced in the presence of HGF (P<0.001). These 
findings would be consistent with the perceived role of NWASP as a regulator of 
the actin cytoskeleton. As a corollary of the study, it was observed that the adhesion 
of these cells was expectedly increased. 
An additional finding was the redistribution of the NWASP over time, within the 
cells, when treated with HGF. The expression which was initially found to be 
nuclear and peri nuclear, was found to be within the cytoplasm and the periphery 
of the cells. The exact significance of this is unclear, and perhaps further studies 
will elucidate the same. Finally, the in vivo studies in the athymic mice showed the 
growth of tumours to be significantly reduced in the MDA-231 NWASP cells as 
compared to the MDA-231 WT and plasmid control cells. 
Collectively, these findings suggest that the NWASP, and therefore, by inference, 
the gene that codes for NWASP could have a role as tumour suppressor gene in 
human breast cancer. This study serves to ignite further research into the beneficial 
role that NWASP and its encoding gene could potentially play in therapy of breast 
cancer in the future. This is particularly relevant in times such as these where the 
entire human genome has been deconstructed, and commercially viable Gene 
Expression Profiling Kits such as MammaPrint (Agendia Inc., Irvine, California) 
and Oncotype DX (Genomic Health, Redwood, California) are readily available. 
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5.1 Introduction 
5.1.1 The ECISTM Model 
Application of a mathematical model of the impedance changes due to the 
presence of a cell layer, where the impedance data can be used to calculate cell 
morphological parameters including the barrier function of the cell layer, the 
spacing between the ventral side of the cell and the substratum, and the cell 
membrane capacitance. In the seminal paper by Giaver and Keese, the validity of 
the model was confirmed (Giaever and Keese, 1991). To employ the model to 
refine ECIS data, the resistance and capacitance of the cell free electrode is 
measured at several different AC frequencies. In the model, cells are represented 
as disk shaped objects having insulating membrane surfaces and filled with 
conducting electrolyte. 
Figure 5. 1 Cells modelled as disks. Courtesy (www.biophysics.com)  
Since the focal adhesion plaques of cells represent a very small fraction of the total 
ventral surface of the spread cell, we treat the cells as hovering a small distance 
above the electrode which serves as their substratum. In calculating how the 
impedance changes due to this cell coverage, we assume that the resistance and 
capacitance of the gold surface itself does not change but that the measured 
capacitance and resistance change because the cells alter the path of the current 
flow. The main source of the impedance change can be attributed to the fact that 
some current must flow through the narrow spaces between the ventral surface of 
the cells and the electrode, and that current flows out through the narrow spaces 
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between the cells (barrier resistance). AC current can pass directly through the 
cells since their insulating membranes serve as capacitors themselves. 
ECIS enables us to perform a fully automated wound healing assay that generates 
quantitative data in real time without the need for reopening the incubator door 
once the experiment has been set up. The advantages of this are self-explanatory. 
Additionally, ECIS measurements are label free and, as explained earlier, they 
are highly reproducible. 
5.1.2 ECIS Wounding Assay 
The ECIS wound healing assay replaces the traditional “scratch” or “scrape” assay. 
Traditionally, the cell layer was disrupted mechanically using a toothpick, pipette 
or a needle. A microscope followed the subsequent migration of cells to “heal” the 
wound. ECIS employs electric signals to both wound and monitor the healing 
process. 
ECIS electrical wounding is highly targeted - it only affects a small population of 
cells in contact with the active 250µm diameter ECIS electrode, producing a well- 
defined 250µm wound. This can be verified both by ECIS staining and by ECIS 
measurement. The benefits of this method are the reproducibility and the lack of 
observer bias and variability. Additionally, the protein coating of the cells is 
unaffected by the current, and it remains fully intact. 
5.1.3 ECIS cell migration measurements 
Upon electrically wounding the cells, ECIS returns to its normal mode to 
immediately follow the neighbouring healthy cells as they migrate inward to 
replace the killed cells. Traditionally, as described in earlier chapters, these 
measurements are carried out with extensive labour involving microscopy and 
researcher quantification. The ECIS wound healing/cell migration assay is a 
completely automated assay requiring a minimum amount of labour. Computer 
control enables both cell wounding and measurements of the subsequent healing 
process. 
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ECIS has now been modified (Patent pending) such that automated assays of this 
sort can be performed. In normal ECIS measurements, a current of less than a 
microampere is normally used. This is undetected by the cells, and, in its 
measuring mode, ECIS essentially eavesdrops on cell behaviour electrically. When 
the current is boosted 1000 fold to a milliampere, the resulting voltages across the 
cell membranes result in electroporation. If this is applied for only a few 
milliseconds, the cells recover, and it is possible to insert impermeable molecules 
including DNA constructs into the cytoplasm. When the high current is applied for 
several seconds, cell death ensues due to severe electroporation and possible local 
heating effects. 
The ECIS wound is very well defined, as it includes only those cells on the 250 
µm diameter electrode. Death can be verified both with the ECIS measurement and 
vital staining. Typical ECIS data involving this assay is shown in the figure 5.2. 
Here cells were first grown as complete monolayers and the impedance traces from 
confluent wells can be seen on the graph. At the red dot, an elevated field was 
applied to two of the wells, wounding the cells on the small electrode and causing 
the impedance to drop to that of an open electrode. Over time, these two traces 
return to control values, as the healthy cells outside of the small electrode migrate 
inward to repopulate the wounded area and replace their dead cohorts (healing). 
These types of data are highly reproducible and respond to culture conditions. This 
is evident in the graph showing the similar pattern following the second wounding. 
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 Figure 5.2 Typical ECIS data generated during a wounding assay. 
The term impedance was coined by Oliver Heaviside in July 1886 (Heaviside, 
1971). It is the measure of the opposition that a circuit offers to a current when a 
voltage is applied. In other words, it is the complex ratio of the voltage to the 
current in an alternating circuit. Impedance extends the concept of resistance to 
Alternating Current circuits. Resistance only has magnitude, and hence differs 
from Impedance which has both magnitude and phase.  The symbol for impedance 
is usually Z.  In general, impedance will be a complex number, with the same units 
as resistance, for which the Standardised International unit is the Ohm (Ω) 
Table 5. 1 Comparison of Traditional “Scratch” and newer ECIS methods 
Scratch Method ECIS Wound Healing Assay 
The scratch assay is traditionally carried 
out with simple tools such as needles, 
rakes, pipette tips or even toothpicks. 
The ECIS Wound is carried out by the 
ECIS Software without the need for 
technician manipulation. 
The scratch itself often varies and is not 
highly reproducible. 
The ECIS Elevated Field Module 
produces a 250 um wound every time. 
The scratch method requires hands-on 
measurements. 
ECIS measurements are automated, 
quantifying data in real-time. 
The traditional scratch method almost 
always "scraped" off the cell's protein 
coat. 
With the ECIS Wound the cell's protein 
coating is unaffected by the current, it is 
not "scraped" off. 
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5.2 Materials and Methods 
 
In our department, we have available the ECIS 9600 and ECIS 1600R purchased 
from Applied Bio-physics. In the current study, the ECIS 1600R was used for the 
experiments. 
The electronics are consolidated in a single case that sits beside a tissue culture 
incubator. Two leads connect the electronics to an electrode array holder within 
the incubator space – this, in turn, makes contact with up to two consumable 
arrays. A USB cable provides communication to a PC that controls all data 
acquisition, storage and analysis. In addition to the ECIS electronics and software, 
the system is supplied with a state-of-the-art PC/monitor, colour inkjet printer and 
an initial supply of electrode arrays. An optional compact CO2 tissue culture is 
also available. The ECIS software runs on a Window’s TM platform with user-
friendly software for all operations. 
 
Figure 5.3 ECIS Working Assembly 
 
Specifications 
Maximum number of wells: 16 
Frequency range: continuous from 100Hz to 100kHz 
Operating System: Windows XP 
System Controller: Desktop or laptop PC 
Front Panel Controls: Power on/of 
Front Panel Indicators: Power, Measurement in Progress, 
Wounding/Electroporation 
Mode Activated (optional) 
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PC to 1600R communications: USB 
Power: 120-240 VAC 50/60Hz 
Dimensions: 17.25 x 8.5 x 20 inches (WxHxD) 
Weight: 40 lbs 
System includes: dual slot array holder, colour matrix printer, laptop or desktop 
PC 
Array Holder dimensions: 5.5x 1.5x 6.0 inches (WxHxD) 
Array Holder material: Lexan ® polycarbonate 
Array holder to instrument cable length: 4.5 ft (a port in the incubator is 
desirable, 5/8 inch diameter minimum). 
As mentioned in detail in chapter 2, the core working element is the 8 chamber 
well with the gold electrodes. In order to ensure that no deposits accrue on the 
electrodes, these need to be cleaned. Deposits would cause added impedance, and 
hence erroneous readings. Cleaning was achieved using 200 µl of 10 mM L-
cysteine into each of the 8 wells and allowing the same to stand for 40 minutes. 
Care must be taken to avoid contact with the electrodes as this may damage them. 
This was followed by washing the wells with 300 µl of DMEM F12 (Dulbecco’s 
Modified Eagles Medium). Three rinses ensured an adequately cleaned well. The 
wells were now ready for use for the experiment. The 8 wells were allocated the 
various constituents for the attachment, wounding, and migration studies as is 
described in the following section. The 8 chamber well was now placed in the 
ECIS chamber and subjected to the studies as detailed in the following pages. 
For the attachment study the order of the wells are as follows: 
 
Attach 1: 
3=empty plasmid 
4=NWASP+ 
5=empty plasmid + HGF at 25 ng/ml 
6=NWASP+ + HGF at 25 ng/ml 
 
Attach 2: 
2=empty plasmid 
3=NWASP+ 
 145 
6=Empty plasmid + Wiskostatin at 50 ng/ml 
7=NWASP+ + Wiskostatin at 50 ng/ml 
 
Attach 3: 
2=empty plasmid+ HGF at 25 ng/ml 
3=NWASP+ + HGF at 25 ng/ml 
6=Empty plasmid + Wiskostatin at 50 ng/ml + HGF at 25 ng/ml 
7= NWASP+ + Wiskostatin at 50 ng/ml+ HGF at 25 ng/ml 
 
 
For the Wounding study, the order of the wells is as follows: 
Wounding 1: 
3=empty plasmid 
4= NWASP+  
5=empty plasmid + HGF at 25 ng/ml 
6= NWASP+ + HGF at 25 ng/ml 
 
Wounding 2: 
2=empty plasmid 
3= NWASP+ 
6=Empty plasmid + Wiskostatin at 50 ng/ml 
7= NWASP+ + Wiskostatin at 50 ng/ml 
 
Wounding 3: 
2=empty plasmid+ HGF at 25 ng/ml 
3= NWASP+ + HGF at 25 ng/ml 
6=Empty plasmid + Wiskostatin at 50 ng/ml + HGF at 25 ng/ml 
7= NWASP+ + Wiskostatin at 50 ng/ml+ HGF at 25 ng/ml 
 
5.3 Results 
ECIS-based assays have been established to measure the cell morphologic, 
adhesive, and invasive properties in a real-time, automated, and quantitative 
fashion. Monolayer disruption via the retraction of endothelial cell or loosening of 
tight cell junctions induced by tumour cells may be the major or at least part of the 
causes for the observed electrical resistance changes. The ability of tumour cells to 
induce these changes reflects their invasive potential. It is important to note that to 
date, there is no consensus of opinion for universally analysing ECIS data. 
Typically, data is presented using images derived from ECIS software 
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It has been shown that when endothelial cell layers were challenged with highly 
metastatic cell lines, binding occurred to the endothelial cell layer, followed by the 
retraction of the endothelial cell junctions, and finally the penetration of the cells 
through the endothelial monolayer. This sequence of events has been documented 
using scanning and transmission electron microscopy as well as phase-contrast 
time-lapse microscopy. It has been postulated that this in vitro sequence of events 
mirrors similar invasive activities that occur during the metastatic process in vivo. 
These activities have also been monitored using the ECIS system. As the 
metastatic cells invade the endothelial layer, they break down its barrier function, 
resulting in large drops in impedance. These impedance changes are automatically 
followed over time, and used to quantify the in vitro invasive activities if the cells. 
The ECIS 1600R performs real time data measurement and subsequent analysis. 
 
4 
6 
3 
5 
Figure 5. 4 Attachment study 1 
Attach 1: 
3=empty plasmid 
4= NWASP+ 
5=empty plasmid + HGF at 25 ng/ml 
6= NWASP+ + HGF at 25 ng/ml 
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Figure 5. 5 Attachment study 2 
 
Attach 2: 
2=empty plasmid 
3= NWASP+  
6=Empty plasmid + Wiskostatin at 50 ng/ml 
7= NWASP+ + Wiskostatin at 50 ng/ml 
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Figure 5. 6 Attachment study 3 
 
Attach 3: 
2=empty plasmid+ HGF at 25 ng/ml 
3= NWASP+ + HGF at 25ng/ml 
6=Empty plasmid + Wiskostatin at 50 ng/ml + HGF at 25 ng/ml 
7= NWASP+ + Wiskostatin at 50ng/ml+ HGF at 25 ng/ml 
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The resistance change of the electrode−electrolyte interface increased linearly with 
the number of cells attached on the detecting electrode. The slope of the linear 
relationship appeared to depend on the type of coating protein. As the surface area 
occupied by the cells was also proportional to the cell number, the resistance 
change was in turn proportional to the area covered by the cells. 
Wiskostatin- a cell-permeable N-alkylated carbazole derivative that selectively 
blocks actin filament assembly-was used. It acts as a selective, reversible inhibitor 
of NWASP (neural Wiskott Aldrich syndrome protein), a signal integrating 
protein. Appears to bind to NWASP, stabilize the auto inhibited conformation and 
prevent the activation of Arp2/3 (actin-related protein 2/3) complex. 
Human tumours express large amounts of growth factors and their receptors. A 
tumour will not grow beyond the size of a pinhead without new blood vessels to 
supply oxygen and nutrients. Growth factors are significant because they can 
induce angiogenesis, the formation of blood vessels around a tumour. These 
growth factors also encourage cell proliferation, differentiation, and migration on 
the surfaces of the endothelial cells. 
From the first attachment study (Figure 5.4), it is evident that the NWASP+ cells 
attach even faster when treated with Human Growth Factor [HGF]. The attachment 
study 2 (Figure 5.5) demonstrates that even with the Wiskostatin inhibition, the 
NWASP+ cells have better attachment. In the graph generated in the attachment 
study 3 [Figure 5.6], NWASP+ cells have an increased attachment even when 
treated with HGF and Wiskostatin. 
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Figure 5.7 Wounding 1 
Wounding 1: 
3=empty plasmid 
4= NWASP+ 
5=empty plasmid + HGF at 25 ng/ml 
6= NWASP+ + HGF at 25 ng/ml 
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Figure 5.8 Wounding 2 
 
Wounding 2: 
2=empty plasmid 
3= NWASP+ 
6=Empty plasmid + Wiskostatin at 50 ng/ml 
7= NWASP+ + Wiskostatin at 50 ng/ml 
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Figure 5.9 Wounding 3 
 
Wounding 3: 
2=empty plasmid+ HGF at 25ng/ml 
3= NWASP+ + HGF at 25ng/ml 
6=Empty plasmid + Wiskostatin at 50ng/ml + HGF at 25 ng/ml 
7= NWASP+ + Wiskostatin at 50ng/ml+ HGF at 25 ng/ml 
 
Post wounding, with the attachment and spreading of cells on the gold electrode, 
the impedance increased because the cells acted as insulating particles to restrict 
the current flow. After the cells were fully spread, the measured impedance 
continued to fluctuate to reflect the constant motion and metabolic activity of the 
cells. 
In the wounding experiment (Figure 5.7), it is apparent that there is not much 
difference in migration speeds of the various cells. The graph for the wounding 
experiment 2 (Figure 5.8) shows that Wiskostatin [inhibitor] depressed the 
migration of the empty plasmid, but not the NWASP+ cells. The graph for the 
wounding experiment 3 [Figure 5.9] is more difficult to interpret as it increased 
the migration of the NWASP+ cells, but in combination with Wiskostatin, 
decreased it. 
Essentially, the ECIS experiments and subsequent data generated with the self- 
generated attachment measurements and wounding measurements [generated in 
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real time] lend further support to the previously performed biological assays 
described in the earlier chapters. 
5.4 Discussion 
In the experiments conducted, we have used Wiskostatin as the inhibitor and 
human growth factor [HGF] as a stimulator to act as additional adjuncts to further 
study attachment and migration [wounding]. 
Wiskott-Aldrich syndrome protein (NWASP) stimulates actin-related protein 
(Arp) 2/3-mediated actin polymerization. This leads to diverse downstream 
effects, including the formation and remodelling of cell surface protrusions, 
modulation of cell migration, and intra-cytoplasmic propulsion of organelles and 
pathogens. Selective inhibitors of individual Arp2/3 activators would enable more 
exact dissection of NWASP dependent cellular pathways. Wiskostatin is a 
recently described chemical inhibitor that selectively inhibits NWASP-mediated 
actin polymerization in vitro. A growing number of recent studies have utilized 
this drug in vivo to uncover novel cellular functions for NWASP. However, the 
selectivity of Wiskostatin in intact cells has not been carefully explored. Studies 
with this drug have shown rapid and dose-dependent inhibition of NWASP-
dependent membrane trafficking steps. It has also been seen that the addition of 
Wiskostatin inhibited numerous other cellular functions that are not believed to be 
NWASP dependent. Further studies have revealed that Wiskostatin treatment 
causes a rapid, profound, and irreversible decrease in cellular ATP levels, 
consistent with its global effects on cell function. 
There exists significant experimental data that suggests that hypophyseal 
hormones influence certain phases of cancer induction and growth (Ball, 1932). 
Human growth hormone has clearly been implicated as one of the factors that 
favour the chemical induction of cancer, and increasing the rate of appearance and 
growth of a variety of cancers (Moon et al., 1950). For these reasons, Wiskostatin 
and Human growth factor were selected to aid this part of the experiments. 
Referring to the results section, the first attachment study shows that the NWASP+ 
cells attach even faster when treated with Human Growth Factor [HGF]. The 
attachment study 2 demonstrates that even with the Wiskostatin inhibition, the 
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NWASP+ cells have better attachment. In the graph generated in the attachment 
study 3, NWASP+ cells have an increased attachment even when treated with 
HGF and Wiskostatin. In order for cells to leave the primary tumour mass and 
disseminate, there must be a reduction in the normal adhesion to other cells as 
well as changes in their adhesion to the surrounding extracellular matrix. The 
migration of cells through the matrix and across the vessel walls allows such 
dissemination. This migration is dependent upon stable adherence and traction 
produced by adhesion molecules and their ligands. This would support the 
hypothesis that NWASP has a role to play in decreasing the metastatic potential of 
cells by enhancing attachment capability. 
In the wounding experiment, a very minor difference in migration speeds of the 
various cells was observed. The graph for the wounding experiment 2 shows that 
Wiskostatin [inhibitor] depressed the migration of the empty plasmid, but not the 
NWASP+ cells. This was contrary to the expected finding that the NWASP cells –
should they be inhibited by Wiskostatin- should also show a decreased migratory 
capacity. The graph for the wounding experiment 3 poses even more difficulty in 
interpretation, as it increased the migration of the NWASP+ cells, but in 
combination with Wiskostatin, decreased it. These results suggest that there are 
more than one and possibly a myriad of complex interactions that will govern the 
net effect of external forces on behaviour. Further studies would be needed to 
elucidate the same. 
In summary, the results support the idea that the measured resistance changes 
reflect the ability of cells to adhere, and also to migrate. This, in turn, is a marker 
of the metastatic potential of the cells. Attachment and Wounding assays 
conducted using the ECIS system represented several advantages and/or unique 
features when compared with other invasion measurement methods used. First, 
attachment and migration of breast cancer cells – which are important to assess 
metastatic potential- is measured, which better mimics in vivo events compared 
with Matrigel-coated chamber assays. Second, the ECIS system has high 
sensitivity. Finally, ECIS follows real-time changes during cell invasion, 
illustrating the kinetics of this process, whereas the Matrigel method only 
measures one end-point result at a time. 
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6.1 General Discussion 
This is the first study to show aberrant expression of NWASP transcript in human 
breast cancer. The results demonstrate that NWASP is significantly down-
regulated in human breast cancer, being reduced in node positive tumours and 
having a negative correlation with the NPI status. Moreover, reduced expression is 
associated with poor outcome for patients, i.e. metastatic disease, local recurrence 
and death from breast cancer. These data are supported by the reduced expression 
at the protein level of NWASP, particularly in invasive tumours as deduced from 
immunohistochemistry. In vitro studies determined that over-expression of 
NWASP led to human breast cancer cells having reduced motility and invasion 
but with increased adhesion. The over-expression of the NWASP protein was 
spatially modulated by HGF over time (90 min incubation) from a nuclear/peri 
nuclear location to the periphery of the cell-particularly at the leading edge. In 
vivo studies revealed that these altered breast cancer cells had significantly 
reduced tumour growth. These data collectively indicate that NWASP is a 
potential tumour suppressor in breast cancer. 
Increased motile behaviour in cancer cells is a prerequisite for the successful 
metastasis. Therefore, proteins involved in the regulation of cancer cell motility 
could be the key in the understanding of how this process occurs, might be 
prevented and could then be used as potential prognostic indicators. NWASP 
family proteins, including WASP, NWASP and Scar/WAVE, are potent 
activators of the Arp2/3 complex (Kowalski et al., 2005) and together they are 
important nucleators of new actin filaments in response to signals causing cell 
shape and motility changes (Parsons et al., 2005). GTP-loaded CDC42 and 
phosphatidylinositol-4, 5-bisphosphate [PtdIns (4, 5) P2] synergistically enhance 
NWASP-induced actin nucleation by the Arp2/3 complex (Higgs and Pollard, 
2000). Although identified arising from the Wiskott-Aldrich Syndrome, which 
gives rise to a number of malignancies (Perry et al., 1980, ten Bensel et al., 1966, 
Sullivan et al., 1994), NWASP has not been greatly investigated in clinical 
samples of other tumour types with most of the work being concentrated on the 
signalling/control of actin reorganisation at the molecular level (Jones et al., 
2002). Previously in breast cancer cells, phosphoinositide 3-kinase (PI3K), small 
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Rho GTPases, such as CDC42 and Rac1, and NWASP have been demonstrated as 
vital effectors in the regulation of dynamic changes to the actin cytoskeleton and 
during cell migration. Divergent signalling occurs downstream of PI3K in MDA-
MB-231 cells after uPA- and EGF-stimulated chemotaxis, cytoskeletal 
rearrangements and activation of CDC42, Rac1 and NWASP. The activity of 
PI3K was found to be unnecessary for these uPA-induced chemotactic responses. 
However, EGF induced changes were entirely dependent upon PI3K. The PI3K-
independent chemotactic signalling by uPA involved the disruption of interactions 
between β1-integrins and NWASP and translocation of NWASP to the actin 
cytoskeleton (Linder et al., 1999). 
The data presented here indicates that the loss of NWASP in human breast cancer 
samples may indicate a dysregulation in the regulation of changes in the actin 
cytoskeleton and hence result in increased migratory potential of the tumour cells. 
As an initial event in the metastatic cascade, it is not surprising that the loss of 
NWASP is, therefore, associated with patients that have metastatic disease, local 
recurrences and eventual death from the disease. 
NWASP is involved mostly in the formation of podosomes (cell-substrate 
adhesion sites) (Yamazaki et al., 2005), or invadopodia (in oncogenic cells) which 
are consisted of filamentous actin-rich cores and surrounding ring structures 
containing adhesive proteins such as vinculin and talin. These are also involved in 
the degradation of the ECM (Yamaguchi et al., 2006) and it has been shown that 
EGF receptor signalling regulates invadopodium formation through the NWASP-
Arp2/3 pathway, with cofilin being necessary for the stabilization and maturation 
of invadopodia in invasive carcinoma cells (Sarrio et al., 2006). 
Interestingly, given that ezrin, one of the ERM protein family (ezrin, merlin, 
radixin, moesin), is associated with malignant progression and metastasis in human 
neoplasias (Martin et al., 2003, Manchanda et al., 2005); it has been discovered 
that merlin and the ERMs can interact with and regulate NWASP (Sukumvanich et 
al., 2004). Merlin and moesin were found to inhibit NWASP mediated actin 
assembly in vitro, a function that appears independent of their ability to bind actin. 
In addition, exogenous expression of constitutively active ERM inhibits NWASP 
dependent Shigella tail formation, suggesting that ERMs may function as inhibitors 
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of NWASP function in vivo. This novel function of merlin and the ERMs 
illustrates a mechanism by which these proteins directly exert their effects on actin 
reorganization. This also provides new insight into the regulation of NWASP and 
provides evidence to support the potential importance of changes in NWASP in 
human breast cancer and how they may relate to cancer progression and metastatic 
disease. We have recently reported that the ERM family and Rho GTPase, are also 
aberrant in the same cohort of patients (Jiang et al., 2003, Martin et al., 2003), 
providing additional evidence that NWASP and its regulatory proteins are amongst 
the molecular complexes that are frequently dysregulated in breast cancer and 
contribute to disease progression in this malignancy. It was interesting to note that 
IHC revealed that, in tumour sections, NWASP showed localisation at the cell 
periphery, rather than the nuclear/peri nuclear location observed in the background 
tissue sections. This may have a bearing on the activation or conformation of the 
NWASP protein as NWASP has been shown to re-locate to the leading edge of 
extending lamellipodia after activation with accompanying reduced peri nuclear 
concentration (Sukumvanich et al., 2004). Moreover, it has been demonstrated 
that unphosphorylated NWASP is located at the nucleus which causes 
suppression of HSP90, HSE and Src family kinases (Suetsugu and Takenawa, 
2003). The active, phosphorylated form of NWASP is then re-located to the cell 
periphery where CDC42 and Src are activated, thus regulating events involving 
the actin cytoskeleton i.e. motility, migration. The differential expression of 
NWASP in human breast cancer could incur aberrant activation in cancer cells 
and may lead to changes in regulation of migration and hence to metastatic 
spread. 
In recent years, much work has centered on the various proteins in the 
cytoskeleton and the complex interactions that govern the pivotal role that these 
play in the two way communication between a cell and its extracellular matrix or 
other cells. Integrins are transmembrane receptors that mediate attachment of cells 
to its surroundings cells or the extracellular matrix. They play important roles in 
cell adhesion, migration, proliferation and survival. Integrins work alongside other 
proteins such as cadherins, selectins and syndecans to mediate cell–cell and cell–
matrix interaction and communication. Integrins bind cell surface and ECM 
components such as fibronectin, vitronectin, laminin, and collagen. Talin and 
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Vinculin are cytoskeletal proteins that form part of a macromolecular complex on 
the cytoplasmic face of integrin mediated cellular junctions with the extracellular 
matrix. The enormous data – genetic, biochemical and structural- generated by 
recent studies have shown that talin is essential for the assembly of such junctions, 
whereas vinculin appears to be important in regulating adhesion dynamics and cell 
migration. 
Among the cytoskeletal proteins that interact directly with the beta-chain 
cytoplasmic domain, talin has emerged as playing a critical role in integrin 
activation and linkage to the actin cytoskeleton. Talin is an elongated flexible 
antiparallel dimer, with a small globular head connected to an extended rod. The 
talin head contains a FERM (4.1/ezrin/radixin/moesin) domain with binding sites 
for several beta integrin cytodomains and the talin rod contains a second lower-
affinity integrin-binding site, a highly conserved C-terminal actin-binding site and 
also several binding sites for vinculin (Ziegler et al., 2008). Vinculin can interact 
with F-actin both in recruitment of actin filaments to the growing focal adhesions 
and also in capping of actin filaments to regulate actin dynamics (Golji and 
Mofrad, 2013). 
In conclusion, NWASP is significantly down-regulated in human breast cancer, 
particularly in aggressive and node positive tumours and in patients with poor 
prognosis. Over expression leads to altered phenotype of human breast cancer 
cells, from an invasive type to that of a significantly less motile and invasive but 
more adhesive phenotype. Moreover, these cells produced tumours of 
significantly reduced growth and volume in vivo. These data suggest that the loss 
of expression of NWASP in breast cancer could be an important step in the 
progression of this disease and as such should warrant further investigation as a 
tumour suppressor in human breast cancer partly by inhibition of motility and 
invasion. 
6.2 Limitations of the current study 
The current study, although comprehensive in itself as regards studying of clinical 
samples and genetic based analysis, merely forms a preliminary phase of a 
possible major investigation into the possibility of NWASP being a putative 
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tumour suppressor gene in relation to breast cancer. While the study has thrown 
up exciting leads, a number of insufficiencies arise, and these could certainly be 
addressed in future studies. The main limitation of this study was the number of 
breast cancer specimens available for study. In order for the data and results to be 
more robust, a larger cohort of samples would be needed. It is realized that the 
“normal breast tissue” samples used in the study, by virtue of being obtained from 
the ipsilateral breast as the cancer, is not the ideal specimen. It lends itself open to 
criticism due to the possibility of field change that may occur in a breast that has a 
cancer within it. The period of follow up is limited to 7 years. It would be 
interesting and more scientifically valid to have a longer period of follow up. This 
would indicate if trends in the initial period of follow up remained or results 
changed dramatically with time.  A clearer link needs to be elucidated between 
mRNA and protein levels. This is because this study has measured mRNA 
expression, which although strongly correlated with protein synthesis, the 
association is not 100%. Moreover, the conclusions of the current study were 
largely drawn from the analysis of the gene transcripts, and additionally from 
limited information that came from protein analysis, i.e., immunohistochemistry 
(IHC).  
The IHC study was limited here in the following two aspects: 
1. Some samples in the cohort were small tumours, and, therefore, it was 
not possible to obtain additional sections for all the samples. This means 
that, in comparison to the gene transcript data, the IHC data is less 
complete. Also, there were rigid time constraints on the research period. 
A future study encompassing larger samples with emphasis on both 
types of analysis would be more desirable. 
2. The type of the IHC analysis and lack of quantitative data from the 
IHC studies. 
 
At the time of IHC staining, the staining was not prepared in a way for 
quantitative analysis during which the sections were already stained with 
Haematoxylin. This presented difficulties during image analysis of the staining. 
The number of available sections at the time of the study did not permit the 
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making of additional runs. A semi-quantitative score for assessment of cellular 
staining by ICC and IHC techniques was, therefore, not carried out, although a 
subjective description of the slides was narrated. There is scope to redress this in 
future studies. 
The establishment of cell lines has been indispensable for biological research for 
several decades. However, recognized disadvantages of cell lines are that they are 
usually derived from tumors and have adapted to growth in culture. Cell culture 
media -by adding appropriate amounts of salt, glucose, amino acids, vitamins, and 
serum-try to mimic the natural physiology. However, the lack of a heterogeneous 
population of cell types and tissue architecture often abolishes cell-cell interaction 
and other functions based on tissue context. Cells in culture are prone to genotypic 
and phenotypic drifting. As a consequence, cell lines can lose tissue-specific 
functions and acquire a molecular phenotype quite different from cells in vivo. 
Acceptance of cell lines as model for biological function varies between fields. 
Cell biological studies on basic mechanisms, such as the cell cycle are routinely 
and overwhelmingly carried out in long-established cell lines. In contrast, there is 
substantial controversy of how well cell lines preserve aspects of the disease and 
whether or not they should be used in cancer drug development. Thus, animal 
experiments are often preferred despite their added complexity. Accurate 
molecular phenotypes to determine whether the function to be investigated is 
preserved in cell lines would enable a rational choice of the most appropriate 
experimental system.  
The main focus from the outset was to focus on NWASP in breast cancer, and the 
functional studies of breast cancer cells transfected with cloned normal NWASP 
gene (MDA-231NWASP+). Nevertheless, the IHC and ICC studies have generated a 
host of high quality photographs which in themselves are of significant value. 
6.3 Future work 
In order to design and deliver targeted and specific therapeutic interventions, 
elucidation of the cellular and molecular mechanisms of breast cancer and its 
spread is of paramount importance. In this light, NWASP and its potential as a 
tumour suppressor may have implications as a potential therapeutic intervention. 
The ongoing studies in molecular biology continue to shed light on the 
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mechanisms underlying carcinogenesis. Much work has centered on the exciting 
possibilities opened up due to newer agents and the promises afforded by Gene 
Therapy. A detailed discussion of this is beyond the scope of this work, but a 
mention of them must be made in light of the subject matter. 
Gene therapy-the use of DNA as a pharmaceutical agent to treat disease- was first 
advocated with caution as early as 1972 (Friedmann and Roblin, 1972). This has 
now mushroomed with over 1700 clinical trials being conducted using a number 
of techniques for gene therapy. In somatic gene therapy, the therapeutic genes are 
transferred into the somatic cells. In germline gene therapy, the desirable 
functional genes are introduced into the germ cells and are subsequently 
integrated into their genomes. The delivery of DNA into the cells is accomplished 
using either recombinant viruses (viral vectors) or using naked DNA or DNA 
complexes (non-viral methods). The most common form of gene therapy involves 
inserting a desired gene at a location within the host genome. The use of 
engineered nucleases-such as the zinc finger nuclease-knocks out specific genes. 
This technique is currently being employed in the knockout of human CCR5 gene 
in T cells to control Human Immunodeficiency Virus infection (Perez et al., 
2008). Of particular reference to this Thesis is the recent report coming out of 
Italy that children with Wiskott Aldrich Syndrome had been treated with a 
partially deactivated lentivirus to replace a faulty gene and that the results at 7-32 
months were promising (Aiuti et al., 2013) . 
It is hoped that future research on NWASP and its coding gene will make it an 
integral part of chemo-immunotherapeutic intervention for breast cancer, and 
indeed for other hematological malignancies which individuals who suffer from 
this condition are susceptible to. These appear far reaching and long term goals, 
but the potential that they afford serves as more than a catalyst to drive further 
research. 
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Introduction: WASP, the Wiskott-Aldrich syndrome protein (WASP) is a 
protein whose abnormality contributes to WAS condition. The WASP which 
belongs to a large protein family, is key regulators to the actin cytoskeleton 
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structure and is central to cell membrane ruffling, adhesion and migration. 
However, the role of WASP in cancer, particularly in breast cancer is not clear. 
The aim of the current study was to examine the impact of WASP on breast 
cancer cells and in clinical breast cancer. 
 
Methods: Full length human WASP cDNA was isolated, cloned and used to 
transfect breast cancer cells. The invasiveness and migration of cancer cells were 
investigated using a Matrigel invasion and a cyto-carrier motility assay. The 
distribution of WASP in human mammary tissues was studied using 
immunohistochemical analysis and expression of WASP transcript quantitative 
reverse transcription PCR. 
 
Results: MDA MB 231 cells stably transfected with WASP (MDA-231WASP+) 
exhibited a significantly reduced in vitro invasiveness compared with control and wild 
type cells (p=0.011). MDA-231WASP+ cells migrated at a slower rate compared with 
control cells, and most notably lost its response to the migration inducer, hepatocyte 
growth factor/scatter factor (HGF/SF) (13.3±1.7 for MDA- 231 WASP+ and 23.2±2.3 in 
control cells, following stimulation with HGF/SF), suggesting that over-expression of 
WASP in breast cancer cells confer cells to low invasive and low migration 
phenotype. In human mammary tissues, epithelial cells stained strongly positive for 
WASP, whereas stromal cells and endothelial cells had little staining. In contrast, 
cancer cell in breast tumour tissues stained very weakly compared with normal 
epithelial cells. WASP transcripts were regularly detected in normal mammary 
tissues, but were frequently lost in tumour tissues, as revealed by RT-PCR. This 
was reflected in the quantitative analysis which showed a significantly lower levels 
of WASP in tumour tissues compared with normal background mammary tissues 
(0.83±0.3 vs 13.6 ±13, p-0.04/Although no significantly correlation between levels 
of the transcript and tumour grade, and TNM staging was seen, lower levels of 
WASP transcript were, however, correlated with the clinical outcome following a 
six year follow up. Patients who developed metastatic disease and who died of 
breast cancer had significantly lower levels of WASP transcript compared with 
those who remained disease free (0.04±0.02 and 0.47±0.3, vs 0.79±0.44, p=0.01 
and p<0.05 respectively). Patients with local recurrence had lower levels of the 
transcript, however the difference was not significant (p>0.05, vs disease free). 
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Conclusion: It is concluded that WASP, a member of the WASP family acts as 
tumour progression suppressor in human breast cancer, partly by inhibition of 
migration and invasion of cancer cells. 
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